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Abstract 
 
Claire Y Hepburn. 
Studies investigating the mechanisms of the cardioprotective effects of CBD. 
A thesis submitted in partial fulfilment for the degree of Doctor of Philosophy. 
 
The phytocannabinoid cannabidiol (CBD) has a complex pharmacology which is thought to include, 
but is not limited to, an ability to act as an inverse agonist at the CB1
 
and CB2 receptors and an 
antagonist of GPR55. Moreover, is has been shown to reduce infarct size and ameliorate reductions in 
left ventricular function in vivo. These improvements in the pathogenesis of experimental MI are 
accompanied by a reduction in inflammatory cell migration to the area at risk. More recently it has 
been shown that CBD is anti-arrhythmic in acute experimental MI. Thus, it was suggested that the 
cardioprotective effects of CBD might be due to an anti-inflammatory action. In addition, GPR55 
receptor activation is acknowledged to mediate mobilisation of intracellular Ca
2+
 (Ca
2+
i) which could 
potentially be pro-arrhythmic and so CBD, as an antagonist may confer cardioprotection via GPR55. 
However, the receptors and/or mechanisms responsible for mediating the cardioprotective effects of 
CBD are get to be determined. The present studies were therefore performed to; (1) better understand 
the pharmacology of CBD by assessing haemodynamic responses to CBD and other cannabinoids 
ligands in anaesthetised rats, (2) investigate the receptors involved in the anti-arrhythmic effect of 
CBD in a rat model of coronary artery occlusion (CAO), and (3) investigate if CBD can alter [Ca
2+
]i in 
isolated rat cardiomyocytes. The characterisation of the pharmacology of CBD in vivo showed that; 
firstly, CB1 receptor activation causes a hypotensive response which can be dose-dependently 
inhibited by AM251; secondly, both CBD and AM251 alone (a CB1 receptor antagonist and GPR55 
agonist) can induce vasodepressor responses and finally, CBD can potentiate the AM251-mediated 
hypotension when co-administered, suggesting possible cross-talk between the CB1 and GPR55. 
Results from CAO studies showed that CBD and AM251 each have the capacity to reduce 
arrhythmias. Moreover, when CBD and AM251 were co-administered the anti-arrhythmic capacity of 
either alone was potentiated. However, the degree of potentiation was dependent on the order of 
administration, suggesting that more than one receptor is involved in the summative anti-arrhythmic 
effects. The investigation of cardiomyocyte [Ca
2+
]i suggested that AM251 can modulate [Ca
2+
]i at the 
level of the cardiomyocyte, while CBD cannot. These data give novel insight into the anti-arrhythmic 
effects of CBD and, moreover, for the first time demonstrate that AM251 is anti-arrhythmic. In 
addition, these data suggest a role for GPR55 in increasing [Ca
2+
]i via AM251. 
 
Keywords: Myocardial Ischaemia, Arrhythmias, Cannabinoids, Cannabidiol, GPR55, CB1 receptor. 
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1.1 Prevalence of cardiovascular disease 
 
Diseases of the heart and circulatory system are known generically as cardiovascular disease (CVD) 
and this terms encompasses myocardial infarction, angina pectoris, heart failure and many more 
conditions (Roger et al., 2012). Each year CVD is the principle cause of mortality in Europe and 
accounts for the deaths of approximately 4.1 million individuals each year in Europe alone (as 
referenced in Nichols et al., 2013). Moreover, CVD is not a disease which manifests only in old age, it 
accounts for 31% deaths before 65 in men and 27% of deaths before 65 in women in Europe (as 
referenced in Nichols et al., 2013). The financial burden of CVD in Europe runs to €196 billion a year 
(as referenced in Nichols et al., 2013). Therefore, the prevention and improved management of CVD 
remains a prominent concern of governments and health care professionals not only across Europe but 
across the globe. 
 
CVD also includes disorders of cardiac rate or rhythm, arrhythmias, (Levick, 2003) and incidences of 
atrial fibrillation (AF) are increasing (Go et al., 2001; Deo and Varosy, 2012), in addition, no single 
treatment has been found that can alone mitigate the effects of AF (Deo and Varosy, 2012) or 
ventricular arrhythmias (Della Bella et al., 2013). As such, any emerging strategies which can help to 
abate the burden arrhythmias and CVD would likely be of significant interest.  
 
1.2 Physiology of the heart 
 
The primary function of the cardiovascular system is to maintain homeostasis within the entire body; 
this is achieved by efficient provision of oxygen and nutrients and removal of products of cellular 
metabolism from tissues. The heart, a double pump that moves blood around the systemic and 
pulmonary circulations, meets these criteria. 
 
The impulse-conducting system of the heart is responsible for initiating and maintaining synchronous 
pumping of the heart. The impulse-conducting system consists of the sino-atrial (SA) node, 
atrioventricular (AV) node and the His-Purkinje system; the electrophysiological properties of each of 
the components of the impulse-conducting system differs which allows for staggered activation of 
myocardial contraction as this permits most efficient pumping. 
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1.2.1 Electrophysiological properties of the myocardium 
 
Synchronous contraction of the heart relies upon ordered transmission of electrical impulses through 
the impulse-conducting system. There are three types of cells in the cardiac tissue capable of electrical 
excitation: the pacemaker cells which are those that are found in the SA and AV nodes, specialised 
tissues of the impulse-conducting system (the His-Purkinje system) and, finally, the ventricular and 
atrial muscle cells.  
 
1.2.1.1  SA node 
 
Under physiological conditions there is a slow depolarisation during phase 4 of the action potential in 
the SA node. This results in spontaneous depolarisation of SA nodal cells, without external activation, 
which subsequently drives depolarisation of the cells downstream in the impulse-conducting system 
and ultimately dictates heart rate (Satoh, 2003; Mangoni and Nargeot, 2008). The genesis of automatic 
electrical excitation is dependent upon diastolic depolarisation following repolarisation, a process that 
drives the next action potential (Mangoni and Nargeot, 2008). The resting membrane potential of the 
SA node is inherently unstable; three principle time-dependent, ionic channel currents bring about its 
decay (Figure 1.1; Satoh, 2003): 
 
1. A small inward flow of sodium (Na+) ions is provided by the funny (If) current by way of the 
HCN2 and HCN4 subunits of the hyperpolarisation-activated cyclic nucleotide-gated (HCN) 
channels (Bucchi  et al., 2012). Expression of these subunits is significantly higher in the SA 
node than in the wall of the right atrium free wall (Yeh et al., 2009). Pharmacological 
blockade of this current slows heart rate and is used clinically in the treatment of angina and 
heart failure, this is only activated by hyperpolarisation (DiFrancesco and Camm, 2004; 
Bucchi et al., 2012).  
2. The Ik current is a slowly decaying, outward potassium (K
+
) current. Rapidly (IKr) and/or 
slowly (IKs) activating channel currents contribute the delayed K
+ 
efflux in nodal cells. The 
contribution of these two currents to spontaneous depolarisation in the SA nodes shows 
variability between species. For example, in the rat SA node, the IKr blocker E-4031 can 
suppress SA nodal cell spontaneity however, a similar effect cannot be achieved with a IKs 
blocker (Shinagawa et al., 2000; Lei et al., 2001). In contrast, in guinea pig nodal cells both 
IKr and IKs currents play an equal role in contributing to spontaneous depolarisation (Matsuura 
et al., 2002). 
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3. The T-type Ca2+ channel (ICa,T) and the L-type Ca
2+ 
channel (ICa,L) currents contribute to 
depolarisation, the latter current when the membrane potential reaches values of ~-55mV; this 
current is the one that provokes action potential formation (Levick, 2003; Mangoni and 
Nargeot, 2008). The α subunits predominantly expressed in the SA node are Cav3.1 and 
Cav3.2 (Cribbs et al., 1998, Satoh, 2003) for the ICa,T current and Cav1.2 for the high-voltage 
activated, ICa,L channel (Bohn et al., 2000, Satoh, 2003). The contribution of the ICa,T to the SA 
spontaneous AP is thought to be small on the basis that the activation threshold for this current 
is similar to the INa channel (Satoh, 2003).  
 
 
Figure 1.1 Typical SA node action potential which illustrates the channels responsible for spontaneous 
depolarisation. Adapted from Levick, (2003). 
 
There is a degree of variability between species in the currents involved in the development of action 
potentials. For example, in the guinea pig a rapidly activating K
+
 current (Ikr) and a sustained inward 
current (Ist) have been shown to also contribute to the spontaneity of the SA nodal cells. In the monkey 
the inwardly rectifying K
+
 (Ik1) with a reduced If current contributes to SA node spontaneity (Guo et 
al., 1997; Shinagawa et al., 2000; Mitsuiye et al., 2000; Satoh, 2003).  
 
The automaticity exhibited by the SA node propagates action potential generation elsewhere in the 
impulse conducting system, including the ventricular myocytes. The action potential of the ventricular 
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myocytes differs in waveform morphology from those of the automatic cells of the heart. The five 
phases of ventricular cell depolarisation are illustrated in Figure 1.2: 
 
 
 
Figure 1.2 An illustration of a ventricular myocyte action potential. The channels which generate each 
phase are detailed in blue, phase numbers in red. Adapted from Nattel and Carlsson, (2006) as referenced 
by Grant, (2009). 
 
 Phase 0: This phase is characterised by rapid depolarisation with reversal of the membrane 
potential. The INa current is responsible for this phase, with activation occurring at around -
60mV. 
 
 Phase 1: Phase 1 brings about early repolarisation of the overshoot caused during phase 0. The 
channels, which bring about this phase carry the transient outward K
+
 (Ito) current and open 
transiently in response to rapid depolarisation of the cell membrane. This phase determines the 
activation of the Ca
2+
-dependent ion channels and thereby its physiological function appears to 
be to modulate the plateau phase of the action potential. Moreover, in rats who exhibit high Ito, 
there is a propensity for action potentials to be extremely short and there is lack of a distinct 
plateau (Gussak et al., 2000; Niwa and Nerbonne, 2010). There are both rapid (Ito,f) and slow 
(Ito,s) facets of this current and the expression of each varies across the myocardium (Oudit et 
al., 2001). Kv4.2/4.3 subunits are responsible for Ito,f and Kv1.4 subunits drive the function of 
Ito,s (Niwa and Nerbonne, 2010). 
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 Phase 2: Unique to the cardiac action potential, this phase is typified by the inward current ICa. 
This phase is crucial in prevention of rapid repolarisation (Bers and Guo, 2005). Ca
2+
 entry in 
this phase is facilitated by L-type Ca
2+
 channels (LTCC; Cav1.2) and to a lesser extent, T-type 
Ca
2+
 channels (Cav3.1 and Cav3.2) and the influx of Ca
2+
 facilitates calcium release from the 
sarcoplasmic reticulum (SR); this process consequently causes contracture of the myocyte 
(Grant et al., 2009; Meza et al., 2013). 
 
 Phase 3: After the plateau of phase 2 has completed, the repolarisation phase begins to 
dominate ion movement once again. Repolarisation is the process of time-dependent increase 
in the conductance of K
+
 and is induced by opening of the delayed inward rectifier K
+ 
channels, of which two distinct channels, IKr and IKs, carry rapid and slow rectification 
currents, respectively (Natell, 2008).  
 
 Phase 4: This phase is termed the resting phase and it is the function of the inward rectifier 
channel K
+
 current (IK1) during this phase that sets the resting membrane potential of the 
subsequent action potential. The IK1 current in ventricular myocytes is a composite of Kir2.1 
and Kir 2.2 voltage-dependent ion channels, and ultimately determines terminal repolarisation 
(Biliczki et al., 2002; Nagy et al., 2013). 
 
The intensity of the rapid upstroke and plateau are readily influenced by the transmembrane potential 
at depolarisation (Gettes and Reuter, 1974). The contraction of cardiac myocytes transpires as a result 
of transient changes in cytosolic calcium concentration; this is directly modified upon transmembrane 
depolarisation (Stern and Lakatta, 1992). 
 
1.2.2 Excitation-contraction coupling 
 
Excitation-contraction coupling is the process that occurs in myocytes whereby action potentials are 
translated into activation of the contractile machinery. This process is reliant on transient changes in 
intracellular calcium (Ca
2+
) ion concentrations and it is critical for guaranteeing the synchronous and 
timely contraction of the heart as a whole (Stern and Lakatta, 1992).  
 
In physiological conditions action potentials in cardiomyocytes are initiated by the pacemaker cells of 
the SA node, this stimulates the cell interior to depolarise concurrently opening voltage-sensitive, 
membrane-bound, LTCC. Ca
2+ 
ions enter the cell interior down their concentration gradient and induce 
intracellular Ca
2+
 ion mobilisation from the SR; this process termed calcium-induced calcium release 
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(CICR). The free cytosolic Ca
2+
 then binds to the troponin C molecules on the actin-troponin-
tropomyosin complex. This induces a conformational change in the troponin C that results in 
revelation of the myosin binding site on the actin filaments. A complex series of protein interactions 
then occurs, terminating in formation of an actin-myosin cross-bridge which facilitates the contractile 
cycle of the myocytes (Levick, 2003; Stern and Lakatta, 1999). 
 
1.3 Myocardial ischaemia 
 
Myocardial ischaemia (MI) is the process whereby occlusion of a coronary artery causes insufficient 
provision of oxygen and nutrients and deficient removal of metabolic waste products from cardiac 
myocytes. The early consequences of ischaemia are metabolic changes accompanied by deterioration 
in ion homeostasis and consequent electrophysiological changes. Late changes include alterations in 
contractile function and induction of cellular necrosis (Carmeliet, 1999). 
 
1.4 Manifestations of ischaemia 
 
The manifestations of ischaemia can be immediate or delayed. The immediate changes occur within 
minutes of occlusion and include depletion of energy-rich phosphate stores. The depleted adenosine 
triphosphate (ATP) concurrently leads to ion derangements, all of which contributes to loss of normal 
contractile function and generation of arrhythmias. 
 
1.4.1 Depleted energy generation 
 
A prolonged reduction in coronary blood flow perturbs substrate metabolism in the myocardium and 
MI is associated with both a reduction in fatty acid oxidation and an increase in glycolysis (Knuuti and 
Tuunanen, 2010). This in turn reduces the production of energy-rich phosphates like ATP (Jaswal et 
al., 2011), which causes reduced tension generation in the myocardium with a concurrent decrease in 
stroke volume. A cascade then occurs involving loss of ion homeostasis and electrical inhomogeneity 
and cardiovascular performance is consequently compromised. In addition, the acute reduction in ATP 
causes an alteration in ion homeostasis and leakage of K
+
 and Ca
2+
 across the myocardial cell 
membrane, thus perturbing the electrophysiological properties of the cardiomyocyte. The rising 
concentrations of purine precursors, which arise as a result of failed ATP generation, are degraded to 
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xanthine and hypoxanthine. These metabolites are substrates for xanthine oxidase, a superoxide 
producer, during ischaemia (Maxwell and Lip, 1997). 
 
1.4.2 Perturbation of normal ion balance 
 
Augmented oxidative phosphorylation causes ion concentrations to be disturbed with Na
+
, K
+
, Ca
2+
 
and hydrogen (H
+
) being the principle victims. Derangement of ion homeostasis can cause immediate 
cell death if extreme and can further impede recovery of those cells that have incurred non-fatal injury 
(Carmeliet, 1999; Piper, Meuter and Schafer, 2003). 
 
1.4.2.1 Na+ 
 
As a result of decreased energy generation during ischaemia, intracellular Na
+
 concentrations [Na
+
] are 
amplified. These changes are brought about by impaired function of the Na
+
 channels which cause a 
persistent inward Na
+
 current (late INa) coupled with reduced active outward flow (Hoyer et al., 2011).  
Although the late INa is present in healthy myocytes and contributes to normal Na
+
 accumulation, it is 
the incomplete block of Na
+
/K
+
-ATPase, caused by the reduction in energy generation upon occlusion, 
which induces reduced removal of  Na
+
 ions from the cytosol. Moreover oxidative stress from oxygen 
free radicals has been implicated as a factor responsible for pump inhibition (Soliman et al., 2012). 
This accumulation is worsened still by acidosis. Acidosis induces the Na
+
/H
+
 exchanger to move H
+
 
across the cell membrane to the cell exterior concomitantly moving Na
+
 into ischaemic myocytes 
(Carmeliet, 1999). Previous studies have shown that blockade of this exchanger can reduce Na
+
 
accumulation post-occlusion, substantiating this hypothesis (Anderson et al., 1991; Pike et al., 1993; 
Carmeliet, 1999). In a bid to counter the accumulation of intracellular Na
+
 and hence depolarisation, 
the Na
+
/Ca
2+ 
exchanger is reversed (Soliman et al., 2012). The prevention of Na
+
 overload 
inadvertently triggers Ca
2+
 overload, a development that induces contracture and thus myocellular 
damage but it is also proarrhythmic (Carmeliet, 1999; Piper, Meuter and Schafer, 2003). Reduction of 
the late INa in isolated ventricular myocytes can suppress arrhythmic activity, for example, delayed 
after depolarisations (DADs) and triggered activity (Song, Shryock and Belardinelli, 2008). 
Furthermore, blocking this current in the isolated guinea pig heart caused a reduction in energy loss 
and an improvement of contractile function (Hoyer et al., 2011). 
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1.4.2.2 K+  
 
Within minutes of cessation of coronary blood flow ischaemic cells within the ischaemic zone 
depolarise (Janse and Kleber, 1981). This depolarisation is directly attributable to extracellular 
accumulation of K
+
 ions whose concentrations can exceed 20mmol l
-1
 (Janse and Kleber, 1981; Janse 
and Wit, 1989; Wilde and Aksnes, 1995; Carmeliet, 1999; Miura et al., 2012). The build up of 
extracellular K
+
 [K
+
]e during ischaemia typically occurs in three phases; a rapid accumulation 
occurring within the first 20 seconds, a plateau which occurs during 3 to 10 minutes post-occlusion, 
and a second accumulation which occurs more slowly during the period 15 to 30 minutes post-
occlusion (Carmeliet, 1999). 
 
Under physiological conditions there is a passive K
+
 efflux from myocytes, which is actively balanced 
by K
+
 uptake by the Na
+
/K
+
 pump; ischaemia disturbs this homeostatic mechanism (Carmeliet, 1999). 
There are three prime factors proposed to be responsible for perturbation of K
+
 homeostasis, these are; 
altered K
+
 efflux, diminished K
+
 influx and osmosis. Accumulation of metabolic waste products alters 
the osmotic balance across the cell membrane of cells in the ischaemic zone, which concurrently 
causes water to move from the extracellular to intracellular spaces, decreasing the volume of the 
extracellular space. Accumulation of osmotically charged particles in the cytosol of ischaemic 
myocytes encourages K
+
 loss to the extracellular environment. The Na
+
/K
+
 pump is responsible for the 
maintenance of K
+
 homeostasis in physiological conditions. Upon coronary occlusion the function of 
this ATP-requiring pump diminishes as intracellular ATP levels are depleted. A direct consequence of 
deteriorating Na
+
/K
+
 pump function is an increase in [K
+
]e due to the passive K
+
 efflux from the cell 
not being actively matched. The weakening of pump activity is by no means extreme but is adequate 
to perturb normal K
+
 ion balance. Interestingly, free radicals have been implicated in depression of 
pump activity in addition to the ATP-related effects (Matsuura and Shattock, 1991; Carmeliet, 1999). 
The final mediator of [K
+
]e accumulation is proposed to be increased K
+
 efflux. Ultimately this 
increased K
+
 efflux will cause cardiomyocytes to depolarise (Carmeliet, 1999).   
 
The elevated [K
+
]e can acutely affect the electrophysiological properties of the ischaemic myocytes. 
As mentioned above, a direct result of ischaemia is depolarisation of those cells in the ischaemic zone 
with concomitant reduction in amplitude of cardiac action potentials. In addition, action potentials of 
reduced size and duration are observed. Together these factors favour the occurrence of reentry-
induced arrhythmias (Carmeliet, 1999). Moreover, the electrophysiological perturbations of ischaemia 
can be mimicked simply by an increase in [K
+
]e (Hill and Gettes, 1980; Hirche et al., 1980). More 
recently, investigators have shown that a regional but not global  increase in [K
+
]e, can initiate 
sustained arrhythmias in a mechanism which is, in part, mediated by Ca
2+
 uncoupling from the 
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myofilaments and thereby, uncoordinated excitation-contraction coupling and non-uniform [Ca
2+
]i 
(Miura et al., 2012).  
 
1.4.2.3 Ca2+ 
 
During ischaemia cytosolic free Ca
2+
 [Ca
2+
]i
 
rises in a more delayed fashion than that observed for 
extracellular K
+
 ion accumulation, although there is disagreement over the precise time-course of Ca
2+ 
ion perturbation during ischaemia (Carmeliet, 1999). 
 
The initial increase in cytosolic free Ca
2+
 ion concentration occurs as a consequence of the 
displacement of Ca
2+
 ions from their binding sites by accumulating H
+
 (Carmeliet, 1999). The 
prolonged build-up of intracellular Ca
2+
 during ischaemia occurs secondary to Na
+ 
ion derangement. 
Reversal of the Na
+
/Ca
2+ 
exchanger occurs in a bid to reduce intracellular Na
+
 levels and a direct 
outcome of this process is an intracellular Ca
2+
 ion overload. Coupled with this, uptake of Ca
2+
 ions by 
the sarcoplasmic reticulum (SR) is decreased. This reduced uptake by the SR is due to lowered Vmax of 
the Ca
2+
-ATPase, a consequence of both low ATP levels and oxygen free radical-induced disulphide 
bridge formation (Griese et al., 1988; Kukreja et al., 1991; Carmeliet, 1999; Ottolia et al., 2013). 
Perturbations in [Ca
2+
]i have also been shown to be caused by regional accumulation of [K
+
]e 
following ischaemia (Miura et al., 2012). 
 
The ability of the cardiomyocyte to coordinate excitation and contraction is altered by perturbations of 
[Ca
2+
]. For example, there is a reduction in conduction velocity and changes in prolonged 
refractoriness, which together can lead to the development of an environment which favours the 
generation of arrhythmias (Downar, Janse and Durrer, 1977). Accumulation of [Ca
2+
]i in isolated 
myocytes have been shown to occur prior to the initiation of spontaneous fibrillation (Thandroyen et 
al., 1991). In addition, Ca
2+
 overload in ischaemia has critical repercussions for the survival of those 
cells that have been reversibly damaged during ischaemia as contracture can develop and induce 
necrosis in potentially viable cells (Piper, Meuter and Schafer, 2003).  The effects of ischaemia-
induced elevations in [Ca
2+
]i are not limited to ischaemia itself but can continue to affect 
cardiomyocytes post-reperfusion. More specifically, the uptake of Ca
2+
 by the mitochondria during 
ischaemia is a critical determinant of the likelihood of the opening of the mitochondrial permeability 
transition pore (mPTP), a large, non-specific conductance pore which spans the inner and outer 
mitochondrial membranes and whose opening facilitates mitochondrial membrane potential collapse 
and ultimately cell death (Crompton et al., 1999; Hausenloy et al., 2003; Hausenloy, Duchen and 
Yellon, 2003; Halestrap, Clarke and Javadov, 2004). 
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1.4.2.4 H+ 
 
When the myocardium becomes ischaemic there is retention of CO2 and an increase in proton 
generation, resulting in a net change in intracellular pH and acidosis (Carmeliet, 1999). The 
intracellular acidosis due to ischaemia results because of increased production of H
+ 
and deficient 
removal of these species. Intracellular H
+
 levels are increased during ischaemia due to three main 
mechanisms; (1) ATP production shifts to the glycolytic pathway for the duration of ischaemia with 
concomitant H
+
 generation, (2) ATP hydrolysis is coupled with the production of H
+
 and (3) H
+
 
removal is deficient due to CO2 retention (Watson et al., 1984; Allen et al., 1985; Eisner et al., 1989; 
Dennis, Gevers and Opie, 1991; Carmeliet, 1999). Intracellular acidosis has been implicated as a 
factor that may contribute to K
+
 accumulation in the extracellular space. Experiments have shown that 
alteration of pH in ischaemic myocardium modifies [K
+
]e immediately (Kleber, Riegger and Janse, 
1987; Janse and Wit, 1989). The electrophysiological consequences of acidosis of ischaemic 
myocardium are a fall in resting membrane potential, reduced upstroke velocity and a concurrent 
increase in action potential duration. These acute changes in the cardiac action potential of cells within 
the ischaemic zone are brought about because of altered ion channel function due to acidosis. Altered 
conduction and cardiac action potential retardation can increase the likelihood of the occurrence of 
triggered activity (Coraboeuf, Deroubaix and Coulombe, 1979; Carmeliet, 1999). 
 
1.4.3 Cell necrosis 
 
Occlusion of a coronary vessel induces ischaemia and irreversible cell death, or necrosis, of 
cardiomyocytes in the area at risk. The incidence of cellular necrosis post-occlusion is well correlated 
with infarct size. The cellular changes which result from ischaemia include alterations in 
mitochondrial structure and contractile machinery of the myocytes with eventual cellular oedema. 
Factors which affect the rate of progression of cellular necrosis upon reperfusion and the likelihood of 
its development include the levels of collateral flow and degree of oxygen consumption at the time of 
occlusion (Schaper and Schaper, 1988). Furthermore, the loss of plasma membrane integrity (LPMI), 
an event typical of necrotic cell death, has been shown to occur within 1 hour of reperfusion and lasts 
for up to 24 hours thereafter. Reactive oxygen species are thought to drive LPMI within the first 3 
hours post-reperfusion, after which time the principal mediator is complement deposition, specifically 
of complement protein 3 (C3; Charlagorla et al., 2013).  
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1.4.4 Functional alterations resulting from ischaemia 
 
The most prominent functional alterations that transpire consequent to MI are arrhythmias. 
Arrhythmias develop within minutes of coronary occlusion and can precipitate fatality (Janse and Wit, 
1989). The electrophysiological changes which ensue subsequent to a reduction in blood flow are the 
main impetus for initiation of arrhythmias (Janse and Kleber, 1981). Moreover, the prolongation of the 
cardiac action potential coupled with the increased [Ca
2+
]i induces negative lusitropic effects, which 
concurrently increase left ventricular end diastolic pressure and cardiac stiffness (Bers, Eisner and 
Valdivia, 2003; Madonna, Cevik and Nasser, 2013).  
 
1.4.5  Ischaemic preconditioning 
 
When a period of ischaemia due to coronary occlusion is repeatedly interrupted by ischaemia and 
reperfusion which precede the prolonged occlusion, the infarct size is reduced by three quarters and in 
addition, the incidence of both ischaemia and reperfusion-induced arrhythmias are reduced (Vegh et al., 
1990; Kaszala et al., 1996). Furthermore, after the initial occlusion event there is no additional ATP loss 
or necrosis (Jennings et al., 1978; Reimer and Jennings, 1979; Murry et al., 1986; Schott et al., 1990). 
This process is termed ischaemic preconditioning. The infarcts in preconditioned models are not 
laterally confluent like those of non-preconditioned models; in addition the infarct size in 
preconditioned animals is smaller regardless of the level of collateral flow (Murry et al., 1986). The 
mechanisms that induce infarct reduction in preconditioning are proposed to be slowing of ATP 
depletion in all occlusion episodes after the first and wash out of catabolites during each reperfusive 
window (Schott et al., 1990). With regard to the anti-arrhythmic effect of preconditioning, the 
cardioprotective effects of preconditioning were shown to be lost when the cyclo-oxygenase pathway 
is blocked (Vegh et al., 1990; Parratt and Vegh, 1994). 
 
1.5 Electrophysiology of the ischaemic myocardium and arrhythmias 
 
Arrhythmias can result from both ischaemia and reperfusion (Janse and Wit, 1989). Numerous factors 
are responsible for the occurrence of arrhythmias and these are termed substrate, trigger, and 
modulating factors. Substrate factors manifest as the physical consequences of ischaemic episodes, for 
example functional conduction block. Trigger factors are required to be present for arrhythmias to 
develop; they include ventricular premature depolarisations and tachycardia. The substrate and trigger 
factors can be altered by the modulating factors, for example electrolyte alterations (Janse and Wit, 
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1989). Together these factors define the risk of susceptibility of arrhythmia development (Shah et al., 
2005). 
 
Experimental coronary occlusion produces electrophysiological changes within minutes, the most 
noticeable change being depolarisation of cells in the ischaemic zone, together with changes in 
transmembrane ion balance (Janse and Wit, 1989). These electrophysiological changes bring about 
changes in cardiac action potential, including shortening and decreased amplitude (Janse and Kleber, 
1981; Janse and Wit, 1989). Ultimately the outcome of sustained ischaemic events is an increase in the 
occurrence of arrhythmias. Following experimental coronary occlusion two periods of arrhythmias 
have been identified; those occurring within the first 2-10 minutes are termed immediate ventricular 
arrhythmias (IVA or phase Ia) and those occurring between 12 and 30 minutes are termed delayed 
ventricular arrhythmias (DVA or phase Ib) (Harris, 1950; Kaplinsky et al., 1979; Janse and Wit, 
1989). These two phases are collectively termed Harris phase I arrhythmias and this bimodal 
appearance of arrhythmias has been identified in many species, including the rat and pig (Harris, 1950; 
Kaplinsky et al., 1979; Hirche et al., 1980; Parratt, 1982; Janse and Wit, 1989).  
 
1.5.1 Altered cardiac action potentials 
 
Along with depolarisation of cells within the ischaemic zone, alterations in action potential 
morphology occur when coronary occlusion is induced. Depolarisation immediately subsequent to 
occlusion perpetuates conditions that favour prolongation of action potential duration and extension of 
the effective refractory period of those cells within the ischaemic zone. These changes in action 
potential morphology are also well correlated with catecholamine flux and transient changes in [K
+
]e 
and the late INa. These changes act negatively on conduction velocity (Waldo and Kaiser, 1973; Janse 
and Wit, 1989; Carmeliet, 1999; Noble and Noble, 2006; Madonna, Cevik and Nasser, 2013). 
Additional changes include a decrease in amplitude and upstroke velocity (Janse and Wit, 1989). 
These reductions in cardiac action potential parameters occur because the K
+
 efflux induced by MI-
stimulated opening of the KATP channels, this causes a small amount of membrane depolarisation and 
thereby a reduction in upstroke velocity (Wirth et al., 2000).  
 
It is the non-homogenous topology of changes in the cardiac action potential in regional ischaemia that 
is the critical mediator in the generation of arrhythmias (Madonna, Cevik and Nasser, 2013). Cells in 
the border zone experience different alterations in ion balance compared with those of the normal 
myocardium and will thus exhibit different alterations in action potential morphology, thus causing 
dispersion in the degree of repolarisation of myocytes within the heart through which injury currents 
flow (Pollard et al., 2002). The inhomogeneity and pathological changes in action potentials provide a 
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suitable milieu for the formation of arrhythmias, for example early afterdepolarisations (EAD) and 
reentry (Carmeliet, 1999; Madonna, Cevik and Nasser, 2013). 
 
1.5.2 Altered automaticity 
 
Automatic depolarisation is a characteristic typical of the pacemaker cells of the SA and AV nodes.  
Altered automaticity has been implicated as a cause of ventricular arrhythmias (Mangoni and Nargeot, 
2008). Spontaneous depolarisations in non-pacemaker cells increase in occurrence following a period 
of MI (Wit and Bigger, 1975). Moreover, in atrial myocytes which exhibit spontaneous depolarisation, 
inhibition if the late INa was found to reduce the frequency of such spontaneous activity (Song et al., 
2008). Other tissues within the impulse-conducting system are capable of automaticity. In 
physiological conditions the more rapid depolarisation of the SA node prevents these alternative sites 
dominating and becoming the automatic focus of the heart. Ischaemia increases the rate of 
depolarisation of these alternative sites and thus increases the likelihood that they become the 
automatic focus (Carmeliet, 1999).  
 
1.5.3 Triggered activity 
 
This form of non-reentrant arrhythmia, as the name suggests, requires the presence of a trigger for its 
initiation. Triggered activity is characterised by both EADs and DADs (Janse and Wit, 1989; 
Carmeliet, 1999). These arrhythmias occur either before or after completion of repolarisation of an 
action potential and are induced by changes in [Ca
2+
]i in the ischaemic cardiomyocyte (Song et al., 
2008; Shryock et al., 2013).  
 
EADs are depolarisations that occur during the plateau or repolarisation phase of the action potential. 
These derangements can result from slow repolarisation and subsequent reactivation of Na
+
 and Ca
2+
 
channels, combined with consequent Na
+
-mediated Ca
2+
-overload (Song et al., 2008). The persistent 
inward sodium current (late INa) which persists in the ischaemic myocardium is responsible for 
prolonging the action potential duration and thereby the induction of EADs (Hoey et al., 1994; Song et 
al., 2008; Hoyer et al., 2011; Shryock et al., 2013). 
 
DADs are transitory depolarisations that appear immediately after repolarisation has completed. The 
conditions required for this form of arrhythmia are spontaneous Ca
2+
 release from the SR and low 
intracellular K
+
, again conditions typical following a period of ischaemia (Luo and Rudy, 1994; 
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Carmeliet, 1999; Shryock et al., 2013). The oscillations in [Ca
2+
]i driven by SR release activate a 
transient inward current (ITI) which consequently facilitates the formation of DADs (Song et al., 
2008).  
 
1.5.4 Reentry 
 
Reentry is characterised by a conduction disorder that results in the reexcitation of tissue by an 
impulse that would ordinarily have died out (Shryock et al., 2013). The conditions required for the 
formation of reentry are; (1) the presence of a functional unidirectional conduction block and (2) slow 
conduction coupled with short refractory periods (Quan and Rudy, 1990). These criteria are fulfilled 
during ischaemia (Carmeliet, 1999). During the initial 30 seconds following ischaemia there is a 
noticeable inhomogeneity between the action potential refractory periods, mainly due to spatial 
dispersion of excitability because of differing [K
+
]e in myocytes of the ischaemic zone and those of the 
border (Wit and Janse, 2001; Sidorov et al., 2011). This dispersion of refractoriness is postulated to 
cause conduction delay and fractionation of wavefronts and this can lead to generation of arrhythmias 
by a reentrant mechanism (Levites, Banka and Helfant, 1975; Ferrier, Moffat and Lukas, 1985). 
 
1.6 Reperfusion injury 
 
Readmission of oxygen-rich blood to the myocardium subsequent to ischaemia is the most effective 
means of salvaging those cells which have undergone pathological changes but which still remain 
retrievable (Litt et al., 1989; Maxwell and Lip, 1997). This process, which is known as reperfusion, is 
itself a double-edged sword; reperfusion may rescue potentially viable cells but can result in additional 
endothelial destruction, lipid peroxidation, and arrhythmias in the form of oscillatory afterpotentials 
and ventricular tachycardia (Ferrier, Moffat and Lukas, 1985; Pogwizd and Corr, 1987; Maxwell and 
Lip, 1997). Reperfusion injury is defined as the death of cells which, although damaged after 
ischaemia, are potentially viable and die as a direct result of the events which occur at reperfusion 
(Kloner, Przyklenk, and Whittaker, 1989; Park and Lucchesi, 1999). Reperfusion injury has been 
identified as occurring both immediately succeeding reperfusion (less than 3 hours) and later (more 
than 3 hours), and different pathologies define each (Litt et al., 1989; Entman et al., 1991; Jordan et 
al., 1999). Furthermore, the pathogenesis of reperfusion has been demonstrated to be due to oxygen-
derived free radicals and/or Ca
2+ 
(Maxwell and Lip, 1997). 
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Mitochondria play a critical role in determining the viability of myocytes subject to ischaemia and 
reperfusion. On one hand, loss of the mitochondrial serine-threonine protein kinase, PTEN 
(phosphatase and tensin homologue on chromosome 10)-induced kinase 1 (PINK1)), can increase the 
likelihood of cell death following ischaemia by, in part, increasing opening of the mPTP, a large, non-
specific pore found in the inner mitochondrial membrane (IMM), whose opening alone upon 
reperfusion of the ischaemic myocardium can induce cell death (Siddall et al., 2013). On the other 
hand, it has been shown that mitochondria may be mediators of ischaemic preconditioning (IPC) by 
sub-lethal opening of this very pore (Hausenloy et al., 2010). 
 
1.6.1 Reperfusion-induced arrhythmias 
 
The appearance of arrhythmias within seconds of reoxygenation of ischaemic myocytes was first 
confirmed by Tennant and Wiggers in 1935. Since then it has be noted that in reperfusion there is a 
high incidence of ventricular tachycardia (VT), ventricular fibrillation (VF) and derangement of the 
idioventricular rate (Levites, Banka and Helfant, 1975; Naimi et al., 1977; Penkoske, Sobel and Corr, 
1978; Pogwizd and Corr, 1987). The mechanisms by which these reperfusion arrhythmias develop are 
thought to differ from those of ischaemic arrhythmias, since ischaemic arrhythmias are slow onset and 
reperfusion arrhythmias appear almost instantaneously (Kaplinsky et al., 1981). There is a correlation 
between the duration of the ischaemic period and the severity and incidence of arrhythmia occurrence 
post-reperfusion (Janse and Wit, 1989). The definitive mechanisms that are responsible for the onset 
and maintenance of reperfusion arrhythmias remains elusive, however, putative mechanisms include 
enhanced automaticity, depression of action potentials and inhomogeneity (Kaplinsky et al., 1981; 
Murdock et al., 1980; Pogwizd and Corr, 1987; Janse and Wit, 1989). Immediately after reperfusion 
has been initiated, VF dominates over VT (Janse and Wit, 1989). Following a period of ischaemia, 
action potentials may be depressed and some cells may even become inexcitable. Re-oxygenation aids 
the recovery of transmembrane action potentials however they still exhibit depressed amplitudes and 
upstroke velocities. This depression of action potential activity is not uniform however and there is 
acute inhomogeneity. This inhomogeneity combined with the intra- and extracellular accumulation of 
metabolites and ions increases the chance of reentry (Janse and Wit, 1989). A non-reentrant 
mechanism was suspected after it was demonstrated the reperfusion is associated with an increase in 
the idioventricular rate (Pogwizd and Corr, 1987). This change in the idioventricular rate enhances 
ventricular automaticity and thus the likelihood of arrhythmic activity, for example ventricular 
tachycardia (Kaplinsky et al., 1981). Finally, prolongation of refractory periods post-reperfusion has 
been shown to be coupled with increases in ventricular ectopic activity, such as EAD and DAD 
(Levites, Banka and Helfant, 1975). In this thesis, I have not studied reperfusion arrhythmias but 
instead focused on ischaemia-induced arrhythmias.  
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1.7 The pharmacology of cannabinoids 
 
Cannabinoids have been used medicinally for almost 4000 years and are the natural bioactive ligands 
of the plant Cannabis sativa (Brown, 2007; Ryberg et al., 2007). This plant produces in excess of 80 
cannabinoids and they principally act at two established cannabinoid receptors, namely the CB1 and 
CB2 receptors, however their activity has been detected at sites distinct from this including the GPR55 
receptor, TRPV1 ion channel and 5-HT3 receptors (Brown, 2007; Pertwee, 2007; Console-Bram, 
Marcu and Abood, 2012). The most abundant compounds derived from Cannabis sativa are (-)-∆9-
tetrahydrocannabinol (∆9–THC) and cannabidiol (CBD) (Turner et al., 1980; Chen and Buck, 2000). 
Synthetic cannabinoid ligands have been produced in the hope of producing compounds that are 
selective for CB1 and CB2 receptors. 
 
1.7.1 Receptors 
 
In the early 1990s molecular cloning established the principal targets of cannabinoid action, they are 
the CB1 and CB2 receptors, however more recent studies have identified putative targets at sites 
distinct from them (Pertwee, 2006; Brown, 2007; Pertwee, 2007). Both the CB1 and CB2 receptors are 
G-protein coupled 7-transmembrane spanning receptors (GPCRs) that exhibit constitutive basal 
activity (Turner et al., 1980; Chen and Buck, 2000; Lepicier et al., 2006; Pertwee, 2006).  
 
1.7.2 CB1 
 
The CB1 receptors are chiefly expressed within neuronal tissues and in particular the nerve terminals 
of the central and peripheral nervous system, where they mediate the psychotropic effects of ∆9-THC 
and inhibit the constitutive release of both excitatory and inhibitory neurotransmitters like 
acetylcholine and noradrenaline (Szabo and Schlicker, 2005; Pertwee, 2006; Brown, 2007; Ralevic 
and Kendall, 2009). In the central nervous system the density and location of CB1 receptors is related 
to the sites at which cannabinoids generate their psychotropic effects (Devane et al., 1988; Pertwee, 
1997). 
 
In addition to those CB1 receptors expressed in the central nervous system (CNS), CB1 receptors have 
been shown to be present in the myocardium and densely populate the cytoplasmic and perinuclear 
area of cardiomyocytes. In addition, the hypotensive effects of cannabinoids are mediated by 
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activation of the CB1 receptors which occupy sympathetic nerve terminals of the peripheral nervous 
system (Ishac et al., 1996; Pertwee, 1997; Weis et al., 2010). 
 
CB1 receptors together with the endocannabinoid ligands are thought to play an important modulatory 
role within the cardiovascular system. In particular, bolus administration of the endocannabinoid, 
AEA, has been shown to induce triphasic changes in cardiovascular parameters in anaesthetised rats 
and mice. More specifically, phase I is characterised by a significant but transient fall in blood 
pressure coupled with a reduction in cardiac contractility and a rise in total peripheral resistance 
(TPR). Phase II is typified by a brief pressor response and a rise in cardiac contractility. Finally, phase 
III produces a protracted fall in blood pressure together with a reduction in cardiac contractility, total 
peripheral resistance (TPR) and heart rate (Lake et al., 1997; Malinowska et al., 2001; Pacher et al., 
2004). Two discrete receptors mediate these AEA-induced effects. Capsazepine and ruthenium red 
have been shown to block the AEA-mediated effects characteristic of phase I, indicative of 
involvement of the vanilloid TRPV1 receptors. The CB1 antagonist, SR141617A, abolished the 
prolonged hypotension of phase III at doses effective at blocking CB1 receptors (Lee and Lundberg, 
1994; Malinowska et al., 2001; Szolcsanyi, 2000). The receptors responsible for phase II may include 
TRPV1 (Pacher et al., 2004); calcium channels (Kwolek et al., 2005) and a combination of N-methyl-
D-aspartate (NMDA) receptors, β-adrenoceptors and thromboxane A2 receptors (Malinowska et al., 
2010). Other cannabinoids only activate part of the effects AEA has the capacity to induce 
(Malinowska, Baranowska-Kuczko and Schlicker, 2012).  
 
CB1 receptors are part of a family of GPCRs and are Class A rhodopsin α-group members (Fredriksson 
et al., 2003). The CB1 receptor sequence is highly conserved between rats and humans with 93% and 
97% identity at the nucleic and amino acids levels, respectively (McPartland and Glass, 2003; 
Console-Bram, Marcu and Abood, 2012). Coupling between the components of the CB1 receptor and 
subsequent downstream signal cascades occurs principally through Gαi/o proteins positively to A-type 
outward and inwardly rectifying potassium channels and also to N- and P/Q-type calcium channels. 
This coupling to calcium channels may be responsible for the signal cascade accountable for 
mediation of the psychoactive effects of cannabinoids (Pertwee, 1997; Lepicier et al., 2006; Pertwee, 
2006; Brown, 2007). CB1 receptors can affect adenylate cyclase activity by one of two routes, 
negatively, if coupled to Gαi/o proteins or positively, if coupled to Gαs proteins. This indiscriminate 
CB1 receptor coupling may be tissue specific and this may explain any tissue specific actions of 
cannabinoids (Pertwee, 2006). 
 
Recent studies demonstrated that the CB1 receptor displays constitutive activity (i.e. activation which 
occurs devoid of an agonist) after it was noted that mitogen activated protein kinase (MAPK) activity 
in CHO cells transfected with the CB1 receptor showed basal MAPK activation levels higher than 
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those in untransfected cells. What is more, the CB1 antagonist, SR141716A could reduce both agonist 
induced changes in MAPK activation and MAPK activation in cells expressing CB1 that had not been 
treated with an agonist (Bouaboula et al., 1997; Console-Bram, Marcu and Abood, 2012). CB1 
receptors also possess at least one allosteric site, occupation of which can modulate positively or 
negatively the activation induced by a direct agonist (Price et al., 2005; Adam et al., 2007; Horswill et 
al., 2007; Navarro et al., 2009; Pertwee et al., 2010) 
 
CB1 receptors have been shown to exist as homomers and also heteromers and oligodimers with other 
classes of GPCRs; which may permit cross-talk between multiple receptors subtypes (Pertwee, 2006; 
Waldeck-Weiermair et al., 2008; Kargl et al., 2012). Furthermore, the biochemical properties of the 
receptors involved in these heteromers can be altered. More specifically, CB1/GPR55 receptor 
heteromers show enhanced activity in terms of both ERK1/2 phophorylation and nuclear factor of 
activated T cell (NFAT) activation (Kargl et al., 2012) and those with the adenosine A2A receptor can 
influence the depressant effects of cannabinoids on motor function (Carriba et al., 2007).   
 
1.7.3 CB2 
 
In 1993 Munro et al. identified a second type of cannabinoid receptor subsequently termed the CB2 
receptor. This receptor showed 44% sequence similarity to the CB1 receptor (Pertwee, 1997). High 
affinity, saturable binding sites identified as the CB2 receptor have been detected in inflammatory 
cells, cells of the haematopoietic system and in the central nervous system in pathophysiological 
settings which are associated with neuroinflammation (Pertwee, 1997; Brown, 2007). 
 
It is widely accepted that CB2 receptors are capable of modulating inflammatory cell migration and 
cytokine release. Furthermore evidence suggests that CB2 knock-out mice can lack T-cell-activating 
responses to ∆9–THC in subtypes of immune cells (Brown, 2007). CB2 receptors are negatively 
coupled to adenylate cyclase and positively coupled to MAPK, unions which are mediated by the Gi/o 
proteins (Pertwee, 2006; Pertwee et al., 2010). 
 
1.7.4 GPR55 
 
A number of the vasoactive effects of cannabinoids are not consistent with those which would be 
expected upon activation of the designated cannabinoid receptors, leading to the suggestion that 
additional cannabinoid receptors exist. More specifically, the synthetic cannabinoid, abnormal 
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cannabidiol (abn-CBD) has been shown to induce mesenteric vasodilatation and SR141716A-sensitive 
hypotension in both CB1
-/- 
and CB2
-/- 
mice. The haemodynamic changes mediated by abn-CBD are also 
susceptible to CBD-mediated inhibition (Jarai et al., 1999).  Furthermore, the concentration of 
SR141716A, a typical CB1 receptor antagonist, required to block the actions of AEA in the vasculature 
are higher than those required to competitively inhibit the CB1 receptor (Hiley and Kaup, 2007). 
Recent studies have identified GPR55, an orphan GPCR, as a putative cannabinoid receptor (Brown, 
2007). Functional fingerprint identification has however, documented that the human GPR55 receptor 
does not share a similar fingerprint to CB1 or CB2 receptors; this may infer that although this receptor 
may operate as a cannabinoid receptor it may not have a typical cannabinoid binding pocket. 
Moreover, GPR55 receptors in their active conformations have a binding pocket which is highly 
hydrophilic in contrast to the highly hydrophobic binding pocket that typifies the CB1 and CB2 
receptors (Petitet, Donlan and Michel, 2006; Henstridge et al., 2011; Kotsikorou et al., 2011). GPR55 
forms part of the purinergic receptor family and was first identified as a possible cannabinoid target in 
a patent from GSK that described activation of this receptor by AM251 and SR141617A in yeast host 
strains that expressed human GPR55 receptors (Brown, 2007). 
 
Over recent years there has been much debate over the likelihood that GPR55 is a legitimate third 
cannabinoid receptor. Early studies demonstrated that GPR55 is activated by the AEA, 2-AG and 
CP55940 in human embryonic kidney 293 (HEK293) cells transfected with this receptor and this 
GPCR was initially purported to be the novel cannabinoid receptor responsible for the vasoactive 
effects of abn-CBD (Hiley and Kaup, 2007; Ryberg et al., 2007). Subsequent study expanded the 
ligand pharmacology to include O-1602 and AM251 (Table 1.2; Fischbach et al., 2007; Johns et al., 
2007; Waldeck-Weiermair et al., 2007). However, Johns et al. (2007) cast doubt on the likelihood of 
GPR55 acting as the endothelial anandamide receptor (eAR) having shown that administration of abn-
CBD in GPR55
-/-
 mice resulted in a rapid hypotension akin to that in wild type (WT) controls. 
Furthermore, vasodilatation responses to both abn-CBD and O-1602 were of similar magnitude in 
mesenteric arteries taken from GPR55
-/-
 and WT control mice. More recently the selectivity of some of 
the previously proposed ligands of GPR55 has been called into question in a study which identified 
only lyosphosphatidylinositol (LPI) as an agonist and discounting the activity of abn-CBD and O-1602 
(Kapur et al., 2009). These data however are not supported by a subsequent study in which it was 
shown that both LPI and O-1602 can  act as agonists at GPR55 to increase miniature excitatory 
postsynaptic currents (mESPCs) in CA1 pyramidal cells (Sylantyev et al., 2013). What is clear is that 
the precise ligand pharmacology of GPR55 remains elusive and, therefore, also the physiological and 
pathophysiological consequences of GPR55 activation. More recently a number of GPR55-selective, 
synthetic benzoylpiperazine compounds have come to the fore which lack activity at CB1 and CB2. 
Interestingly, unlike LPI, these compounds are not equipotent at rodent and human GPR55 but rather, 
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specifically activate the human receptor. This may suggest species-distinct binding domains within 
this receptor family (Brown et al., 2011; Henstridge et al., 2011). 
 
Ryberg et al. (2007) were one of the first groups to attempt to identify the downstream signal 
transduction pathways induced by GPR55 activation. An antibody against the C terminus of Gα13 had 
the capacity to inhibit GTPγS binding, an effect not reproducible with antibodies against Gαi1/2, Gαi3 or 
Gαs. GPCRs shown to couple to G13 proteins have also been revealed as having other G proteins 
targets, those for GPR55 have yet to be identified (Brown, 2007). More recently, Gα13 activation by 
GPR55 have been implicated in Ca
2+
 release from internal stores, transduction conferred by Gα13-
RhoA-ROCK-PLC with subsequent induction of inositol 1,4,5-triphosphate (IP3) and thus Ca
2+
 release 
from the endoplasmic reticulum (ER) (Henstridge et al., 2009; Henstridge et al., 2011; Moreno-
Navarrete et al., 2012). GPR55-induced intracellular Ca
2+
 mobilisation has been shown to induce a 
number of transcriptional factors for example, ERK 1/2 and p38 MAPK, whose activation may be 
involved in modulating cell physiology (Oka et al.,2007; Henstridge et al., 2010; Oka et al., 2010). 
 
There is mounting evidence that GPR55 may play a significant role in physiological function and in 
some instances it may even promote progression of several pathologies. Early studies in GPR55
-/-
 mice 
showed that following adjuvant-induced inflammation there was no inflammatory mechanical 
hyperalgesia for up to 14 days after adjuvant injection (Staton et al., 2008). This pointed to an 
important role for GPR55 in the treatment of neuropathic pain. It is thought that the presence of 
GPR55 on large diameter neurones is why they may play a role in inflammatory pain (Lauckner et al., 
2008; Henstridge et al., 2011). As described earlier, some effects of cannabinoids in the vasculature 
cannot be rationalised as a CB1 or CB2 receptor-mediated response; the vasodilatation induced by ∆
9
-
THC cannot be inhibited by the selective CB1 receptor antagonist, rimonabant (O’Sullivan, Kendall 
and Randall, 2005) moreover; abn-CBD can induce vasorelaxation in rat mesenteric artery from both 
CB1
-/-
 and CB2
-/-
 mice (Jarai et al., 1999). This cannabinoid ligand sensitive vascular receptor was 
purported to be GPR55, however, similar changes in mean arterial blood pressure were observed in 
WT and GPR55
-/-
 mice, thus, the likelihood that this vascular receptor is GPR55 was contentious.  In a 
more recent study, a fluorescent derivative of the reputed GPR55 receptor agonist, AM251, has 
identified GPR55 receptors in mouse mesenteric arteries (Daly et al., 2010). The role of GPR55 in 
regulating inflammatory cell migration and chemotaxis is controversial; that being said, mRNA for 
this receptor has been identified on human neutrophils among other inflammatory cell types (Balenga 
et al., 2011; Henstridge et al., 2011). GPR55 receptors have also been implicated in the control of 
cancer cell proliferation, more specifically, in cancers of the brain, pancreas and breast (Guzman, 
2003; Sarfaraz et al., 2008; Henstridge et al., 2011; Caffarel et al., 2012).  
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1.7.5 Vanilloid receptors 
 
Caterina et al. first cloned the vanilloid receptor in 1997. It is a ligand-gated, non-selective cation 
channel that has a membrane topology and binding domain configuration similar to typical cation 
channels (Malinowska, Kwolek and Gothert, 2001; Hogestatt and Zygmunt, 2002; Howlett et al., 
2002).  It belongs to a family of transient receptor cation channels which have a 6 transmembrane 
spanning domain and a non-selective cation channel (Pertwee et al., 2010). This channel has been 
acknowledged as participating in the mediation of inflammation-induced thermal hyperalgesia with 
ligands for this receptor including heat (>43C), capsaicin and pH (Caterina et al., 2000; Davis et al., 
2000; Hogestatt and Zygmunt, 2002). Although this channel was originally identified as the 
recognition site of capsaicin, studies have demonstrated that some cannabinoids (AEA, N-
arachidonoyl dopamine (NADA), and CBD) can bind and act as full agonists at this site (Zygmunt et 
al., 1999; Smart et al., 2000; Bisogno et al., 2001; Molinowska, Kwolek and Gothert, 2001; Ross et 
al., 2001; Hogestatt and Zygmunt, 2002; Howlett et al., 2002; Pertwee et al., 2010). The site at which 
these cannabinoids interact is thought to be the same as its typical agonist, capsaicin (Jordt and Julius, 
2004). Moreover, CB1 receptors can inhibit vanilloid receptor function by TRPV1 receptor 
dephosphorylation, the consequences of which may influence the pro-inflammatory signaling cascade 
induced by TRPV1 (Yang et al., 2013). TRPV1 receptors and CB1 receptor activation by cannabinoids 
has also been shown to reduce carcinoma invasion (Farsandaj, Ghahremani, and Ostad, 2012). This 
again highlights the potential significance of cannabinoid receptors and their ligands which activate 
both receptors and moreover, their roles in physiological and pathological processes.  
 
1.7.6 Allosteric sites 
 
Literature exists which has described functional allosteric modulation of 5-HT3 receptors by 
cannabinoids, furthermore, a putative allosteric site has been identified on the CB1 receptor itself 
(Barann et al., 2002; Godlewski et al., 2003; Price et al., 2005; Ross, 2007). An allosteric binding site 
is topographically discrete from the typically recognised orthosteric binding site and binding of 
modulators to such a site causes a conformational change in the receptor which facilitates modification 
of binding affinity and efficacy of ligands for the orthosteric site (Price et al., 2005; Ross, 2007). 
 
Cannabinoids can exert effects discrete from those of a psychotropic nature, including modulation of 
emesis and sensations of pain; this is a function shared with 5-HT3 receptors. It has previously been 
acknowledged that 5-HT3 receptors possess sites whose properties permit allosteric modulation. 
Barann et al. (2002), were the first to confirm that cannabinoid receptor ligands inhibit 5-HT3A-
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induced current in transfected HEK293 cells. This modulation of 5-HT3A-induced current was 
proposed to occur as a result of allosteric modulation, since radioligand binding studies confirmed 
absence of the typical cannabinoid receptors in this process. Further study confirmed the presence of 
cannabinoid agonist-induced modulation of 5-HT3 receptors in vivo (Godlewski, Gothert and 
Molinowska, 2003). 
 
In 2005 Price et al. (2005) identified novel allosteric modulators of the CB1 receptor. Three 
compounds, ORG27569, ORG27759 and PSNCBAM-1 have been recognised as having ligand-
dependent effects, typical of allosteric modulators, in HEK293 cells expressing hCB1 receptors. These 
compounds were shown to bind to the allosteric site and induce a conformation change such that the 
agonist affinity for the orthosteric site was increased. This postulated allosteric site on CB1  receptors 
in thought to be recognised by small synthetic molecules (Price et al., 2005; Ross, 2007). More 
recently, it has been shown that ORG27569 and PSNCBAM-1 increase the effect of the orthosteric 
agonist by increasing the rate at which the CB1 receptor is desensitised and delaying its internalisation, 
while the early signalling events driven by CB1 at Gαi are unaffected (Cawston et al., 2013). 
 
Cannabinoid agonists, both synthetic and endogenous, have been shown to modulate ion channel 
function in an allosteric or non-competitive manner (Pertwee et al., 2010). Derivatives of arachadonic 
acid were shown to modulate the 1,4-dihydropyridine (DHP) calcium channel antagonist binding site 
in a manner suggesting that these derivatives were non-competitive antagonists (Johnson et al., 1993). 
A more recent investigation found that AEA blocked the DHP binding site, in addition to 1,5-
benzothiazepine and phenylalkylamine sites on the LTCC (Shimasue et al., 1996). These binding sites 
are acknowledged to interact by way of allosteric modulators and thus, these authors suggested that 
AEA might be acting at one of these sites and that this interaction allosterically modulates the binding 
and/or function of the other sites. Potassium (K
+
) channels have also been shown to be sensitive to 
cannabinoids in a CB1 receptor-independent mechanism and at nanomolar to low micromolar 
concentrations (Pertwee et al., 2010). AEA can inhibit K
+
 conductance by suppressing the delayed 
rectifier outward current of the voltage gated K
+
 channel (Vignali et al., 2009). 
 
Voltage-gated sodium channels are no less affected by allosteric modulation by cannabinoids, namely, 
2-AG and NADA. These cannabinoids inhibit binding of [(3)H]batrachotoxinin A-20alpha-benzoate 
([(3)H]BTX-B) to site 2 of the sodium channel in a non-CB1 dependent, allosteric manner (Duan, et 
al., 2008; Duan, Zheng and Nicholson, 2008). 
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1.7.7 Ligands 
 
The agonists of the classical cannabinoid receptors include those which are synthetic or natural ligands 
of Cannabis sativa and those that are endogenous cannabinoids. Stereoselectivity for each of the 
receptors occurs; furthermore, these ligands are capable of acting at sites distinct from the CB1 and 
CB2 receptors. Development of selective cannabinoid receptor antagonists rapidly followed the 
discovery of the cannabinoid binding sites. Pertinent examples include AM251, SR141617A and 
AM630 (Pertwee, 1997; Howlett et al., 2002; Pertwee et al., 2010). 
 
1.7.8 Agonists 
 
The agonists (Table 1.1) of the classical cannabinoid receptors are typically classified according to 
their chemical structure, for example; 
 
The classical cannabinoids – A category that includes dibenzopyran analogues and derivatives e.g. 9-
THC and CBD. 
The non-classical cannabinoids – A category comprising of bi- and tri-cyclic analogues of 9-THC, for 
example CP 55,940 and DALN. This group was crucial in finding functional cannabinoid receptors 
within the brain.  
The aminoalkylindole cannabinoids – Typified by WIN-55,212-2, and JWH-015. 
The eicosanoid cannabinoids – The endocannabinoids are all eicosanoids and pertinent examples 
include N-arachidonylethanolamide, also known as AEA, and 2-arachidonyl glycerol (2-AG). The 
eicosanoids are susceptible to hydrolysis by fatty acid amide hydrolase (FAAH) or monoacylglycerol 
lipase (MAGL) (Johnson and Melvin, 1986; Pacheco et al., 1991; Martin et al., 1991; Devane et al., 
1992; Pertwee, 1997; Howlett et al., 2002; Pertwee, 2006). 
 
The identification of the CB1 receptor subsequently led to the discovery of an endogenous ligand 
active at the CB1 receptor, namely, AEA (Di Marzo et al., 1998). The endocannabinoid system (ECS) 
describes the principal cannabinoid receptors and their endogenous ligands, the endocannabinoids. 
Endocannabinoid synthesis and subsequent release is initiated by post-synaptic increases in 
intracellular calcium (Pertwee, 2007). Some of the cannabinoid receptor agonists are capable of 
marked stereoselectivity for either receptor; this is principally due to the presence of a chiral centre 
within the compound. However, CB1 and CB2 selective agonists have been developed, examples being 
arachidonyl-2’-chloroethylamide (ACEA) and L-759633 respectively. CB1  selective agonists are 
chiefly AEA analogues and CB2 selective agonists 
9
-THC analogues (Pertwee, 1997; Howlett et al., 
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2002). The authentication of reputed cannabinoid receptor agonists is reliant upon in vivo and in vitro 
bioassays such as the mouse tetrad for CB1 receptor agonists and membrane transfection experiments 
for CB1 and CB2 receptors agonists (Pertwee, 1997). 
 
 
  
- 2
6
 - 
Cannabinoid Receptor Experiment Properties Pharmacological target Species Reference 
(-)-∆9-THC 
CB1 
In vitro displacement of 
[
3
H]CP55,940 
Ki 35.3 (nM) 
Partial agonist of CB1 and 
CB2 receptors 
Rat 
Rinaldi-Carmona 
et al. (1994) 
Pertwee (2008) CB2 Ki 3.9 (nM) 
SR141716A CB1 
Hypothermia (in vivo 
antagonism of 
WIN55212-2) 
ED50 i.p 0.11 mg 
kg
-1
 
Antagonist at CB1 Rat As above 
CBD 
CB1 
GTPγS binding 
(antagonism of EC50 of 
CP55,940) 
IC50 >30000 
(nM) 
Partial agonist at CB1 and 
CB2 receptors 
Rat 
Ryberg et al. 
(2007) 
Thomas et al. 
(2007) 
CB2 
AM251 
CB1 GTPγS binding 
(antagonism of EC50 of 
CP55,940) 
IC50 8 (nM) 
Antagonist at CB1 Rat 
Ryberg et al. 
(2007) CB2 IC50 2915 (nM) 
ACEA CB1 
Radioligand binding 
assay 
Ki 1.4 (nM) Agonist at CB1 Rat 
Hillard et al. 
(1999) 
ACEA CB2 
Radioligand binding 
assay Ki 3.1 (µM) 
Agonist at CB1 Rat 
Hillard et al. 
(1999) 
 
Table 1.1 The pharmacology of selected cannabinoids at the CB1 and CB2 receptors.  
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Cannabinoid Receptor Experiment Properties Pharmacological 
target 
Species Reference 
CBD GPR55 
GTPγS binding 
(antagonism of EC50 
of CP55,940) 
IC50 445 (nM) 
Antagonist at 
GPR55 
Rat 
Ryberg et al. 
(2007) 
AM251 GPR55 
GTPγS binding 
(antagonism of EC50 
of CP55,940) 
 Agonist at GPR55 Rat 
O-1602 GPR55 GTPγS binding EC50 1.4 (nM) Agonist at GPR55 
HEK293 cells 
expressing GPR55 
Johns et al. (2007) 
 
Table 1.2 Pharmacology of selected cannabinoids at the GPR55. 
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1.7.9 Antagonists 
 
Some notable competitive, surmountable antagonists of the cannabinoid receptors have been 
identified. Among those are SR141716A, WIN 56,098, AM251 and AM630, of which some have 
receptor selectivity (Pertwee, 1997; Howlett et al., 2002; Pertwee, 2006).  
 
The first cannabinoid receptor antagonist to be identified was WIN 56,098 after it was shown that this 
compound antagonises WIN 55212-2-induced inhibition of cAMP generation. Subsequently, 
SR141716A demonstrated [
3
H] CP 55,940 displacement from cannabinoid receptors; furthermore this 
compound was shown to inhibit typical cannabinoid-induced effects (Pacheco et al., 1992; Rinaldi-
Carmona et al., 1994; Pertwee, 1997). Curiously however, later publications reported that SR141716A 
produced effects opposite to those expected of a cannabinoid agonist at CB1 receptors, a response 
characteristic of an inverse agonist. It was further proposed that the CB1 receptor must exist in a 
constitutively active state, capable of downstream signal transduction despite the absence of an agonist 
and that SR141716A must bind and induce the receptor to assume a constitutively inactive state 
(Milligan et al., 1995; Compton et al., 1996; Pertwee, 1997; Pertwee, 2005; Pertwee, 2006). However, 
studies in models of mutant CB1 receptor and CB1 transfected endocannabinoid-free Chinese hamster 
ovary (CHO) cells, have shown that some of the inverse agonist effects of SR141716A occur 
independently of endocannabinoid activation of the receptor (Bouaboula et al., 1997; Pan et al., 1998; 
Pertwee, 2005). 
 
Selective cannabinoid receptor antagonists which block agonist induced activation of CB1 or CB2 
receptor have been developed and include AM251, the CB1 receptor selective antagonist and AM630, 
the CB2 receptor antagonist. Antagonists of cannabinoid receptors have been exploited in the clinic for 
the treatment of obesity, such as rimonabant (Despres, Golay and Sjostrom, 2005; Van Gaal et al., 
2005; Pertwee, 2006). Other selective antagonists of the CB1 receptor include, AM251 and AM281, 
whose use has also highlighted the potential for inverse agonism at the CB1 receptor. AM251 can 
induce depression of food intake in rats (McLaughlin et al., 2003; Pertwee, 2005) and AM281 can 
increase locomotor activity in mice (Cosenza et al., 2000; Pertwee, 2005). It is likely that some of the 
inverse agonist activities of these compounds are due to antagonism of the effects of endocannabinoid 
induced activation of CB1 receptors. 
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1.8 Cannabidiol 
 
CBD was first isolated in the early 1940’s yet its structure was not fully described until the early 
1960’s (Mechoulam, Parker and Gallily, 2002). This constituent of the plant Cannabis Sativa is non-
psychotropic and most abundant only after ∆9–THC and, like ∆9–THC, CBD is a classical cannabinoid 
(Pertwee, 1997, Pertwee, 2006). The structure of CBD is depicted in figure 1.3: 
  
 
HO
OH
 
 
Figure 1.3 The chemical structure of the phytocannabinoid (-)-cannabidiol. Adapted from Pertwee., 
(2007). 
 
Like many other cannabinoids CBD is a chiral molecule, the (-) (3R, 4R) enantiomer occurs naturally 
in Cannabis sativa, whilst the (+) (3S, 4S) enantiomer is a synthetic derivative. The chirality of CBD 
can affect receptor activity (Hanus et al., 2005; Pertwee, 2004). In [
3
H]CP55940 displacement 
experiments CBD was shown to displace at concentrations in the micromolar range, suggesting low 
affinity for the classical cannabinoid receptors (Showalter et al., 1996; Thomas et al., 2004; Pertwee, 
2007; Thomas et al., 2007). Indeed, CBD has been shown to antagonise CP55940-induced inhibition 
of electrically evoked contractions of vas deferens however, this antagonism occurred at 
concentrations below those required for established CB1  receptor activity (Pertwee et al., 1995; 
Pertwee et al., 2002; Thomas et al., 2004). It was concurrently recognised that CBD’s activity at the 
CB1 receptor was similar to that observed for the CB1 -selective antagonist, SR141716A (rimonabant). 
Furthermore, like rimonabant, a CB1 inverse agonist/antagonist, CBD exhibits an ability to increase 
electrically evoked contractions in mouse vas deferens (Pertwee et al., 1995; Pertwee et al., 2002; 
Thomas et al., 2004; Thomas et al., 2007). Therefore, despite brief confusion regarding whether CBD 
could indeed act at classical cannabinoid receptors, evidence to date infers that CBD can act as a non-
competitive antagonist of CB1 receptors. What's more it has also been proposed that any inverse 
agonist activity exhibited by CBD is CB1 receptor-mediated following experiments which showed no 
inhibition of [
35S]GTPγS binding in untransfected CHO cells membranes compared with hCB1-CHO 
cell membranes (Pertwee, 2007; Thomas et al., 2007). With regard to CB2 receptors, Thomas et al., 
(2007) identified that in hCB2-CHO cell membranes CBD had a Ki of 4.9µM for the displacement of [-
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3
H]CP55940, furthermore CBD demonstrated inhibition of [
35S]GTPγS binding in these membranes 
similar to that of the CB2 receptor inverse agonist, SR1445283. 
 
Further putative sites of action for CBD have been identified and include; the post-synaptic 1-
adrenoceptor (at which allosteric modulation by CBD is proposed), a possible site of the dopamine D2 
receptor and the AEA membrane transporter, which results in modulation of endocannabinoid uptake 
(Bloom, 1984; Bloom and Hillard, 1985; Howlett et al., 2002; Pertwee et al., 2002; Pertwee, 2004). 
The activity of CBD at GPR55 has also been investigated and it was identified that although it does 
not affect GPR55 GTPγS binding and thus is probably not an agonist, it has the capacity to antagonise 
that action of CP55940 in the same assay. CBD was also shown to block the activation of rhoA, rac1 
and cdc42 in GPR55-expressing HEK293 cells stimulated with AEA or O-1602. Thereby, these data 
suggest a role for CBD as an antagonist at GPR55 (Ryberg et al., 2007). Finally, CBD has been shown 
to modulate the transcriptional activity of peroxisome proliferator-activated receptor gamma (PPARγ; 
O’Sullivan et al., 2006). 
 
CBD is capable of initiating a plethora of actions some of which may confer cardioprotective effects, 
for example: 
 
 Inhibition of delayed rectifier K+ channels in isolated guinea-pig ventricular myocytes. 
Derangement of potassium channel function has been implicated in the pathophysiology of 
MI-reperfusion injury (Carmeliet, 1999; Mamas and Terrar, 1998). 
 
 Further modulation of ion channel function includes that of the cardiac LTCCs, which in the 
presence of 0.32 to 3.2M CBD, have demonstrated reduced Ca2+ movement (Mamas and 
Terrar, 1998). Conversely, another group have demonstrated that CBD facilitated elevations in 
[Ca
2+
]i in hippocampal cells in a partly LTCC-dependent manner (Drysdale et al., 2006; 
Pertwee et al., 2010). Ca
2+
 overload is noted to play a significant role in the perturbation of 
normal electrophysiological properties of cardiac myocytes during MI-reperfusion injury 
(Lubbe, Podzuweit and Opie, 1992; Ugdyzhekova et al., 2001). 
 
 In in vivo models of stroke CBD was shown to reduce infarct volume, which is thought to be 
due principally to the ability of CBD to alter inflammatory cell migration. Functional inverse 
agonist activity at the CB2 receptor is acknowledged to accompany retarded immune cell 
migration to sites of inflammation (Chen and Buck, 2000; Hampson et al., 2000; Pertwee, 
2004; Pertwee, 2007).  
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 It has been found that in addition to modulating immune cell function, CBD is capable of 
modifying production and/or release of mediators of immune cell function, for example 
cyclooxygenase, lipooxygenase and inflammatory cytokines like TNF-. (White and Tansik, 
1980; Furmukong et al., 1991; Watzl, Scuderi and Watson, 1991a; Watzl, Scuderi and 
Watson, 1991b; Srivastava, Srivastava and Brouhard, 1998; Costa et al., 2002; Pertwee, 
2004). In a viral model of multiple sclerosis, CBD was shown to protect from inflammation by 
reducing expression of vascular cell adhesion molecule (VCAM) expression and cytokine pro-
interleukin-IL-1β (IL-1β) (Mecha et al., 2013). VCAM expression is significantly up-
regulated following acute MI in rats (Grieve et al., 2013). Moreover, Il-1β expression also 
increases after induction of MI in rats (Sandanger et al., 2013). Thus, the cardioprotective 
effects of CBD could be in part attributed to an anti-inflammatory action. 
 
 CBD is a potent anti-oxidant, as determined by cyclic voltammetry and through analysis of a 
spectrophotometric assay of oxidation in a Fenton reaction. Moreover, CBD has been shown 
to offer comparable protection with butylated hydroxytoluene (BHT) in a model of glutamate 
neuronal toxicity (Hampson et al., 2000; Booz et al., 2011). Generation of ROS occurs during 
MI and it is thought that the accumulation of ROS and opening of the mPTP upon reperfusion 
may be key protagonists in reperfusion-induced myocardial injury (Halestrap, Clarke and 
Khaliulin, 2007; Santos et al., 2011). 
 
 The endogenous autocoid adenosine plays a significant cardioprotective role during both 
ischaemia and reperfusion by impeding development of necrosis and moderating endothelial 
cell injury, effects mediated by A1, A2 or A3 receptors (Olafsson et al., 1987; Babbitt, Virmani 
and Forman, 1989; Pitarys et al., 1991; Zhao et al., 1993; Jordan et al., 1997).  Durst et al. 
(2007) postulated that the cardioprotective effect of CBD observed after left anterior 
descending (LAD) coronary artery ligation was conferred by the adenosine receptors. 
Adenosine accumulates in the ischaemic myocardium and it has been suggested that its 
cardioprotective actions are the product of inhibition of neutrophil migration in to the 
ischaemic and necrotic zones, inhibition of platelet aggregation and inhibition of ATP-
sensitive K
+
 channels (Cronstein et al., 1983; Cronstein et al., 1989; Engler et al., 1986; 
Kitakaze et al., 1991; Gross and Auchampach, 1992; Toombs et al., 1992; Zhao et al., 1993). 
CBD has been shown to transactivate adenosine receptors and thus enhance adenosine 
signalling which could be cardioprotective (Wainwright and Parratt, 1993; Mecha et al., 
2013). 
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 CBD has been established as being a modulator in endocannabinoid signalling. CBD can 
inhibit both hydrolysis and uptake of the endocannabinoid, AEA, which has been shown to 
induce a triphasic change in cardiovascular parameters (Bisogno et al., 2001; Malinowska, 
Kwolek and Gothert, 2001; Ross, 2003). 
 
 CBD has been demonstrated to protect against serum-deprived cell death at submicromolar 
concentrations. This action is thought to be brought about by antioxidant-based mechanisms 
(Chen and Buck, 2000), which would prove beneficial following the burst of oxygen free 
radicals that occurs immediately upon reperfusion (Kloner, Przyklenk, and Whittaker, 1989). 
 
Durst et al. (2007) demonstrated that CBD can reduce infarct size and also ameliorate reduction in left 
ventricular function following the induction of experimental occlusion. They noted that the reduction 
in infarct size was accompanied by a reduction in inflammatory cell migration to the area at risk. 
Furthermore, studies from our laboratory have demonstrated that acute administration of CBD is 
significantly anti-arrhythmic when given prior to the induction of coronary occlusion (Walsh et al., 
2010). In a model of diabetic cardiomyopathy in mice, Rajesh et al. (2010) showed that chronic CBD 
treatment has the capacity to reduce cardiac dysfunction, fibrosis, ROS formation and NF-ΚB 
activation.  Most recently, it was shown that CBD can ameliorate cardiotoxicity induced by 
doxorubicin (Fouad et al., 2013). This cardioprotection is thought to be afforded by reducing 
inflammatory mediators like TNFα, preventing the reduction of vital components of cardiac 
antioxidant reserves like selenium and zinc, and finally by stabilising [Ca
2+
]i. Moreover, CBD has 
been shown to be safe during chronic use and it has no detrimental effects on cardiovascular 
parameters (Bergamaschi et al., 2011; Martin-Santos et al., 2012; Fouad et al., 2013). Moreover, it can 
induce vasorelaxation in pre-constricted human arterial segments (Stanley and O’Sullivan, submitted 
for publication, see Stanley et al., 2013). Although there is evidence to suggest a cardioprotective role 
for CBD, there remains no firm consensus as to which receptors CBD may confer its effects through. 
It may be possible that the cardioprotective effects of CBD may be owed to the antagonism of CB1 
receptors and thereby, preferential activation of infarct sparing CB2 receptors by upregulated 
endocannabinoids (whose synthesis and degradation is modulated such that concentrations are 
increased;  Hajrasouliha et al., 2008; Kourliouros et al., 2009;  Lim et al., 2009; Barana et al., 2010). 
 
1.9 The endocannabinoid system and the cardiovascular system 
 
As discussed earlier in this chapter (sections 1.7.2 and 1.7.3), CB1 and CB2 receptors are expressed in 
healthy myocardium (Weis et al., 2010). Recently, discussion regarding the modulation of the ECS as 
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a potential target for the pathologies of the cardiovascular system has increased (Batkai and Pacher, 
2009; Montecucco and Di Marzo, 2012; Tuma and Steffens, 2012; Stanley et al., 2012; Pacher and 
Kunos, 2013; Pertwee, 2013). Functional ablation of the ECS in healthy animals produces little 
functional effect and therefore suggests that the ECS contributes little to normal physiological function 
(Pacher, Batkai and Kunos, 2006; Pacher and Mechoulam, 2011; Pacher and Kunos, 2013), moreover, 
the ECS produces endocannabinoids in response to pathophysiological stimuli. Initiators of such 
synthesis include; oxidative stress and inflammation, conditions apparent during episodes of 
tachyarrhythmias. Interestingly, neuronal tissues which contain excess [Ca
2+
]i and are highly 
stimulated, are also characterised by upregulated endocannabinoid synthesis, an environment 
classically perpetuated during instances of atrial fibrillation (Kourliouros et al., 2009; Barana et al., 
2010). The haemodynamic effects of cannabinoids are less apparent in conscious animals except in 
conditions of hypertension (Gardiner et al., 2002; Batkai et al., 2004; Wheal et al., 2007). This would 
again suggest that in pathological conditions the ECS may play an important role in cardiovascular 
function.  Endocannabinoid function with respect to hypotension can have significant implications in 
the pathogenesis of some cardiovascular conditions, for example, the AEA generated by macrophages 
and the 2-AG generated by platelets in rats suffering from shock can induce hypotension when 
administered to healthy rats. Thus, suggesting that the endocannabinoids produced by these cells can 
contribute to shock-induced hypotension (Wagner et al., 1999). Given the potential role that 
endocannabinoids play in the exacerbation of cardiovascular pathologies it is important to give due 
consideration to their investigation of their involvement in such conditions and also the effects on 
normal physiological function. Moreover, even in healthy animals, the activation of CB1 receptors 
induces negative ionotropy (Pacher et al., 2008). Agonism of the CB2 receptor by HU-210 has been 
shown to reduce the area of necrosis and confers anti-arrhythmic effects following experimentally-
induced ischaemia (Krylatov et al., 2001; Ugdyzhekova et al., 2001; Ugdyzhekova et al., 2002; Durst 
et al., 2007). In preclinical studies and in clinical trials, the selective antagonism or inverse agonism of 
CB1 receptors improved cardiovascular risk factors in obese individuals (Despres, Golay and 
Sjostrom, 2005; Van Gaal et al,. 2005; Scheen et al., 2006; Nissen et al., 2008; Rosenstock et al., 
2008; Despres et al., 2009; Hollander et al., 2010; Pacher and Kunos, 2013). Thus, both of the 
cannabinoid receptors have been shown to play a role in the modulation of cardiovascular function in 
health and disease.  
 
1.10 Statement of aims 
 
It is clear that the diverse pharmacology of CBD may grant some cardioprotective effects, however as 
yet the clear mechanisms of these reputed benefits are not established. Thus, the aim of this project is 
to further characterise the cardioprotective mechanisms of CBD. 
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The specific objectives of this project were to: 
 
(a) Better understand the pharmacology of CBD by investigating the effect of bolus CBD 
administration on haemodynamic variables in vivo by pharmacological manipulation of the 
CB1 and GPR55 receptors; 
 
(b) Investigate and identify the receptors involved in the anti-arrhythmic effects of CBD in acute 
MI; 
 
(c) Determine whether the cardioprotective effects of CBD are mediated by modulation of [Ca2+]i 
at the level of the cardiomyocyte. 
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2. General Methods 
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2.1 In vivo studies 
 
All in vivo studies were carried out in accordance with the Animal (Scientific Procedures) Act 1986 
under personal licence number 60/1116. Animals were maintained to standards set out in the Home 
Office Code of Practice for the Housing and Care of Animals used in Scientific Procedures (Part 1, 
Section 2). They were housed in a specific pathogen-free facility, in conventional open caging, with a 
12 hour light/dark cycle and had access to CRM pelleted diet (SDS diets, Essex, UK) and water ad 
libitum. Animals were accommodated in groups not exceeding 4 animals per cage and their 
environment enriched with corn cob, paper wool and a play tunnel. The temperature range in which 
they were accommodated was 19-22°C and humidity of 55 ± 10%. Animals were obtained on a daily 
basis from the Medical Research Facility (Aberdeen University) and transferred to the short-term 
holding facility within the Robert Gordon University. Animals did not undergo any experimental 
procedure until a 30 minute acclimatisation period had elapsed.  
 
2.2 Surgical procedure 
 
Animals were anaesthetised via intraperitoneal injection of sodium pentobarbital salt (60mg kg
-1
), with 
maintenance of anaesthesia via bolus intravenous injection (3-4mg kg
-1
). The necessity for 
administration of maintenance anaesthesia was determined by assessment of the pedal withdrawal 
reflex, with return of this reflex indicative of requirement for anaesthetic top-up. The assessment of 
the animal’s reflex responses was carried out every 15-30 minutes. The left carotid artery and right 
jugular vein were isolated by blunt dissection using forceps and cannulated with portex polythene 
tubing (0.58mm ID x 0.96mm OD: Smiths Medical International Ltd., Kent, UK) to permit 
measurement of arterial blood pressure and drug administration, respectively. The arterial cannula 
contained heparised saline (NaCl; 40U ml
-1
) and the venous cannula, saline (NaCl).  A tracheostomy 
was also performed to allow artificial respiration on room air (54 strokes min
-1
, volume 1.5ml 100g
-1
) 
in order to maintain blood pCO2, pO2 and pH within physiological limits (18-24mmHg; 100-
130mmHg and 7.4, respectively; Harvard small animal respiration pump, Harvard Apparatus Ltd, 
Kent, UK). Mean arterial blood pressure (MABP) was recorded from the left carotid artery using a 
physiological pressure transducer (MLT844 physiological pressure transducer; ADIntruments, 
Oxfordshire, UK) and calculated using the following equation: 
 
                                             
Equation 2.1 Equation for the calculation of MABP 
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Heart rate (HR) was calculated from a lead I ECG recorded from subcutaneous limb electrodes. Both 
MABP and HR data were relayed to the LabChart software (ADInstruments, Oxfordshire, UK) from 
the transducer via a bridge amplifier and Animal Bio Amplifier (ADIntruments, Oxfordshire, UK). 
Body temperature was monitored by a digital rectal thermometer and maintained at 37-38°C by way of 
a Vetcare heat pad (Harvard Apparatus Ltd, Kent, UK). 
 
2.2.1  Surgical procedure for experimental coronary artery occlusion 
 
Following completion of the basic surgery described in section 2.1, animals were prepared for in vivo 
experimental coronary artery occlusion (CAO), as previously described by Clark et al. (1980). In brief, 
the thorax was opened by performing a left thoracotomy between the third and fourth intercostal 
spaces, 2mm from the border of the sternum. The incision was then extended by cutting the third and 
fourth ribs, before the pericardium was removed by way of passing blunt dissection forceps carefully 
around the borders of the heart. The heart was then gently excised from the pericardium and 
externalised from the chest cavity, by application of gentle pressure to the right side of the chest and 
pushing the left side of the chest under the heart by means of forceps. A reverse cutting needle 
attached to silk suture (6/0, 11mm, 3/8c reverse cutting needle, Ethicon, Edinburgh, UK) was then 
passed around the left coronary artery, 3-4mm distally from its egress from the aorta, at the point distal 
to its emergence from the left atrial appendage. Subsequent to occlusion of the ligature, the heart was 
replaced in the chest cavity and the animal was allowed 25 minutes to stabilise before commencement 
of the experimental protocol. Ischaemia was induced by placing the suture ends in a round-ended 
plastic stopper, pulled firm so that the stopper made contact with the surface of the myocardium and 
secured in place using an augmented pipette tip, leading to occlusion of the coronary artery (Figure 
3.1). Regional ischaemia was induced for 30 minutes; successful ligation of the coronary artery was 
confirmed by an increase in amplitude of the ECG, specifically the QRS complex, coupled with a fall 
in MABP. Any animal that experienced dysrhythmia or a MABP of less than 70 mmHg during the 
stabilisation period was excluded from further study. Cardiovascular variables were monitored 
throughout the protocol. Following completion of the experimental protocol, animals were terminated 
by anaesthetic overdose of sodium pentobarbital salt. 
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  Figure 2.1 Occlusion device schematic 
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2.2.2 Analysis of haemodynamic responses 
 
Haemodynamic responses to both occlusion and bolus drug administration were recorded using 
LabChart software, the data being relayed to this by way of a pressure transducer connected to an 
arterial cannula. To fully quantify both the magnitude and duration of the blood pressure changes, area 
under the curve analysis was performed on the 120 seconds pre- and 300 seconds post-bolus drug 
administration. 
 
2.2.3 Analysis of ventricular arrhythmias 
 
Ventricular arrhythmias were analysed according to the Lambeth Conventions (II): guidelines for the 
study of animal and human ventricular and supraventricular arrhythmias (Walker et al., 2013). A 
ventricular arrhythmia was defined as being a ventricular premature beat (VPB) which appears as an 
isolated premature QRS complex devoid of the accompanying P wave. A salvo referred to two 
(couplet) or three (triplet) consecutive VPB’s. A succession of four or more VPB’s, was defined as 
VT. The presence of VT was also associated with a slight fall in MABP (the BP trace remained 
pulsatile) and a HR which exceeded 500 beats min
-1
. The occurrence of VF was defined as a lack of 
definable QRS complexes which tended to be associated with a precipitous fall in MABP to 0 mmHg. 
Arrhythmias were quantified as single VPB’s, salvos, VT, total VPB’s and total percentage incidence 
of both reversible and irreversible VF (r.VF and ir.VF, respectively). The distribution of arrhythmias 
occurring over the entire ischaemic period was also quantified. The incidence of arrhythmias that 
occurred over the entire ischaemic period was recorded. 
 
2.3 Histological staining 
2.3.1 Tissue processing 
  
Following removal from the animal, whole heart tissues were fixed in ready-to-use 10% formalin 
(Shandon Formal Fixx) for 1-2 days, after which the hearts were sliced from base to apex in 2-3 mm 
slices and stored in phosphate buffered saline (PBS) at room temperature. Heart tissue samples were 
processed in cassettes through a sequence of graded alcohols, histosolve and paraffin wax using an 
autoprocessor (Citadel 1000, Thermo Shandon, Cheshire, UK) which employed the following steps: 
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Tissue processing protocol 
 
1 Absolute alcohol  (100%) 2 hours 
2 Absolute alcohol  (100%) 2 hours 
3 Absolute alcohol/Histosolve (50:50)  1 hour 
4 Histosolve (100%) 1 hour 
5 Paraffin wax 2 hours 
6 Paraffin wax 2 hours 
 
Table 2.1 Tissue processing protocol employed for processing of tissue samples   
  
Upon completion of tissue processing, heart tissues were embedded in paraffin wax using a tissue 
embedding centre (Histocentre 2, Thermo Shandon, Cheshire, UK). 4-5 µm sections were cut from 
blocks using a microtome (Finesse 325, Thermo Shandon, Cheshire, UK). Sections were floated out in 
a tissue floatation bath at 40˚C. These sections were then mounted on superfrost glass slides (for 
standard histology; Thermo Scientific, Leicestershire, UK) or polysine adhesion slides (for 
immunohistochemistry; Thermo Scientific, Leicestershire, UK). Drying was completed in a section 
dryer at 70˚C for 2-3 hours. Sections were mounted on slides at least 24 hours prior to commencement 
of histological analysis. 
 
2.3.2 Immunohistochemical staining for GPR55 
 
Detection of the presence and locality of GPR55 staining by immunohistochemistry (IHC) in 
myocardial tissue sections was completed by colleagues at AstraZeneca in Molndal, Sweden.  
In brief, sections were cut (3-4 µm) from wax-embedded myocardial blocks, prepared as detailed in 
section 2.3.1, before being mounted on SuperFrost Ultra Plus adhesion slides (Thermo Scientific, 
Germany). Drying was completed at 60°C for 30-60 minutes. The IHC protocol described in the 
subsequent paragraph was completed in the automated IntelliPATH Flex Immunostainer (Biocare 
Medical, Concord, USA). Antigen unmasking was completed with the aid of a pressure cooker and 
DIVA decloaker and was completed in 5 minutes, followed washing with TBS automation wash 
buffer (TBS buffer). Non-specific antigen binding by the primary antibody was prevented using 
Peroxidazed 1, which quenched endogenous peroxidise activity, for 5 minutes, followed by the 
universal blocking reagent, Background Sniper, for 10 minutes. Each of these steps was succeeded by 
a wash in tris buffered saline (TBS) buffer solution. Following completion of the blocking steps, the 
slides were subject to incubation with the primary rabbit polyclonal antibodies directed to GPR55 (LS-
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A162 and LS-A6817) for 1 hour. Once incubation with the primary antibody was complete, slides 
were washed in TBS buffer before continuing with primary antibody detection using the MACH 3 pre-
prepared, biotin-free, micro-polymer detection kit; the first step using a horseradish peroxidise (HRP) 
probe lasted 10 minutes, with subsequent incubation with a HRP polymer for 10 minutes, each 
incubation with the detection kit called for TBS buffer washes to be completed twice. The chromogen 
used was Betazoid DAB chromogen kit and incubation with this agent persisted for 5 minutes, 
followed by rinsing in distilled water. Counterstaining was completed by addition of Tachas 
haematoxylin for 5 minutes. Following counterstaining, sections were dehydrated and cleared as 
described in  
Table 2.2, before being permanently mounted in Mountex Mounting Medium and viewed at between 
x5 and x40 magnification. In these studies, positive controls were employed and in this instance, 
pancreatic tissue samples used. The negative control involved substituition of the MACH detection 
system with buffer. This aided in identifying any non-specific secondary antibody binding to tissue 
samples. 
 
Dehydration and clearing protocol for GPR55 IHC 
 
1 80% Alcohol 2 min 
2 95% Alcohol 2 min 
3 99.5% Alcohol 2 min 
4 99.5% Alcohol 2 min 
5 Xylene 5 min 
6 Xylene 5 min 
 
Table 2.2 Dehydration and clearing protocol employed by AstraZeneca in IHC for GPR55 
 
2.4 Cardiomyocyte isolation 
2.4.1 Preparation of cell extracts from adult rat ventricles 
 
Those animals from which tissues were to be harvested for either histological analysis or isolation of 
cardiomyocytes, were euthananised under Schedule 1 by CO2 asphyxiation, followed by cervical 
dislocation. The hearts were rapidly excised and the aorta cannulated before being mounted on the 
self-contained Langendorff apparatus (ML176 V; ADInstruments, Oxford, UK). The method used for 
enzymatic dispersion was an adaptation of a method described by Bates and Gurney, (1999). In brief, 
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retrograde perfusion at  37°C and a rate of 12ml min
-1
 was initiated with a nominally Ca
2+
-free buffer 
solution ( 
Table 2.3).  
 
Nominally Ca2+-free buffer 
 
 NaCl 120mM 
 KCl 5.4mM 
 MgSO4 5mM 
 Na-Pyruvate 5mM 
 Glucose 20mM 
 Taurine 20mM 
 HEPES 10mM 
 Distilled water 1000ml 
 pH 6.96 
 
Table 2.3 Composition of nominally Ca
2+
-free buffer solution for cardiomyocyte isolation 
 
This ensured that any residual blood was washed from the coronary vasculature, allowing the 
subsequent, enzyme-containing solutions, to fully perfuse the tissues via the coronary circulation.  
After 6 minutes, the buffer solution was changed to nominally Ca
2+
-free buffer solution containing 
proteinase (4u ml
-1
; Type XXIV), for 3 minutes, followed by perfusion with a nominally Ca
2+
-free 
buffer solution containing collagenase (0.3mg ml
-1
; Type II from Clostridium histolyticum) and 
hyaluronidase (0.6mg ml
-1
; Type I-S) for 11 minutes. The hearts were then removed from the 
Langendorff apparatus, the atria removed and discarded and the ventricles incubated twice in 
collagenase (0.3mg ml
-1
; Type II) at 37°C for 10 minutes. The tissue was then washed in Krebs-
Henseleit buffer solution to prevent continued digestion and finely minced with a scalpel and stored at 
37°C in Krebs-Henseleit buffer solution until required for loading with fluorescent dye ( 
Table 2.4). All buffer solutions used in the preparation of cell extracts were oxygenated with 95% 
O2/5% CO2. 
  
 - 43 - 
 
Krebs-Henseleit buffer solution 
 
 NaCl 120mM 
 KCl 2.5mM 
 MgCl2 2.5mM 
 NaH2PO4 0.5mM 
 KH2PO4 0.5mM 
 NaHCO3 15mM 
 CaCl2 1mM 
 Glucose 10mM 
 HEPES 5mM 
 Distilled water 1000ml 
 pH 7.4 
 
Table 2.4 Krebs buffer solution for cardiomyocyte isolation 
 
2.4.2 Detection of intracellular Ca2+ in isolated ventricular myocytes 
 
Intracellular Ca
2+
 was detected by observing changes in fluorescence intensity in cells loaded with the 
Ca
2+
-sensitive, cell-permeant, non-fluorescent acetoxymethyl (AM) ester of fluo-4. Once inside the 
cell, non-specific esterases cleave the lipophilic groups, which aid passage into the cell, yielding the 
green fluorescent, Ca
2+ 
indicator, fluo-4. A small sample of minced ventricular tissue was placed in a 
1.5ml micro-centrifuge tube containing 1ml of Krebs-Henseleit buffer solution and subjected to gentle 
mechanical separation by trituration with a glass-fired pipette. The cell extracts were then incubated 
with fluo-4 AM (5µM) for 30 minutes at room temperature (20 ± 3 °C). The fluorescence-labelled cell 
suspension (100µl) was then pipetted onto a cell perfusion chamber (capacity ~1ml) and mounted on 
the stage of a Leica DMI 4000B (Leica Microsystems, Milton Keynes, UK), before being washed with 
1ml of Krebs buffer. Cells were first brought into focus using phase light and since fluo-4 exhibits a 
spectral wavelength of excitation maxima of 494nm and emission maxima of 516 nm when Ca
2+
 is 
bound, cells were illuminated using the red-green-blue (RGB) filter. Dye loading between different 
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cell isolates showed slight variability, as such, conditions for optimal image capture (aperture size, 
exposure etc) were set at the beginning of each experiment and maintained for the duration. Digital 
adjustment of the fluoresced cells was made on each isolate to ensure the ideal digital output. 
 
2.5 Statistical analysis 
 
All results are presented as mean ± SEM, unless otherwise stated. N indicates the number of animals 
used and n indicates the number of cells, each is detailed in the methods section of each chapter. 
Statistical significance (P<0.05) was determined by T-tests, ANOVA and Fisher’s exact test as 
appropriate and the details are provide in the relevant methods section of each chapter. 
 
2.6 Materials 
 
For a detailed list of suppliers and preparation methods for each chemical, refer to appendix I. 
 
All of the agents used in the in vivo studies were sourced from Sigma-Aldrich (Gillingham, UK), with 
the exception of heparin from Leo Laboratories (Buckinghamshire, UK) and finally, Immu-mount 
from Anatomical Pathology International (Cheshire, UK). 
 
All chemicals for the completion of histological and immunohistochemical analyses were purchased 
from Biocare Medical (Concord, USA), with the exception of; PBS, TTC and Haematoxylin, Gill no.3 
from Sigma-Aldrich (Gillingham, UK), normal horse blocking serum, ImmPRESS reagent, rabbit IgG, 
VectaMount and Vector VIP from Vector Laboratories (Burlingame, USA), Formal Fixx and toluidine 
blue from Thermo Fisher Scientific (Leicestershire, UK), CB1 receptor primary antibody and  AKT1 
primary antibody from Abcam (Cambridge, UK), DIVA Decloaker and pertex mounting medium from 
HistoLab products (Gothernburg, Sweden), and finally, GPR55 primary antibody from MBL 
International Corporation (Massachusetts, USA).  
 
All of the agents used in the isolation and study of cardiomyocytes were from Sigma-Aldrich 
(Gillingham, UK), with the exception of fluo-4 AM which was sourced from Molecular Probes 
Invitrogen (Paisley, UK).  
All salts used in the preparation of buffer solutions were obtained from Sigma-Aldrich (Gillingham, 
UK), with the exception of NaCl and MgCl2 from Fisher Scientific (Loughborough, UK), tri-sodium 
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citrate and glucose from Fisons (Loughborough, UK), trypsin from Invitrogen (Paisley, UK), 
NaHCO3, Na-pyruvate and KOH from BDH Chemicals (Poole, UK).  
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3. Characterisation of the 
anaesthetised rat model of 
myocardial ischaemia 
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3.1 Introduction 
 
The induction of experimental MI was first reported in 1862 (Bezold and Boyemann, 1862) and since 
then advances in the technique, be it in vivo or ex vivo, have produced highly reproducible models. 
Many of these models are regarded as being realistic representatives of clinical MI and have been 
routinely used to investigate novel cardioprotective agents (Johnston, MacLeod and Walker, 1983; as 
reviewed by Mitsos et al., 2009). The parameters commonly quantified in the rat model of acute MI 
include changes in heart rate and blood pressure, size of infarcted tissue and finally, the incidence and 
development of ischaemia-induced ventricular ectopic activity.  
 
As discussed in Chapter 1, the distribution of arrhythmias over a 30 minute period of ischaemia in 
animal models is acknowledged to be bimodal and, although in close temporal association, both are 
defined by distinct phases (Clark et al., 1980). Those arrhythmias which occur in the first 10 minutes 
after ligation of a coronary artery are termed phase Ia (or immediate ventricular arrhythmias) 
arrhythmias. During phase Ia the subepicardial zones in the ischaemic myocardium have been 
demonstrated to exhibit significant diastolic bridging, indicated by fractionated ECGs and likely due to 
non-homogenous conduction, which indicates a re-entry-based mechanism of induction (Scherlag et 
al., 1970; Boineau and Cox, 1973; Waldo and Kaiser, 1973; El Sherif, Scherlag and Lazzara, 1975; 
Kaplinsky et al., 1979; Russell et al., 1984; Carmeliet, 1999). In contrast, the arrhythmias that 
characterise phase Ib (delayed ventricular arrhythmias) are devoid of the slowed conduction within 
epicardial tissues and the heterogeneity that typifies phase Ia (Kaplinsky et al., 1979; Russell et al., 
1984; Carmeliet, 1999). Phase Ib arrhythmias emerge between 12 and 30 minutes after cessation of 
local regional circulation, a time when action potentials are recovering but when ischaemic tissues 
experience significantly higher plasma levels of catecholamines. This phenomenon is induced by 
transmembrane efflux of catecholamines via the reversal of carrier-mediated transport (Schomig et al., 
1984; Carlsson, Abrahamsson, and Almgren, 1985; Schomig et al., 1987; Schomig et al., 1988; 
Schomig et al., 1991). 
 
3.2 Aim 
The aim of the experiments described herein was to perform a series of control experiments using the 
anaesthetised rat CAO model, in order to characterise the effect of acute ischaemia on haemodynamics 
and the development of ventricular ectopic activity. This data was then used to identify the most 
important variables for subsequent drug intervention experiments detailed in Chapter 5. 
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3.3 Methods 
3.3.1 Surgical procedure for experimental coronary artery occlusion 
 
Male Sprague Dawley rats (250-450g; n=11) were prepared for surgery and experimental coronary 
artery occlusion as described in sections 2.2 and 2.2.1. 
3.3.2 Assessment of haemodynamic parameters and occurrence of 
ventricular premature beats (VPBs) 
 
Haemodynamic parameters and occurrence of VPBs were monitored throughout each experimental 
protocol, as described in sections 2.2.2 and 2.2.3. 
 
3.3.3 Exclusion Criteria 
 
Any animal that displayed a starting MABP of less than 70mmHg or those animals in which 
spontaneous arrhythmias developed in the stabilisation period were discounted from analysis. 
Furthermore, any animal which experienced irreversible VF were excluded from arrhythmia 
quantification. 
 
3.3.4 Experimental Protocol 
 
Figure 3.1 illustrates the experimental protocol used in this study. All control animals were allowed a 
25 minute stabilisation period, which followed the completion of surgery but was before induction of 
coronary artery occlusion and was achieved by compressing the occlusion device against the surface 
of the myocardium (Figure 2.1). Coronary occlusion was maintained for 30 minutes, at which point 
the animals were euthanised by anaesthetic overdose. The exclusion criteria used in this study are 
defined in 3.3.3. 
 
3.3.5 Statistical analyses 
 
For the haemodynamic data, a one way ANOVA with Dunnett’s post hoc test was used to compare 
pre- and post-ligation MABP and HR to determine the effect of ligation of the LAD coronary artery. 
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Figure 3.1 Experimental protocol for the characterisation of the haemodynamic and electrocardiographic 
response to CAO in anaesthetised rats. 
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3.4 Results 
 
16 animals underwent the surgical procedure for experimental coronary occlusion.  Of these, 5 died 
prior to or during the stabilisation period either as a result of excessive post-surgery bleeding or 
premature arrhythmias and were considered technical exclusions. Of the remaining 11 animals, 3 
succumbed to post-ligation, ischaemia-induced, irreversible VF and were identified as arrhythmia-
associated mortalities. The remaining 8 animals survived the entire period of coronary occlusion and 
the resultant ischaemia-induced ventricular arrhythmias were analysed.  
 
3.4.1 Haemodynamic and electrocardiographic responses to coronary 
artery occlusion 
 
The ligation of the coronary artery resulted in an instantaneous reduction in MABP with an 
accompanying increase in the amplitude of QRS complexes as evidenced by changes in R-wave height 
and ST segment elevation. Examples of these changes in haemodynamics are shown in Figure 3.2 and 
Figure 3.3. Induction of coronary artery occlusion resulted in a fall in MABP of approximately 55%, 
from 143 ± 8 mmHg (at the end of stabilisation) to 64 ± 12 mmHg (1 minute post-occlusion; 
P<0.0001; Figure 3.4). Blood pressure showed only a partial recovery to pre-ligation values during the 
occlusion period. In contrast, coronary occlusion had little effect on HR (442 ± 19 at the end of 
stabilisation vs. 427 ± 16 BPM at 1 minute post-occlusion; Figure 3.5). 
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Figure 3.2 Baseline MABP and ECG trace. A typical example of a trace of arterial blood pressure (top 
panel) and ECG (bottom panel) in an anaesthetised rat. 
 
 
 
Figure 3.3 Ischaemia-induced changes in MABP and ECG. A typical trace example of changes in MABP 
and ECG observed on ligation of the coronary artery in an anaesthetised rat (indicated by the dashed 
line). There is a fall in MABP and an increase in the amplitude of the R wave of the ECG immediately 
upon CAO. 
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Figure 3.4 The impact of CAO on MABP. MABP was recorded throughout the surgical protocol . Data is 
expressed at mean ± SEM (n=8).  
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Figure 3.5 The impact of CAO on HR. HR was recorded throughout the surgical protocol. Data is 
expressed at mean ± SEM (n=8). 
  
 - 54 - 
 
3.4.2 Characterisation of ischaemia-induced ventricular arrhythmias 
 
Ligation of the coronary artery resulted in the development of ectopic activity within 3 minutes of 
occlusion. VPBs were defined as isolated, premature QRS complexes, devoid of an associated P wave 
and classified according to the Lambeth Conventions (Walker et al., 2013). Activity was categorised 
into single VPBs (Figure 3.6), salvos (couplets and triplets; Figure 3.7), VT (Figure 3.8) and VF 
(Figure 3.9).  
3.4.3 Quantification of ischaemia-induced arrhythmias and VF incidence 
 
Ventricular ectopic activity during a 30 minute period of ischaemia was composed of the VPBs 
defined above. However, the vast proportion of this activity occurred in the form of VT (Figure 3.10). 
Of those animals that underwent ligation of the coronary artery, 63% experienced reversible VF, and 
27% died from irreversible VF. All of those animals in which irreversible VF was observed had 
experienced a preceding reversible VF event. Total incidence of VF for this group was 73% (Figure 
3.11). The majority of ventricular ectopic activity occurred in the 7-20 minute post-occlusion period, 
with peak ectopic activity occurring 9 minutes post-ligation (242 ± 69 VPBs; Figure 3.12). 
Furthermore, the majority of arrhythmias presenting as single VPBs and salvos occurred during the 
Phase Ia period of (0-10 minutes post-occlusion) ischaemia-induced ventricular arrhythmias (979 vs. 
788 VPBs; Phase Ia vs. Phase Ib, respectively). 
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Figure 3.6 Ventricular ectopic beat (VPB). A typical trace of a series of single VPBs, as indicated by the 
arrows, with associated fall in MABP. 
 
 
 
Figure 3.7 Salvos. A typical trace showing salvos (triplet), as indicated by the black arrows, with the 
associated fall in MABP. Note the single VPBs, as indicated by the grey arrows. 
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Figure 3.8 Ventricular tachycardia (VT). A typical trace showing VT, as indicated by the arrows, with the 
associated fall in MABP. 
 
 
 
Figure 3.9 Ventricular fibrillation (VF). A typical trace showing VF, as indicated by the arrows, with the 
associated fall in MABP. VF is preceeded by a short period of VT, as indicated by the grey arrow. 
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Figure 3.10 Quantification of ischaemia-induced ventricular arrhythmias. The total numbers and types of 
ventricular ectopic activity during 30 minutes of ischaemia, following ligation of the coronary artery. Data 
is expressed as mean ± SEM (n=8).  
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Figure 3.11 Incidence of reversible VF (r.VF) and irreversible VF (ir.VF). The % incidence of r.VF and 
mortality post-ligation of the LAD coronary artery. Data is expressed as % of n (n=11). 
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Figure 3.12 Time distribution of ischaemia-induced ventricular arrhythmias. The number of VPBs 
observed over 30 minutes of ischaemia. Data is expressed as mean ± SEM (n=8). 
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3.5 Discussion 
3.5.1 Animal models of myocardial ischaemia 
 
Animal models that mimic MI can help identify the mechanistic effect of CAO, and may assist in the 
development of novel cardioprotective agents. The predominant models used to investigate MI and 
reperfusion, are the in vivo coronary artery occlusion model and the Langendorff isolated perfused 
heart model primarily in small rodents, although many more are in existence (Abarbenell et al., 2010). 
 
The in vivo coronary artery occlusion rat model, as employed in this study, has significant advantages 
over in vitro models in that it allows for the systemic responses to the trauma of ischaemia and 
reperfusion to be quantified.  For example, use of an in vivo model allows the sampling of circulating 
blood for the analysis of platelet aggregability or the quantification of inflammatory cell infiltration 
(Verdouw et al., 1998; Black, 2000; Vidavalur et al., 2008; Abarbanell et al., 2010), in addition to 
quantification of the occurrence of ischaemia and reperfusion-induced ventricular arrhythmias. In 
these present studies the rat was employed for two reasons; firstly because a previous study in our 
laboratory investigating the potential anti-arrhythmic effects of CBD was performed in rats (Walsh et 
al., 2010), thus allowing direct comparison with the intervention studies in this thesis; second, the rat 
represents a consistently reliable model of ischaemia-induced arrhythmias because of the inherent 
absence of extensive coronary collaterals, thereby ensuring severe ischaemia in the myocardium 
downstream of the ligation site (Johns and Olson, 1954). The ex vivo Langendorff isolated heart 
model, the antecedent of which was developed in 1866 (as reviewed by Skrzypiec-Spring et al., 2007; 
Zimmer, 1998), relies upon retrograde perfusion of the heart with physiological solution (e.g. Krebs 
Henseleit buffer) through an aortic cannula. Pressure transduction by way of the intraventricular 
balloon allows for quantification of pressure related-parameters; left ventricular developed pressure, 
end diastolic pressure, contraction rate and relaxation rate. In this model either global or regional 
ischaemia can be induced in a system devoid of systemic influences (Abarbenell et al., 2010). With 
respect to this study, the in vivo coronary artery occlusion model was utilised, because it was 
important to maintain influences of the systemic circulation and central and autonomic nervous 
systems because cannabinoids receptors are present at these sites in addition to on cardiomyocytes 
themselves and we were not sure where the cardioprotection afforded by CBD was a local or more 
systemic effect in the outset. 
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3.5.2 Study findings 
 
As part of this study it was necessary to first characterise the response to coronary artery occlusion in 
the anaesthetised rat since the severity of arrhythmias can vary from operator to operator. Ligation of 
the left anterior descending coronary artery resulted in a significant fall in MABP (55%) when 
compared with the MABP of the stabilisation period. The same effect was not observed with respect to 
HR. With respect to MABP, these data are consistent with previously published studies e.g. Clark et 
al. (1980) who, during development of this model of coronary artery ligation, observed a significant 
fall in MABP, with negligible effects observed on pre- vs. post-ligation HR. This is further 
substantiated by other published data (Johnston et al., 1983), and these data are consistent with results 
from other studies performed in this laboratory (Walsh et al., 2009; Walsh et al., 2010). The 
mechanism of the fall in MABP upon ligation of a coronary artery is most likely due to a decrease in 
stroke volume due to a decreased force of contraction induced by the ion perturbations. 
 
Arrhythmias occurring following ligation of the coronary artery were quantified by type and a vast 
proportion of the arrhythmias observed in the 30 minute occlusion period occurred in the form of VT. 
These data are in concordance with existing literature (Johnston et al., 1983; Crockett et al., 2000; 
Canyon and Dobson, 2004; Kloner et al., 2011). The mechanism of genesis of VT is postulated to be 
reentry. Within 15 to 30 seconds following induction of ischaemia, electrophysiological perturbations 
begin to manifest. Observable ECG changes at this time include depression of the TQ segment and 
elevation of the ST segment. The events hypothesised to engender these perturbations are of a 
metabolic and ionic origin, for example; extracellular accumulation of K
+
, intracellular proton 
accumulation, intracellular Ca
2+
 overload, fatty acid accumulation and augmented circulating 
catecholamine concentrations (Corr and Sobel, 1979; Hirche et al., 1980; Janse and Kleber, 1981; 
Nayler, 1981;  Kanayama et al., 1982; Sugiyama et al., 1982; Weiss and Shine, 1982; Kodama et al., 
1984; Fozzard and Makielski, 1985;  Reimer and Ideker, 1987). 
 
Ligation of the coronary artery also induced VF, the total incidence of which was 73%. This is 
corroborated by the study by Canyon and Dobson (2004), which presented an incidence of 75% VF in 
the control group, although this group observed an incidence of irreversible VF of 58% whereas in this 
present study the incidence of irreversible VF was recorded as 27%. Mortality from VF is, however, 
variable across studies and has been reported to range between 5 and 46% (Crockett et al., 2000; 
Johnston et al., 1983; Philp et al., 2006). Mortality as a result of irreversible VF has previously been 
identified as being correlated with HR, in as much as HR was higher in those animals that experienced 
irreversible VF compared with those that did not (Bolli, Fisher and Entman, 1986). No such 
correlation was observed in our study (455 vs. 492 BPM; rats with irreversible VF vs. those without). 
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This correlation, in terms of HR and VF incidence, is clearer in dogs than in rats (Johnston et al., 
1983; Bolli et al., 1986). The incidence of reversible VF (rat hearts can spontaneously revert to sinus 
rhythm) observed in this study was 63%, which is slightly greater than observed in comparable 
studies, where reversible VF incidence was found to be between 42% and 55% (Johnston et al., 1983; 
Crockett et al., 2000; Philp et al., 2006). Variability in the incidence of reversible VF may be due, in 
part, to operator dependent differences in placement of the ligature, since a ligature placed higher will 
increase the area at risk and concurrently the incidence of VF. In this study, death due to surgery, be it 
excessive post-surgery bleeding or premature coronary occlusion induced by trauma during ligature 
placement, was greater (31%) compared with a similar experimental procedure employed by Johns 
and Olson (1954), in which they observed an incidence of operative deaths of 21%. 
 
Induction of experimental MI resulted in the onset of a relatively intense period of ventricular ectopic 
activity, which typically occurred around 5 minutes after cessation of regional coronary circulation, 
which is consistent with previous studies (Philp et al., 2006). A small burst of ectopic activity was also 
observed within the first minute of ligation; however, it is more likely that this arrhythmic activity is 
induced by the mechanical ligation process, as opposed to early onset of ischaemia-induced 
arrhythmias. Peak ectopic activity was observed between 7 and 20 minutes post-ligation. Indeed, these 
results are similar to that observed in comparative studies. In the anaesthetised rat model established 
by Clark et al. (1980), onset of ventricular ectopic activity was observed from 5 minutes after 
induction of ischaemia. Furthermore, peak arrhythmias in the study were observed to occur between 4 
and 18 minutes after ligation. The slightly later onset of peak activity observed in the present study 
when compared with the Clark et al., (1980) study may purely be a result of operator dependent 
differences in technique. As with previous studies (Clark et al., 1980; Johnston et al., 1983), 
ventricular ectopic activity was evident in both phase Ia and phase Ib, the former having an 
electrophysiological mode of onset and the latter, brought on by a flux in circulating catecholamine 
concentrations (Kaplinsky et al., 1979; Janse and Kleber, 1981; Russell et al., 1984). 
 
There are two distinct phases of ventricular arrhythmia following acute ischaemia and each phase, 
although temporally related, is distinct in aetiology. These phases, termed phases Ia and Ib are 
separated by a period free of VPBs (Harris, 1948). This period of quiescent ectopic activity was not 
observed in this study, with arrhythmias being recorded during both phases. This may be in part due to 
the distribution of arrhythmias into distinct phases being more evident in the dog, than rat (Kaplinsky 
et al., 1979; Russell et al., 1984; Janse et al., 1999).  
 
In summary, these preliminary experiments have shown that in response to ligation of the left anterior 
descending coronary artery in anaesthetised rats, there is an immediate fall in MABP and the onset of 
ventricular ectopic activity within minutes post-occlusion, the severity/magnitude of both being 
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similar to those reported previously in the literature. Moreover, this same model has been shown to be 
sensitive to arrhythmia suppression by cannabinoid agents. Thus, it was confirmed that the model was 
a suitable method for subsequent experiments assessing the effect of cannabinoid drug interventions 
on ventricular arrhythmias. 
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4. Characterisation of the 
pharmacology of CBD in 
vivo  
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4.1 Introduction 
4.1.1 The complex haemodynamic responses to cannabinoids 
 
In addition to the well-documented psychotropic effects of cannabinoids, they can also cause complex 
changes in blood pressure (BP) which are dependent on; species, cannabinoid and type of anaesthesia 
(Malinowska, Baranowska-Kuczko and Schlicker, 2011). What is more, the endogenous cannabinoids, 
AEA and 2-AG, and the cannabinoid receptors (CB2 and CB2) have been identified as potential 
mediators of the pathogenesis of several cardiovascular conditions, namely, hypertension and 
atherosclerosis and myocardial infarction (Batkai and Pacher, 2009; Malinowska, Baranowska-
Kuczko and Schlicker, 2011). Given the BP changes induced by cannabinoids and the potential role 
endocannabinoids play in cardiovascular disease, the ECS has become a source of interest with respect 
to treating pathologies of the cardiovascular system. 
 
In anaesthetised rats, the endocannabinoid AEA, when administered by I.V. bolus injection, causes 
triphasic changes in cardiovascular parameters (Malinowska, Baranowska-Kuczko and Schlicker, 
2011). Specifically, transitory bradycardia and associated hypotension with a successive pressor 
response and finally, a protracted depression of BP (Jarisch and Richter, 1939; Szolcsanyi et al., 1991;  
Varga et al., 1995; Lake et al., 1997; Malinowska, Kwolek and Gothert, 2001; Hogestatt and 
Zygmunt, 2002; Wheal et al., 2007).  
 
The triphasic changes in cardiovascular parameters have been shown to be mediated by different 
receptors. Phase I is defined by a pronounced but transient bradycardia and fall in BP (also known as 
the Bezold Jarisch reflex; Lupinski et al., 2011), which is coupled with a fall in cardiac contractility 
and an increase in TPR. This phase was shown to be absent in TRPV1
-/-
 mice (Pacher et al., 2004), can 
be blocked by a selective TRPV1 receptor antagonist and induced by a TRPV1 agonist (Malinowska 
et al., 2001; Pacher et al., 2004), suggesting that this phase was induced by activation of the vanilloid 
TRPV1 receptor (Malinowska, Baranowska-Kuczko and Schlicker, 2011).  
 
Phase II of the triphasic changes induced by bolus AEA administration consists of a brief pressor 
response which is not a causal effect of the preceding hypotension of phase I (Varga et al., 1995; 
Kwolek et al., 2005), but more likely partially due to activation of TRPV1 receptors as it was again 
shown to be absent in TRPV1
-/-
 mice. Additional receptors have also been implicated in the mediation 
of phase II, including the L-type Ca
2+
 channel (Kwolek et al., 2005; Malinowska, Baranowska-Kuczko 
and Schlicker, 2011). 
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It has been shown that the main mechanism responsible for the prolonged hypotension which 
characterises phase III is activation of the CB1 receptor, as there was attenuation of the hypotension in 
CB1
-/-
 mice (Jarai et al., 1999; Ledent et al., 1999) and following the administration of either 
rimonabant or AM251 (Varga et al., 1995; Varga et al., 1996; Vidrio et al., 1996; Lake et al., 1997; 
Malinowska et al., 2001; Kwolek et al., 2005; Zakrzeska et al., 2010; Malinowska, Baranowska-
Kuczko and Schlicker, 2012). It is thought that the CB1 receptors that mediate the phase III 
hypotension in response to AEA are presynaptic CB1 receptors located within the sympathetic nervous 
system (Varga et al., 1996; Szabo et al., 2001). However, it has also been suggested that postsynaptic 
CB1 receptors located in the myocardium induce a negative ionotropic response which may also, in 
part, mediate phase III (Bonz et al., 2003; Pacher et al., 2004; Batkai and Pacher, 2009; Malinowska, 
Baranowska-Kuczko and Schlicker, 2012). 
 
Marked differences exist in the haemodynamic responses to cannabinoids observed in rodents 
depending on whether they are conscious or anaesthetised. This is mostly due to the prevailing 
inhibitory effects of anaesthesia on numerous phases of the haemodynamic response (Malinowska, 
Baranowska-Kuczko and Schlicker, 2012). In conscious rodents, there is a brief pressor response to 
AEA, with additional bradycardia and hypotension at high doses (Lake et al., 1997; Gardiner e  al., 
2001; Gardiner et al., 2002; Gardiner et al., 2009; O’Sullivan et al., 2007), while the protracted 
hypotension of phase III is absent in conscious rodents (Malinowska, Baranowska-Kuczko and 
Schlicker, 2012).  There are also significant regional differences in the haemodynamic responses to 
AEA. In rat isolated mesenteric and hepatic arteries, AEA induced vasodilatation (Zygmunt et al., 
1999), while in conscious rats, AEA produced transient vasoconstriction of renal, mesenteric and 
hindquarter vascular beds (Gardiner et al., 2002). 
 
4.1.2 Non-vanilloid, non-CB1 receptor-mediated haemodynamic responses 
 
Some cannabinoid ligands have been shown to modulate blood vessel function through sites 
independent of CB1 or vanilloid receptors (Jarai et al., 1999; Wagner et al., 1999; Ho and Hiley, 2003; 
Ho and Hiley, 2004; Johns et al., 2007; Unpublished findings Wainwright et al.).  
 
Abn-CBD, a synthetic analogue of the CBD, induces hypotension in vivo and relaxation of isolated 
blood vessels from mice devoid of the CB1 and CB2 receptors implying an action at a vascular site 
other than the ‘classical’ cannabinoid receptors (Jarai et al., 1999; Ho and Hiley, 2004). Although this 
vasorelaxation is sensitive to SR141716A, it is not sensitive to other potent CB1 selective antagonists 
such as HU-210, suggesting that this vascular site is potentially a third cannabinoid receptor (Jarai et 
al., 1999).  The recently de-orphanised GPCR GPR55 was initially purported to be the novel 
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cannabinoid receptor responsible for the vasoactive effects of abn-CBD (Hiley and Kaup, 2007; 
Ryberg et al., 2007) since the GPR55 agonist, O-1602, causes vasorelaxation through an endothelium-
dependent and SR-141716A sensitive mechanism (Jarai et al., 1999).  Furthermore, although the 
GPR55 antagonist CBD does not induce hypotension itself (Adams et al., 1977), it does inhibit the 
vasorelaxation induced by abn-CBD (Jarai et al., 1999).  However, Johns et al. (2007) cast doubt on 
the likelihood of GPR55 as the novel cannabinoid receptor having shown that I.V. administration of 
abn-CBD in GPR55
-/-
 mice resulted in a rapid hypotension akin to that in WT, controls. Furthermore, 
vasorelaxant responses to both abn-CBD and O-1602 were of similar magnitude in mesenteric arteries 
taken from GPR55
-/-
 and WT control mice. That being said, recent data from our laboratory has shown 
GPR55 receptor activation in WT mice can induce a vasodepressor response which is absent in 
GPR55
-/-
 mice (unpublished findings Wainwright et al).  Moreover, CBD induces vasodilator 
responses in isolated mesenteric arteries (Ho and Hiley, 2004), although it has no apparent 
hypotensive effect in vivo (Adams et al., 1977; Jarai et al., 1999) 
 
4.2 Aim 
 
Much of the contention around whether or not GPR55 mediates vasodepressor responses appears to 
arise from the nature of the ligands used, as it is now becoming apparent that some “selective” CB1 
ligands also possess activity at GPR55 receptors, and vice versa for GPR55 ligands (Ryberg et al., 
2007; Thomas et al., 2007). In order to better understand which receptors are involved in mediating 
the previously reported anti-arrhythmic effects of CBD (Walsh et al., 2010), this initial study was 
undertaken to clarify the cardiovascular pharmacology of CBD in vivo. To do this I investigated 
whether CBD was acting at the CB1 receptors by comparing it with a known CB1 receptor agonist 
(ACEA) both in the presence and absence of a CB1 receptor antagonist (AM251). Then to confirm 
whether, as the literature suggests, CBD acts as a GPR55 antagonist, I sought to block the effects of 
O-1602 (a proposed GPR55 agonist) with CBD.  
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4.3 Methods 
 
4.3.1 Investigation of the effect of CBD and AM251 on CB1 and GPR55 
mediated haemodynamic responses 
 
Following stabilisation, control BP and HR responses to bolus doses of ACEA (3mg kg
-1
) or vehicle 
(tween 80, dimethyl sulfoxide (DMSO) and NaCl in the ratio 1:2:8, respectively) were obtained (n=8-
14).  Once the BP had returned to normal (~25 min), AM251 (1 mg kg
-1
) was given and a response to 
ACEA obtained 10 minutes later. Following normalisation of BP, a third response to ACEA was then 
obtained following a higher dose (3 mg kg
-1
) of AM251.  In a separate group of rats (n=8) this 
protocol was repeated in the presence CBD (50µg kg
-1
), which was given 10 min prior to the 
administration of the control dose of ACEA.  As described in section 2.2 the cardiovascular variables 
of each animal were recorded throughout using LabChart 5 software. 
 
4.3.2 Investigation of the effect of ACEA and O-1602 on CB1 and GPR55 
mediated haemodynamic responses 
 
The protocol followed was as described above with the exception that O-1602 (30ng kg
-1
; chosen from 
the literature) was employed in place of ACEA  (n=4 for AM251 alone; n=6 for AM251 + CBD). 
 
4.3.3 Determination of the dose-dependent effects of O-1602 on 
cardiovascular variables 
 
In light of the finding that the dose of O-1602 employed in the experiments described above was 
insufficient to induce a marked fall in arterial blood pressure, a dose-response study of the effects of 
O-1602 (5, 15, 30, 50, 65 and 100ng kg
-1
; n=4) was performed. Intravenous bolus injections were 
given in increasing doses every 5-10 minutes (or until cardiovascular parameters had returned to pre-
injection levels) and the responses measured.  Each animal operated as its own control. 
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4.3.4 Data expression 
 
To take account for variable response times to administration of cannabinoids on MABP, 
measurements were taken from 100 seconds prior to and 300 seconds post-administration. Changes in 
MABP from baseline were calculated as % change and the time course of MABP changes were plotted 
to allow area above the curve (AAC) analysis for depressor responses. All results are presented as 
mean values ± SEM. 
 
4.3.5 Statistical analysis 
 
All % change in MABP data were subjected to analysis by two-way ANOVA followed by a 
Bonferroni post-hoc test and all comparisons were made to the control responses. All AAC analyses 
were subject to a Student’s test and comparisons were made with vehicle control responses. n indicates 
the number of animals which underwent an experimental procedure. 
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4.4 Results 
4.4.1 The effect of CB1 receptor activation on MABP and HR in vivo 
 
Bolus I.V. ACEA (3mg kg
-1
) administration produced a significant depressor response which peaked 
60 seconds after administration (7987 ± 1172 (ACEA) vs. 482 ± 108 AAC (vehicle); P<0.005; Figure 
4.1 and Figure 4.3). This effect was restricted to an effect on MABP with no observable effect on HR 
(Figure 4.2). Baseline MABP in these groups was 151 ± 3 and 134 ± 5 mmHg, vehicle control and 
ACEA, respectively. Baseline HR was 455 ± 13 and 422 ± 22 BPM, vehicle control and ACEA, 
respectively. 
 
4.4.2 The effect of AM251 on the ACEA-mediated depressor effects in 
vivo 
 
The CB1 receptor antagonist AM251 attenuated the depressor response mediated by ACEA (Figure 
4.3) in a dose dependent manner (4798 ± 1667 (1mg kg
-1
 AM251) and 1641 ± 1223 (3mg kg
-1
 
AM251; P<0.05) vs. 7987 ± 1172 AAC (Control response)).   
 
4.4.3 Investigation of the effect of CBD on CB1 receptor-mediated 
hypotension 
 
Pre-treatment with CBD appeared to ameliorate the ACEA-mediated fall in MABP, but this was not 
significant. In contrast, CBD inhibited the AM251-mediated blockade of the ACEA response (Figure 
4.4). 
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Figure 4.1 Effect of ACEA on MABP in vivo. Bolus ACEA (3mg kg
-1
) I.V administration was made at 0 
seconds. Data is expressed as  mean % change in MABP ± SEM (n= 8-14). 
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Figure 4.2 Effect of ACEA on HR in vivo. Data is expressed as mean % change in HR ± SEM (n=8-14). 
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Figure 4.3 Effect of CB1 receptor antagonism on area above curve (AAC) of MABP responses to ACEA. 
Data is expressed as mean AAC of MABP ± SEM (n=8-14). * indicates P<0.005 vs. vehicle and # indicates 
P<0.05 vs. ACEA (3mg kg
-1
).  
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Figure 4.4 Effect of CBD and AM251 alone and in combination on the depressor responses to ACEA in 
vivo. Data is expressed as mean AAC ± SEM (n=5-14). * indicates P<0.05 vs. ACEA (3mg kg
-1
) alone. 
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4.4.4 The effect of CBD on AM251-mediated hypotension 
 
AM251 alone produced no significant change in MABP. However, the presence of CBD unmasked a 
pronounced dose-dependent depressor response to AM251, which was significant at the higher dose of 
AM251 (P<0.001; Figure 4.5).  
 
4.4.5 Determination of the effect of AM251 and CBD on responses to O-
1602 
 
When tested across a wide dose range, O-1602 did not induce any changes in either MABP or HR in 
(Figure 4.6 and Figure 4.7).  Although a single bolus dose of O-1602 (30ng kg
-1
) produced a negligible 
haemodynamic response, a small depressor response was unmasked by AM251 at the highest dose 
(p=0.09; Figure 4.8). This depressor response to O-1602 was not observed when the rats were pre-
treated with CBD (Figure 4.8). 
 
4.4.6 Investigation of the effect of CBD on MABP and HR in vivo 
 
CBD itself induced a small but significant depressor response upon bolus I.V. administration (1286 ± 
324 vs. 316 ± 69; AAC; P<0.05; Figure 4.9, and Figure 4.11), whilst having no effect on HR ( 
Figure 4.10). Baseline MABP in these groups was 151 ±3 and 146 ± 5 mmHg, vehicle control and 
CBD, respectively. Baseline HR in these groups was 455 ± 13 and 413 ± 9 BPM, vehicle control and 
CBD, respectively. 
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Figure 4.5 Effect of AM251 on MABP in the presence and absence of CBD. Data is expressed as mean 
AAC ± SEM (n=7-14). * indicates P<0.001 vs. vehicle and CBD. 
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Figure 4.6 The dose-dependent effects of O-1602 on MABP in vivo. Data is expressed as mean % MABP ± 
SEM (n=4).  
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Figure 4.7 The dose-dependent effects of O-1602 on HR in vivo. Data is expressed as mean % HR ± SEM 
(n=4). 
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Figure 4.8 AAC of depressor responses induced by O-1602 in the presence of AM251 and CBD. Data is 
expressed as mean AAC ± SEM (n=3-5). 
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Figure 4.9 Effect of CBD on MABP in vivo. CBD (50µg kg
-1
) was administered as a bolus dose (I.V.) at 0 
seconds. Data is expressed as mean % change in MABP ± SEM (n=7-14).  
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Figure 4.10 Effect of CBD on HR in vivo. CBD (50µg kg
-1
)was administered as a bolus dose at 0 seconds. 
Data is expressed  as mean % change in HR ± SEM (n=7-14). 
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Figure 4.11 AAC of depressor responses to CBD in vivo. Data is expressed as mean AAC ± SEM (n=6-10). 
* indicates P<0.05 vs. vehicle.  
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4.5 Discussion 
 
This series of experiments sought to better understand the involvement of CB1 and GPR55 receptors in 
mediating changes in haemodynamic variables in vivo. In addition experiments were carried out to 
confirm that AM251 is a selective CB1 receptor antagonist and furthermore, to establish the ability of 
CBD to block GPR55. These studies sought to inform the interpretation of the studies regarding the 
potential anti-arrhythmic effects of cannabinoids described later in this thesis. The data shows that in 
the anaesthetised rat the proposed GPR55 agonist, O-1602 did not significantly affect cardiovascular 
parameters. In contrast, ACEA-induced CB1 receptor activation led to a significant depressor effect 
reversed by AM251. Administration of CBD not only abrogated the antagonistic effect of AM251 on 
ACEA-induced hypotension but also revealed an AM251-mediated depressor response which was 
absent when AM251 was administered alone. 
 
4.5.1 Activation and antagonism of CB1 receptors - the effect of MABP in 
vivo 
 
The first finding from these experiments was that the CB1 receptor agonist ACEA caused a fall in 
MABP in the anaesthetised rat while having no effect on HR, which may suggest that the former is 
due to a fall in peripheral vascular resistance (Haddy, Overbeck and Daugherty, 1968; Levick, 2003). 
Ford et al. (2002) showed that in an isolated rat heart model, bolus ACEA administration produced a 
fall in left ventricular developed pressure and coronary vasodilatation. Furthermore, Montecucco and 
Di Marzo (2012) showed that CB1 receptor activation induces transient bradycardia and hypotension. 
It has been demonstrated previously that the coronary vasodilator haemodynamic responses to ACEA 
are unaffected by a CB2 receptor agonist (JWH015) (Ford et al., 2002), however, the effect of a CB1 
receptor antagonist on ACEA-induced hypotension in vivo has not been investigated until now. The 
depressor response induced by ACEA was blocked by the CB1 receptor antagonist AM251 in a dose-
dependent manner, providing evidence that the depressor effects of ACEA are mediated by the CB1 
receptor and that AM251 is acting as a CB1 antagonist. 
 
Although classified as a GPR55 antagonist (Ryberg et al., 2007), CBD attenuated the hypotension 
induced by ACEA, although this was not statistically significant, suggesting that under the present 
experimental conditions it is exhibiting some activity as a CB1 receptor antagonist. Indeed, it has been 
shown that CBD can act as a weak antagonist and inverse agonist at the classical cannabinoid 
receptors, CB1 and CB2 in mouse brain membranes and in CHO cells stably expressing CB1 or CB2 
receptors (Thomas et al., 2007). CBD was also found to reverse the ability of AM251 to block ACEA-
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induced hypotension. Since both CBD and AM251 are pharmacologically active at CB1, it is 
conceivable that pre-treatment with CBD prevents the inhibition of ACEA-induced vasodepression by 
AM251 because the receptor site is already occupied by CBD. 
 
Interestingly, CBD itself induced a depressor response, which supports existing literature in which 
CBD was found to reduce mean, systolic and diastolic blood pressure in pithed rats (Zakrzeska et al., 
2010) and to induce vasorelaxation in rat aorta (O’Sullivan et al., 2009). This is consistent with data 
from our own laboratory which has shown that CBD induces a depressor response in both WT and 
GPR55
-/-
 anaesthetised mice (unpublished findings, Wainwright et al.), demonstrating that this effect is 
independent of an action at GPR55.  Zakrzeska et al. (2010) also investigated the involvement of CB1 
receptors and the haemodynamic responses to AEA; they found that CBD antagonised the phase III 
effects of AEA, leading to the conclusion that both AEA and CBD were acting at a non-CB1 vascular 
cannabinoid receptor.  
  
4.5.2 Determination of the involvement of GPR55 in the mediation of 
haemodynamic responses 
 
The consequences of GPR55 receptor activation with regard to blood pressure have not been fully 
characterised, although Johns et al. (2007) have shown that baseline BP and HR are not significantly 
different between WT and GPR55
-/-
 mice, suggesting that GPR55 activation does not contribute to 
normal BP control. I have shown that the selective GPR55 agonist, O-1602 produced no discernible 
change in either MABP or HR in the anaesthetised rats across a wide range of doses, suggesting a lack 
of GPR55 receptors in the vasculature and/or myocardium.  This is in contrast to the study by Johns et 
al. (2007) who found that O-1602 could reverse phenylephrine-induced tone in mouse mesenteric 
arteries. However, controversy exists regarding the ligand pharmacology of GPR55. For example, O-
1602 has been shown to increase GPR55-dependent GTPγS signalling (Johns et al., 2007) but not β-
Arrestin-2 GPR55 complex formation (Kapur et al., 2009). What is more, it is proposed that the 
primary pharmacological target of O-1602 is GPR18 and not GPR55 (McHugh and Ross, 2009). 
Although it was initially proposed that the vasoactive effects of O-1602 were mediated by GPR55, 
subsequent investigation of the pharmacology of GPR55 has led to speculation of the specificity of the 
ligands for GPR55 (Fischbach et al., 2007; Hiley and Kaup, 2007; Johns et al., 2007; Ryberg et al., 
2007; Waldeck-Weiermair et al., 2007; Kapur et al., 2009; Sylantyev et al., 2013). Therefore, it is 
possible that rather than reaching the conclusion from the present experiments that GPR55 activation 
does not induce hypotension, it might be a case that O-1602 is not causing activation of GPR55. 
 
 - 85 - 
 
In the experiments to determine the effects of AM251 on ACEA-induced depressor responses it was 
identified that AM251 caused a transient fall in MABP. Although AM251 was initially used as a 
selective CB1 receptor antagonist, since CB1 receptor activation causes a transient bradycardia and 
prolonged hypotension (Montecucco and Di Marzo, 2012), the brief depressor response observed in 
response to AM251 cannot be rationalised as a CB1-dependent effect, since CB1 receptor antagonism 
would be expected to increase rather than decrease BP.  Recent accounts of the pharmacology of this 
ligand suggest that it is not as selective as anticipated, as it is reported to possess potent agonist 
activity at GPR55 (EC50 = 39nM; Ryberg et al., 2007). Moreover, recent data from this laboratory has 
shown that, similar to the current observation in rats, AM251 induces a depressor response in WT 
mice.  The absence of a response in GPR55
-/-
 mice suggests that this effect is through an action GPR55 
(unpublished observations, Wainwright et al.).   
 
To confirm whether the transient hypotension caused by AM251 was GPR55 mediated, CBD was 
used as a GPR55 receptor antagonist.  Interestingly, when CBD was given prior to AM251, there was 
a marked potentiation of the depressor response to AM251, which based on their reported opposing 
pharmacologies at GPR55 was unexpected and this may suggest that both AM251 and CBD have ‘off 
target’ effects beyond those their initial pharmacological profiles suggested. However, CB1 receptors 
and GPR55 receptors are acknowledged to be co-localised (Kargl et al., 2012) and evidence exists in 
the literature which describes cross-talk between GPR55 and CB1 receptors, through integrin 
clustering. In particular, when the integrins are unclustered, CB1 receptor activation results in a 
signalling cascade which includes, but is not limited to, spleen tyrosine kinase (Syk), which in turn 
inhibits a key protein in the GPR55 signal transduction cascade. However, when integrins are 
clustered, Syk is no longer able to inhibit GPR55 signalling (Waldeck-Weiermair et al., 2008).  As 
such, it is feasible that instead of acting as an antagonist at GPR55, CBD is acting at CB1 receptors in 
a manner which relieves CB1-receptor mediated inhibition of GPR55, thereby unmasking a GPR55-
mediated vasodilator response to AM251. 
 
4.5.3 Summary and conclusions 
 
In summary, this series of experiments have shown that CB1 receptor activation by ACEA results in a 
significant fall in MABP which can be dose-dependently inhibited by the CB1 receptor antagonist and 
GPR55 receptor agonist, AM251. Furthermore, the data shows that both CBD and AM251 themselves 
can induce transient depressor responses by mechanisms that may be CB1 mediated and GPR55-
mediated, respectively. While the ‘selective’ GPR55 agonist, O-1602 does not induce hypotension in 
the anaesthetised rat, the lack of response may be due to the poorly defined pharmacology of this 
compound rather than an indication that GPR55 does not mediate a vasodilator response.  Finally, 
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CBD has been shown to be capable of potentiating AM251-induced hypotension, suggesting possible 
cross-talk between these two receptors. Moreover, these findings suggest that neither AM251 nor 
CBD are selective antagonists for CB1 or GPR55, respectively. 
 
Taken together these findings led to the design of the subsequent series of experiments outlined in the 
next chapter of this thesis focusing on assessing the ability of each agent, alone and in combination, 
against ischaemia-induced arrhythmias rather than using AM251 simply as a pharmacological tool to 
rule out or confirm the role of CB1 receptors in the cardioprotective effect of CBD.  
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5. Assessment of the 
effects of CBD and AM251 
on ischaemic arrhythmias 
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5.1 Introduction 
 
5.1.1 Cannabinoids and arrhythmias 
 
Cannabinoid receptors are widely expressed in a multitude of tissues, including cardiomyocytes, 
where they can inhibit activity of adenylate cyclase (AC) and synthesis of cAMP, thereby 
cannabinoids may potentially play a significant role in arrhythmia initiation and propagation (Li and 
Ng, 1984; Lubbe et al., 1992; Pacher and Hasko, 2006). The endocannabinoid, AEA has been shown 
to protect against adrenaline-induced arrhythmias in a rat model, an effect unchanged by addition of 
CB1 (SR141716A) or CB2 (SR144528) receptor antagonist (Ugdyzhekova et al., 2001). Moreover, it 
has been identified that cannabinoids are involved in mediating cardioprotection. In addition, AEA 
and its metabolically stable analogue, R-(+)-methanandamide, reduce ischaemia and reperfusion-
induced arrhythmias (Krylatov et al., 2002). More recently, Li et al. (2009 and 2012), showed that 
AEA mediates its anti-arrhythmic effects by suppressing AP duration, modulating LTCC function, 
suppressing Ito currents by a non-CB1/2-dependent pathway and finally, by increasing IKATP current by a 
CB2-dependent pathway.  
 
5.1.2 Cannabidiol and the cardiovascular system 
 
CBD, the non-psychotropic derivative of Cannabis sativa, most abundant only after ∆9-THC, was first 
isolated by Mechoulam and Shvo (1963). This phytocannabinoid has been shown to act in an 
anomalous manner at the CB1 and CB2 receptors, following observations that CBD was shown to 
produce dextral shifts in the [
35
S]
 GTPγS binding dose-response curves of CP55940 and WIN55212, 
initially indicating non-competitive antagonist-like pharmacology. It was also observed that alone 
CBD had the capacity to inhibit [
35
S]
 GTPγS binding, indicating inverse agonism at CB1 and CB2 
(Thomas et al., 2007). In addition, CBD is an inhibitor of fatty FAAH (Wantanabe et al., 1996), an 
agonist at the 5-HT1A receptor (Russo et al., 2005), and an antagonist of GPR55 (Ryberg et al., 2007). 
Although the exact pharmacology of CBD is still, as yet, not completely clear, existing evidence 
suggests that it may be tissue protective. Indeed, CBD is cerebroprotective following episodes of 
cerebral ischaemia, an effect attributed to reductions in neutrophil accumulation and inhibition of 
myeloperoxidase activity (Hayakawa et al., 2007). Furthermore, Durst et al. (2007) observed that in an 
in vivo model of MI and reperfusion, chronic CBD administration reduced infarct size. This effect was 
attributed to a reduction in inflammatory infiltration into the ischaemic and necrotic zones of the 
myocardium. Interestingly, this protective effect was not observed in a comparative in vitro model, 
further substantiating the role of systemic influences on the mediation of the observed protection.  In 
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the acute phase of in vivo MI CBD is protective inasmuch as it can reduce ischaemia-induced 
ventricular arrhythmias and reduce infarct size (Walsh et al., 2010). 
 
5.1.3 The putative cannabinoid receptor, GPR55 
 
First isolated in 1999, the GPCR receptor, GPR55 has been identified as a putative cannabinoid 
receptor (Sawzdargo et al., 1999). The GPR55 receptor demonstrates only 13.5% sequence homology 
with the CB1 receptor (Ryberg et al., 2007). Investigation of the functional fingerprints of both the 
classical cannabinoid receptors and GPR55 revealed that human GPR55 does not share a functional 
fingerprint with CB1 and CB2 receptors (Petitet, Donlan and Michel, 2006). Functional fingerprints are 
the key residues involved with dealing with the binding and/or activity of ligands. The ligands 
examined in the identification of the functional fingerprints of GPR55, CB1 and CB2 receptors were 
those purported to be active at all three receptors and as such the data would suggest that although 
GPR55 may be activated by cannabinoids, it does not possess a binding pocket similar to that of CB1 
and CB2 receptors (Petitet, Donlan and Michel, 2006). Confirmed agonists of GPR55 are 
lysophosphatidylinositol (LPI), rimonabant and AM251 (Kapur et al., 2009).  CBD can antagonise 
[
35
S]
 GTPγS binding with AEA, CP55940 and O-1602 in HEK293 cells transfected with GPR55 
(Ryberg et al., 2007). When activated GPR55 is coupled with either G13, Gq and G12 and there is a 
resultant increase in cytosolic [Ca
2+
]i in a IP3-mediated manner (Ryberg et al., 2007; Lauckner et al., 
2008; Henstridge et al., 2009; Kapur et al., 2009; Henstridge et al., 2010; Pertwee et al., 2010).  
 
It has recently been demonstrated that activation of GPR55 by the proposed endogenous ligand, LPI, 
can, in cultured ventricular myocytes, induce Ca
2+
 mobilisation via LTCCs, IP3 receptors or endo-
lyososomes, depending on the site of activation and may therefore suggest a role for GPR55 in the 
myocardium. Moreover, the LPI-induced Ca
2+
 release from endo-lysosomes requires signalling via 
NAADP and can consequently increase SR Ca
2+
 load and this may infer that the recently de-
orphanised receptor could modulate contraction of cardiomyocytes (Yu et al., 2013). Data from our 
laboratory has demonstrated that GPR55 expression or function is modified by ischaemia because LPI 
was only able to increase infarct size when global ischaemia in Langendorff perfused hearts, and not 
post-ischaemia (Robertson-Gray, unpublished). The complexity of the data so far gleaned from 
investigation of the pharmacology of GPR55 means that identification of a functional effect of GPR55 
receptor activation in the cardiovascular system more intriguing.  
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5.2 Aim 
 
Numerous studies have investigated the effects of cannabinoids in the cardiovascular system, 
including identification of the negative ionotropic effects of CB1 receptor activation (Ford et al., 2002; 
Bonz et al., 2003) and examination of the variable vasodilator effects of the endocannabinoid AEA 
(Mukhopadhyay et al., 2002; O’Sullivan et al., 2004). Moreover, AEA has been demonstrated to 
reduce arrhythmia incidence, although it is not likely that CB1 or CB2 are involved (Ugdyzhekova et 
al., 2001; Krylatov et al., 2002; Li et al., 2009; Li et al., 2012). Phytocannabinoids, like CBD, have 
also been shown to be anti-arrhythmic, although the pharmacological target is not known (Walsh et 
al., 2010). CBD has a complex pharmacology including, but not limited to, a capacity to act as an 
antagonist at the recently deorphanised GPR55, a receptor whose role in the CVS is still not clear but 
may involve modulation of Ca
2+
i handling (Ryberg et al., 2007; Yu et al., 2013).  
In the previous chapter we identified that neither CBD nor AM251 are selective antagonists for CB1 
and GPR55, respectively. Moreover, we demonstrated that AM251 appears to induce haemodynamic 
changes via GPR55 activation. Therefore, the aim of this series of experiments was to identify the 
ability of CBD and AM251, alone and in combination against ischaemia-induced ventricular 
arrhythmias. 
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 CBD AM251 
CB1 receptor Inverse agonist (Pertwee, 2003; Thomas 
et al., 2007) 
Antagonist (Pertwee, 2005) 
Antagonist (Lan et al., 1999) 
GPR55 Antagonist (Sylantyav et al., 2013) Agonist (Ryberg et al., 2007; 
Henstridge et al., 2010) 
 
Table 5.1 Pharmacological targets for CBD and AM251. 
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5.3 Methods 
5.3.1 Surgical procedure for experimental coronary artery occlusion 
 
Male Sprague Dawley rats (250-450g; n=30 before any exclusion criteria were applied) were prepared 
for surgery and experimental coronary artery occlusion as described in sections 2.2 and 2.2.1. 
 
5.3.2 Assessment of haemodynamic parameters and occurrence of VPBs 
 
Haemodynamic parameters and occurrence of VPBs were monitored throughout each experimental 
protocol, as described in 2.2.2 and 2.2.3. Quantification as described by the Lambeth conventions 
(Walker et al., 2013) was completed as described in 3.4.2. 
 
5.3.3 Experimental Protocol 
 
Figures 5.1-5.4 illustrate the experimental protocols used in this study. All animals were allowed a 25 
minute stabilisation period before bolus drug administration at 5 minute intervals. Experimental 
groups were; (i) vehicle control (n=6), (ii) CBD (50µg kg
-1
) alone (n=6), (iii) AM251 (1mg kg
-1
) alone 
(n=6), (iv) CBD followed by AM251 (n=6), and (v) AM251 followed by CBD (n=6). The vehicle 
control was a combination of the vehicles used for CBD and AM251, which was EtOH and a tween, 
DMSO, NaCl mixture (in the ratio 1:2:8), respectively. After the final administration of the vehicle 
control or drug, induction of coronary artery occlusion was commenced by compressing the snare 
against the surface of the myocardium, thereby ligating the LAD coronary artery. A timetable of drug 
treatments was prepared in advance of completion of this series of experiments in order to randomise 
the completion of each drug intervention over the duration of this series of experiments. Moreover, the 
files for each experiment were labelled by date rather than drug treatment in order to maximise 
randomization of drug interventions. 
 
5.3.4 Immunohistochemical staining for GPR55 
 
In order to identify whether GPR55 receptors were present in the rodent myocardium, colleagues at 
AstraZeneca in Molndal, Sweden performed IHC staining for its detection, as described in section 
2.3.2. Whole heart sections were fixed, processed and embedded before being cut at 3-4µm and 
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mounted on slides for IHC staining with a specific antibody directed against GPR55. The primary 
antibody, GRP55-A162T750 was diluted 1:750 using DaVinci Green Diluent before incubation with 
the myocardial sections. Staining was performed in sham (those which has undergone the full 
experimental procedure with the exception of having the heart exteriorized and ligature loosely placed 
around the LAD coronary artery) hearts, hearts subject to ischaemia by ligation of the LAD coronary 
artery and hearts subject to ischaemia but pretreated with CBD (50µg kg
-1
). 
 
5.3.5 Exclusion criteria 
 
Any animal that displayed a starting MABP of less than 70mmHg, or those animals in which 
spontaneous arrhythmias developed in the stabilisation period, were discounted from further study. 
Furthermore, any animal which experienced irreversible VF were excluded from VPB quantification 
and arrhythmia time course analysis. All data sets, once collated were subject to analysis by the 
Grubbs’ test to identify if there were any significant outliers from the rest of the data set. If a 
significant outlier was detected, it was excluded from further analysis and was not included for 
presentation in this chapter. 
 
5.3.6 Statistical analyses 
 
For analysis of haemodynamic variables, an unpaired T test was used to compare the pre- and post-
injection MABP and HR data to determine any effect of bolus administrations of the drugs. A one-way 
ANOVA with Dunnett’s post-hoc test was used to compare the pre- and post-occlusion values to 
determine the effect of ligation of a coronary artery on MABP and HR. A two-way ANOVA with 
Bonferroni post-hoc test was used to determine the effects of drug treatments on ischaemic MABP and 
HR. For the arrhythmia studies, a two-way ANOVA with Bonferroni post-hoc test was used to 
investigate the effect of drug treatment on number of VPBs in each of the quantified arrhythmia 
groups. The analysis of the drug treatment on distribution of arrhythmias in the 30 minutes ischaemic 
period was completed using a two-way ANOVA with Bonferroni post-hoc test. The Fisher’s exact test 
was used to compare the effects of the drug interventions on the incidence on VF and in comparison of 
the onset on VF following drug treatment, a one-way ANOVA and Dunnett’s post-hoc test was 
employed. 
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Figure 5.1 Experimental protocol for the characterisation of the outcome of CAO in anaesthetised rats in 
the presence of CBD (50µg kg
-1
). 
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Figure 5.2 Experimental protocol for the characterisation of the outcome of CAO in anaesthetised rats in 
the presence of AM251 (1mg kg
-1
). 
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Figure 5.3 Experimental protocol for the characterisation of the outcome of CAO in anaesthetised rats in 
the presence of AM251 followed by CBD. 
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Figure 5.4 Experimental protocol for the characterisation of the outcome of CAO in anaesthetised rats in 
the presence of CBD followed by AM251. 
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5.4 Results 
 
5.4.1 Exclusions 
 
A total of 5 animals were excluded from analysis having met the exclusion criteria. 4 animals (3 from 
vehicle control and 1 from CBD (50µg kg
-1
)) were excluded after not presenting changes in the ECG 
that indicate successful induction of MI, 1 (CBD (50µg kg
-1
)) animal was excluded on the basis of low 
pre-occlusion BP.  
Following quantification of VPBs for each experimental group, 4 animals (1 from AM251 (1mg kg
-1
), 
2 from CBD then AM241 and 1 from AM251 then CBD) were also excluded from VPB quantification 
and arrhythmia time course analysis, having developed irreversible VF. 
 
5.4.2 Haemodynamic effect of pre-ischaemic treatment with CBD and 
AM251 
 
Changes in MABP to bolus drug administration were also calculated in order to identify if any of the 
treatments significantly affected MABP in the 300 seconds post-administration (Figure 5.5 and Figure 
5.6). CBD alone caused no change in MABP post-administration (Figure 5.5). Pre-treatment with 
AM251 caused a small but non-significant fall in MABP which recovered by bolus administration of 
CBD.  
Bolus AM251 administration when given alone or when preceeded by CBD had no significant effect 
on MABP (Figure 5.6).   
 
5.4.3 Haemodynamic effects of drug intervention and coronary artery 
occlusion  
 
Occlusion of the LAD coronary artery induced an immediate fall in MABP of approximately 50% 
(115 ± 13 vs. 58 ± 13 mmHg; -25 and 1 minute, respectively; Figure 5.5 and Figure 5.6). Rats given 
CBD alone showed change (55% fall) in MABP similar to that observed in vehicle control treated 
animals following coronary occlusion (Figure 5.5). When CBD treatment was preceeded by AM251, 
the change in MABP upon CAO were similar to those seen with either CBD alone or vehicle control.  
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Post-ligation MABP recovery showed a trend toward improvement with AM251 both alone and when 
preceeded by CBD treatment (24% and 29%, respectively vs. 37%; % recovery between 1 and 30 
minutes; Figure 5.6).   
None of the treatment groups had any significant effect on HR changes observed in vehicle control 
animals (Figure 5.7 and Figure 5.8).  
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Figure 5.5 The effect of CBD, alone and in combination with AM251, on CAO-induced changes in MABP 
in anaesthetised rats. MABP was recorded prior throughout the protocol. Data is expressed as mean ± 
SEM (n= 3-6). 
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Figure 5.6 The effect of AM251, alone and in combination with CBD, on CAO-induced changes in MABP 
in anaesthetised rats. MABP was recorded throughout the protocol. Data is expressed as mean ± SEM (n= 
3-6). 
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Figure 5.7 The effect of CBD, alone and in combination with AM251, on CAO-induced changes in HR in 
anaesthetised rats.  HR was measured throughout the protocol. Data is expressed as mean ± SEM (n= 3-6). 
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Figure 5.8 The effect of AM251, alone and in combination with CBD, on CAO-induced changes in HR in 
anaesthetised rats. HR was measured throughout the protocol. Data is expressed as mean ± SEM (n= 3-6). 
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5.4.4 Effect of CBD and AM251 on ischaemia-induced ventricular 
arrhythmias 
 
Induction of experimental coronary artery occlusion induced all the forms of arrhythmic activity 
quantified in this study. This ventricular ectopic activity was present in all drug treatment groups 
(Figure 5.9 and Figure 5.10). In the vehicle control group, the majority of VPBs manifested as VT. 
None of the drug treatments had any significant effect on the number of arrhythmias which occurred 
as singles or salvos.  
 
Administration of CBD alone prior to ischaemia attenuated the number of VPBs which occurred as 
VT (715 ± 205) when compared with the vehicle control (1441 ± 1049 VPBs; Figure 5.9) and 
consequently reduced the total number of VPBs (977 ± 229 vs. 1645 ± 974 VPBs; Figure 5.9) 
although this effect was not statistically significant. When bolus CBD administration was preceeded 
by AM251, there was a significant reduction in both the incidence of VT and the total number of 
VPBs when compared with the vehicle control (37 ± 16 (VT) and 133 ± 31 (total VPBs) vs. 1441 ± 
1049 and 1645 ± 974; VPBs P<0.05 Figure 5.9). 
 
Administration of AM251 alone reduced the number of arrhythmias which occurred as VT (253 ± 105 
vs. 1441 ± 1049 VPBs) and total VPBs (496 ± 84 vs. 1645 ± 974; P>0.05; Figure 5.10) compared to 
vehicle control. When CBD was given 5 minutes prior to administration of AM251 a reduction in both 
VT and the total number of VPBs, similar to that seen with AM251 alone was observed (400 ± 220 
(VT) and 351 ± 314 (total VPBs) vs. 1441 ± 1049 and 1645 ± 974; CBD then AM251; Figure 5.10).  
 
5.4.5 Effect of CBD and AM251 on the time distribution of ischaemia-
induced ventricular arrhythmias 
 
In control animals, ventricular ectopic activity occurred predominantly in the 7-17 minutes post-
ligation, with peak activity occurring at 11 minutes after cessation of regional blood flow (Figure 
5.11). Arrhythmias were present in both phase Ia (2-10 minutes post-occlusion) and Ib (12-30 minutes 
post-occlusion) of the ischaemic period.  
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Figure 5.9 Effect of CBD (50µg kg
-1
), separately and in combination with AM251 (1mg kg
-1
), on 
ischaemia-induced ventricular arrhythmias. The incidence of each type of arrhythmia induced by ligation 
of a coronary artery was quantified and the data expressed as mean ± SEM (n=3-5).  * indicates P<0.05 vs. 
vehicle control. 
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Figure 5.10 Effect of AM251 (1mg kg
-1
), separately and in combination with CBD (50µg kg
-1
), on 
ischaemia-induced ventricular arrhythmias. The incidence of each type of arrhythmia induced by ligation 
of a coronary artery was quantified and the data expressed as mean ± SEM (n=3-5).  
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Figure 5.11 Time distribution of ischaemia-induced ventricular arrhythmias in control rats. The number of VPBs 
observed over 30 minutes of ischaemia. Data is expressed as number of VPBs (n=3). 
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Animals treated with CBD prior to ischaemia showed a similar time to onset of ventricular ectopic 
activity i.e. 5 minutes,  and there was no marked difference in the distribution of arrhythmias within 
phase Ia and Ib when compared with the vehicle control treated animals (Figure 5.12) There was no 
significant differences in the overall arrhythmia distributions (Figure 5.12).  
 
When CBD administration was preceded by AM251 (AM251 then CBD) VPB activity only presented 
in phase Ia (6-11 minutes post-occlusion), while in the vehicle control group, it occurred in both 
phases (Figure 5.13). The bi-phasic presentation of VPB activity which was observed with CBD alone 
was not observed when CBD treatment was preceded by AM251. Significant reductions in VPBs were 
seen at 8 (151 ± 69 vs. 272 ± 269 VPBs; P<0.05; Figure 5.13), 10 (10 ± 6 vs. 316 ± 159 VPBs; 
P<0.001; Figure 5.13) and 11 (68 ±45 vs. 354 ± 163 VPBs; P<0.001; Figure 5.13) minutes post-
occlusion, when compared with vehicle control.  
 
Animals treated with the CB1 receptor antagonist and proposed GPR55 agonist, AM251, demonstrated 
a similar time to onset of ventricular ectopic activity as was seen with the vehicle treated animals (5 
minutes; Figure 5.14). However, distribution of VPBs in this group was quite distinct from that 
observed in the vehicle control group as all VPBs  occurred toward the latter stages of phase Ia and the 
beginning of phase Ib, in that a bi-phasic appearance of VPB activity was observed between 6-12 
minutes (phase Ia) and the latter between 22-23 minutes (phase Ib) post-occlusion. Although, the 
period from onset to cessation of VPB activity in this group was lengthier than in control animals, 
there were significant reductions in the number of VPBs at 10 (10 ± 6 vs. 316 ± 159 VPBs; P<0.001) 
and 11 (68 ± 44 vs. 354 ± 163 VPBs; P<0.005; Figure 5.14) minutes post-occlusion (the phase when 
re-entry induced arrhythmias predominate) when compared to the control. 
 
Interestingly, co-administration of both compounds in the reverse order (CBD then AM251) did not 
provide as intense an additive effect, as was observed with AM251 then CBD (Figure 5.15). In this 
drug treatment group, the onset of VPBs was slightly later than that observed in control animals (6 
minutes vs. 5 minutes). VPB activity was present in both phases in this group. That being said, there 
were significant reductions in the number of VPBs at; 10 (63 ± 27 vs. 316 ± 159 VPBs; CBD then 
AM251 vs. vehicle control; P<0.05; Figure 5.15) and, 11 minutes (17 ± 17 vs. 354 ± 163 VPBs; CBD 
then AM251 vs. vehicle control; P<0.001; Figure 5.15). Compared with AM251 alone, CBD then 
AM251 didn’t potentiate the reduction seen with AM251 alone, but the significant reductions in VPBs 
observed at 10 and 11 minutes post-occlusion remained. 
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Figure 5.12 Effect of CBD (50µg kg
-1
) on the distribution of ischaemia-induced ventricular arrhythmias. 
The number of VPBs observed over 30 minutes of ischaemia. Data is expressed as number of VPBs (n=4). 
* indicates P<0.05 vs. corresponding time point in vehicle control. 
 
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
7 0 0
*
T im e  p o s t-o c c lu s io n  (m in u te s )
N
u
m
b
e
r
 o
f 
V
P
B
s
*
A M 2 5 1  th e n  C B D
*
P h a s e  Ia P h a s e  Ib
 
 
Figure 5.13 Effect of AM251 followed CBD on the distribution of ischaemia-induced ventricular 
arrhythmias. The number of VPBs observed over 30 minutes of ischaemia. Data is expressed as number of 
VPBs (n=5).  
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Figure 5.14 Effect of AM251 (1mg kg
-1
) on the distribution of ischaemia-induced ventricular arrhythmias. 
The number of VPBs observed over 30 minutes of ischaemia. Data is expressed as number of VPBs (n=5). 
* indicates P<0.05 vs. corresponding time point in vehicle control. 
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
7 0 0
*
T im e  p o s t-o c c lu s io n  (m in u te s )
N
u
m
b
e
r
 o
f 
V
P
B
s
C B D  th e n  A M 2 5 1
*
P h a s e  Ia P h a s e  Ib
 
 
Figure 5.15 Effect of CBD followed by AM251 on the distribution of ischaemia-induced ventricular 
arrhythmias. The number of VPBs observed over 30 minutes of ischaemia. Data is expressed as number of 
VPBs (n=4). 
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5.4.6 Effect of CBD and AM251 on the incidence of ventricular 
fibrillation following coronary artery ligation 
 
Occlusion of the LAD coronary artery in the vehicle control group, induced a total incidence of VF of 
77%, of which 60% was reversible and 17% resulted in mortality (Figure 5.16 and 5.17). Pre-
ischaemic administration of CBD abrogated the incidence of irreversible VF (0 vs. 17%; CBD and 
vehicle control, respectively) and also, brought about a reduction in the incidence of reversible VF. 
AM251 pre-treatment also induced a reduction in reversible VF (40 vs. 60%; AM251 and vehicle 
control, respectively) although, irreversible VF in this group was still present, total VF was reduced to 
50%. Co-administration of AM251 then CBD induced a significant reduction in total VF (17 vs. 77%; 
AM251 then CBD vs. vehicle control; P<0.05) and elimination of reversible VF (0 vs. 60%) compared 
with vehicle control. No such effect was observed with CBD followed by AM251; in contrast, in this 
drug treatment group there was exacerbation of all forms of VF. Overall, mortality was reduced by all 
drug treatments, with the exception of the co-administration of CBD followed by AM251, in which, 
mortality showed a trend toward being increased. 
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Figure 5.16 Effect of CBD with and without AM251 pre-treatment, on the incidence of VF following 
ligation of a coronary artery. The incidence of total, irreversible and reversible VF were quantified and 
the data expressed as % incidence (n=1-4). * indicates P<0.05 vs. vehicle control. 
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Figure 5.17 Effect of CBD and AM251, together and separately, on the incidence of VF following ligation 
of a coronary artery. The incidence of total, irreversible and reversible VF were quantified and the data 
expressed as % incidence (n=1-4).  
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5.4.7 Effect of CBD and AM251 on ventricular fibrillation following 
coronary artery ligation 
 
VF was present in all drug treatment groups (Table 5.2). CBD alone reduced the time to onset of VF 
compared with vehicle control (480 ± 36 vs. 696 ± 54; CBD vs. vehicle control, respectively). Pre-
treatment with AM251 did not affect CBD-mediated changes in time to VF onset. AM251 alone 
significantly reduced time to VF onset (437 ± 102 vs. 696 ± 54; AM251 vs. vehicle control, 
respectively; P<0.05). This AM251-mediated reduction in time to VF onset was potentiated by pre-
treatment with CBD (8 vs. 696 ± 54; CBD then AM251 vs. vehicle control, respectively) although, VF 
was only recorded in 1 rat in this group and thus statistical significance could not be ascertained. 
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Table 5.2 Effect of CBD (50µg kg
-1
) and AM251 (1mg kg
-1
), separately and in combination, on the onset of 
ischaemia-induced VF. The onset of VF was quantified from ECG recordings following ligation of a 
coronary artery. * indicates P<0.05 vs. vehicle control. Data is expressed as mean ± SEM (n=1-4). 
            
Time to onset 
(secs) 
Vehicle control 
n=3 
CBD 
(50µg kg-1) 
n=3 
AM251 
(1mg kg-1) 
n=3 
CBD then 
AM251 
n=1 
AM251 then 
CBD 
n=4 
VF 696 ± 54 480 ± 36 437 ± 102* 8 408 ± 138 
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5.4.8 Identification of GPR55 receptor in rodent myocardium 
 
Rodent myocardium stained by IHC with a specific antibody directed against GPR55 showed positive 
staining. In sham tissue this staining was observed in cardiomyocytes, endothelial cells and also in 
inflammatory cells (Figure 5.18). In the sections from hearts subject to MI there is evident damage to 
the myocardium as it appears the cardiomyocytes had become separated from one another. However, 
staining for GPR55 was still evident in the cardiomyocytes and endothelial cells of the lumens of 
blood vessels (Figure 5.19). GPR55 staining in hearts subject to pre-ischaemic bolus CBD treatment 
showed more diffuse positive staining in cardiomyocytes, however, endothelial cells were stained to a 
similar degree as was observed in sham and ischaemic heart sections (Figure 5.20).  
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Figure 5.18 IHC staining for GPR55. Light micrographs of sections of rat heart tissue at (A) x100 and (B) 
x200 magnifications and an antibody concentration of 1:750. Image (A) shows positive staining for GPR55 
in the cardiomyocytes (CM) and endothelial cells (EC). Image (B) shows, at a higher magnification, 
positive staining in inflammatory cells (IC). Scale bar is 170µm. 
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IC 
IC 
CM 
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Figure 5.19 IHC staining for GPR55 in ischaemic heart tissue. Light micrographs at (A) x100 and (B) 
x400 magnifications. Image (A) shows positive staining for GPR55 in the cardiomyocytes (CM) and 
endothelial cells (EC). Image (B) shows positive staining for GPR55 in the inflammatory cells (IC). Scale 
bar is 170µm. 
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IC 
EC 
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Figure 5.20 IHC staining for GPR55 in CBD-treated ischaemic heart tissue. Light micrographs at (A) 
x100 and (B) x200 magnifications. Image (A) shows diffuse positive staining for GPR55 in cardiomyocytes 
(CM) and positive staining in endothelial cells (EC) which is shown in detail in image (B). Scale bar is 
170µm. 
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5.5 Discussion 
 
5.5.1 Effects of CBD on ischaemia-induced ventricular arrhythmias, 
MABP and HR 
 
In this study bolus CBD administration was shown to have no apparent effect on MABP or HR before 
or during CAO. 
 
The phytocannabinoid CBD, when administered prior to the onset of a period of MI, possesses the 
capacity to reduce ischaemia-induced ventricular arrhythmias by reducing VT, although this was not 
statistically significant. The anti-arrhythmic effect was principally due to a reduction in phase Ia 
arrhythmias. VF incidence was unaffected by treatment with CBD. These findings are consistent with 
those previously reported (Walsh et al., 2010). In the presence of AM251, data in this study 
demonstrated that CBD significantly reduced VPBs and abolished arrhythmias in phase Ib. Moreover, 
there was a marked reduction in VF incidence. 
 
In hearts subjected to coronary artery occlusion, ventricular action potentials undergo a biphasic 
change which includes an initial lengthening, followed by a more prolonged shortening. In addition 
the refractory period of the ventricular action potential shortens in line with the shortening of action 
potential duration (Brooks et al., 1960; Janse and Wit, 1989). These changes in refractoriness, coupled 
with the slowed conduction in the ischaemic myocardium, provide a suitable milieu for the facilitation 
of reentry (Osadchii, 2010). It has been proposed that reentry is the dominant mechanism responsible 
for the initiation of ventricular tachycardia in the early stages of myocardial infarction (Boineau and 
Cox, 1973; Janse and Wit, 1989). During MI, activation of delayed rectifier potassium current (Ik1) 
prevents excess activation of myocytes in the ischaemic zone and therefore, may prevent the 
generation of arrhythmias. Ik1 has been shown to be induced by activation of the CB1 receptor (Felder 
et al., 1995) while CBD has been reported to inhibit both the rapid and slow activating facets of Ik1 in 
isolated ventricular myocytes (Mamas and Terrar., 1998). In light of the findings in Chapter 4 that, at 
the dose used in the present study, CBD appears to exhibit some CB1 antagonist activity; this could 
conceivably represent the mechanism of its anti-arrhythmic effects. However, since CBD does not 
prolong QT interval prior to ischemia or potentiate ischaemia-induced QT interval prolongation, it 
seems unlikely that this is the mechanism by which CBD is anti-arrhythmic (Walsh et al., 2010). In 
the presence of AM251, the effects of CBD could not be reversed but instead enhanced its effects. It 
demonstrated that AM251 is itself anti-arrhythmic. This may also infer that the CB1 receptor is not 
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involved in the mediation of the anti-arrhythmic effect of CBD. Moreover, the failure of AM251 (CB1 
antagonist) to reverse the effects of CBD similarly points to a lack of involvement of CB1. 
An alternative explanation could be a direct action of CBD at LTCCs, since compounds which block 
LTCCs, aid in the protraction of conduction and refractoriness in the myocardium (Harrison, 1985) 
and are used clinically as a first-line treatment for prevention of fatal arrhythmias following 
myocardial infarction (British National Formulary, 2013). Indeed CBD has been observed to slow 
intracellular Ca
2+
 accumulation by inhibition of LTCCs (Mamas and Terrar, 1998). Further 
investigation of the effect of CBD on intracellular Ca
2+ 
homeostasis and excitation-induced Ca
2+
 
mobilisation are discussed in chapter 6. 
 
The complex pharmacology of CBD is such that involvement of non-classical cannabinoid receptors 
in the mediation of cardioprotection must be given due consideration. Indeed, evidence from our 
laboratory shows that CBD is unable to prevent the hypotensive effect of the CB1 receptor agonist 
ACEA in vivo, suggesting that CBD is not operating as an antagonist at the CB1 receptor. It is now 
well established that CBD acts as an antagonist of the de-orphanised GPCR, GPR55. Daly et al. 
(2010) used a novel, putative, fluorescent form of AM251 (also known to act as a GPR55 ligand) to 
identify the localisation of a cannabinoid-type receptor purported to be GPR55 in the small arteries of 
the tail and mesentery of C57Bl/6J mice and Wistar rats. Positive staining for GPR55 was localised to 
the endothelium of rat tail arteries and around the nucleus of Schwann cells. In addition, histological 
analysis of GPR55 in the myocardium and vasculature by our laboratory has shown that GPR55 is 
located in both the heart and the vasculature. Furthermore, GPR55 receptor localisation is observed to 
be concordant with that of the classical cannabinoid receptors suggesting that GPR55 may be involved 
in the mediation of the cardioprotective effects of CBD and that there may be an element of 
dimerisation or synergism between cannabinoid receptors and GPR55 (Ryberg et al., 2007; Staton et 
al., 2008; Daly et al., 2010). 
 
Another consideration as to the mechanism of CBD-induced cardioprotection is the involvement of the 
purine nucleoside, adenosine. Adenosine is widely distributed within the body but interestingly, the 
extracellular concentrations of it are significantly amplified during periods of ischaemia (Schulte and 
Fredholm, 2003; Cohen and Downey, 2008). What is more, adenosine is profoundly anti-arrhythmic 
(Wainwright & Parratt, 1988), has been found to initiate ischaemic preconditioning by direct coupling 
to protein kinase C (PKC), and has been used in the treatment of supraventricular arrhythmia (Liu et 
al., 1991; Cohen and Downey, 2008). CBD has been shown to transactivate adenosine receptors 
(Wainwright and Parratt, 1993) and thus enhancement of adenosine signalling which is known to anti-
arrhythmic may play a role in its cardioprotective effects. 
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5.5.2 Effects of AM251 on ischaemia-induced ventricular arrhythmias 
 
This study has demonstrated for the first time that the CB1 receptor antagonist AM251 has significant 
anti-arrhythmic effects when administered before the onset of ischaemia. This is in contrast to the 
findings by Hajrasouliha et al. (2008), who showed that AM251 provided no anti-arrhythmic benefit 
in a rat study whose experimental design was comparable with the present study. However, the VT 
count in the control group in the Hajrasouliha et al., study was much lower than that observed in 
control animals in the present study and similar to that observed in the AM251 treatment group and. 
The control animals in our study showed VT and total VPB incidences comparable with those in 
existing literature (Johnston et al., 1983; Crockett et al., 2000; Canyon and Dobson, 2004; Kloner, 
Dow and Bhandari, 2011). Since the Hajrasouliha et al. study had a lower starting arrhythmia counts, a 
reduction in arrhythmias by AM251 was likely compromised.   
 
While the rationale for the use of AM251 in this present study was fundamentally to further 
investigate the pharmacology of CBD’s anti-arrhythmic effects and to determine whether or not CBD 
was acting at CB1 receptors, the fact that AM251 itself was anti-arrhythmic merits some discussion. 
The mechanisms involved in the suppression of arrhythmias by AM251 may be in part due to 
blockade of the CB1 receptor, thereby allowing cardioprotective endocannabinoids (upregulated 
following ischaemia) to preferentially act at the CB2 receptor, since the CB2 receptor has been well 
characterised to confer cardioprotection (Krylatov et al., 2001; Zhang et al., 2008; Lim et al., 2009). 
Indeed there is evidence that CB1 receptor expression is downregulated in the presence of increased 
endogenous AEA levels (e.g. in MI), representing a possible endogenous response to protect against 
ischaemia-induced injury/electrophysiological disturbances (Mukhopadhyay et al., 2007; Nucci et al., 
2007; Cappellano et al., 2013). The involvement of both cannabinoid receptors in the induction of 
resistance to ischaemia and prevention of arrhythmias has been shown previously with the CB1/2 
receptor agonist, HU-210 in a rat model of global ischaemia in the isolated heart.  The addition of HU-
210 in vitro was associated with a reduction in the biomarker creatine phosphokinase in the coronary 
effluent and a reduction in left ventricular developed pressure (Krylatov et al., 2001; Lasukova et al., 
2008).  In addition, it has previously been proposed that CBD-mediated increased in [Ca
2+
]i may 
stimulate endocannabinoid release, which may in turn activate the cannabinoid receptors (CB1/2; 
Drysdale et al., 2006). That being said, more recent data questions the likelihood that 
endocannabinoids protect against ischaemia-induced ventricular arrhythmias, since in a rat an isolated 
heart model of acute ischaemia, AEA and 2-AG both failed to reduce the incidence reperfusion-
induced VF (Andrag and Curtis, 2013). In addition, they showed that in the late stage of acute regional 
ischaemia (30-60 minutes), AM251 exacerbated the incidence and duration of episodes of VF. 
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Lim et al. (2009) identified that a different CB1 receptor antagonist, rimonabant, reduces infarct size. 
They hypothesised that the beneficial effects of rimonabant were associated with increased levels of 
the infarct sparing, anti-fibrillatory, fat-derived protein, adiponectin (Li and Liu, 2009; Kourliouros et 
al., 2011). However, although adiponectin has been shown to be synthesised in cardiomyocytes 
(Ishikawa et al., 2003; Takahashi et al., 2005) and rimonabant to increase its levels in adipose tissue 
(Bensaid et al., 2003), adiponectin levels in blood serum and heart tissue were only marginally 
different from those observed in control animals (Lim et al., 2009). Furthermore, there was no 
significant correlation between circulating adiponectin concentrations and the incidence of atrial 
fibrillation (Rienstra et al., 2012). Since it is unclear whether AM251 affects adiponectin synthesis, 
whether or not adiponectin plays a part in the anti-arrhythmic mechanism of AM251 remains to be 
determined. 
 
An interesting finding in the present study was that AM251-had a marked suppressant effect on phase 
1b arrhythmias, which are largely due to catecholamine flux.  Existing literature has shown that CB1 
receptor agonists reduce, rather than increase, electrically evoked (and thus noradrenaline-dependent) 
contractions in nerve-muscle preparations (Schlicker and Kathmann, 2001).  This would therefore rule 
out a mechanism for AM251 involving a reduction in noradrenaline (NA) release. Further evidence 
against a role for an effect of AM251 on NA release comes from the work of Kurihara et al. (2001), 
which showed that in rat heart sympathetic neurons, AM251 reversed the HU-210-induced inhibition 
of NA release. What is more, AM251 did not affect basal NA release, highlighting that the CB1 
receptor is not tonically activated by endogenous ligands. Taken together, this suggests that the anti-
arrhythmic effects of AM251 observed in our study are not mediated by reductions in NA release from 
sympathetic neurons in the heart. That being said, although AM251 may not affect NA release from 
nerve terminals, literature exists to suggest that AM251 has the capacity to reduce NA synthesis. 
Catecholamine synthesis is rate-limited by a step early in the cascade of synthesis, which is catalysed 
by tyrosine hydroxylase. AM251 has been shown to reduce tyrosine hydroxylase expression in fawn-
hooded rats (Femenia, et al., 2010). If a reduction in expression occurred in the present study, 
downstream adrenaline and NA synthesis would be hindered. Thus, this may possibly explain the 
reduction in catecholamine-induced arrhythmias of phase Ib recorded in rats treated with AM251 
(1mg kg
-1
). 
 
Alternatively, activation of a non-classical cannabinoid receptor by AM251 may be responsible for the 
observed cardioprotection. Indeed, the studies described in Chapter 4 show clearly that at the dose 
used in this study AM251 is activating GPR55. AM251 is acknowledged to trigger the extracellular 
signal-regulated kinase, ERK, and the phosphatidylinositide-3-OH kinase (PI3K) through GPR55; 
these kinases are key players in the initiation of the anti-apoptotic, pro-survival kinase cascade known 
as the reperfusion injury salvage kinase (RISK) pathway (Cross et al., 2000).  Activation of ERK and 
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PI3K in the setting of MI and reperfusion is acceded to mediate cell protection and survival (Shimiza 
et al., 1998; Yue et al., 2000). The means by which this is thought to be mediated include the 
prevention of cytoplasmic Ca
2+
 overload by promotion of SR-mediated re-uptake, inhibition of 
conformational changes in pro-apoptotic kinases thereby preventing apoptosis (Marzo et al., 1998; 
Yamaguchi et al., 2001; Tsuruta et al., 2002) and inhibition of the opening of the mPTP (Marzo et al., 
1998). While it is plausible that AM251 mediates its infarct sparing effect by activation of the RISK 
pathway, this pathway is not linked to arrhythmia generation. However, since there is a paucity of 
literature between any link between GPR55 and electrophysiological changes in the heart, an action at 
this receptor cannot be ruled out. That being said, a recent study from Yu et al, (2013) showed that 
GPR55 activation by its endogenous ligand LPI induces mobilisation of Ca
2+
i. If AM251 were acting 
as an agonist at GPR55, then these data suggest that there would be an increase in [Ca
2+
]i, which 
would be pro-arrhythmic, rather than anti-arrhythmic. 
 
CBD and AM251 alone acted with the same effect on arrhythmias, albeit to different extents. They 
also acted in an analogous manner on MABP (as described in Chapter 4). Nonetheless, this would 
suggest that the effects of CBD and AM251 on MABP and VPBs are mediated by the same receptor. 
 
No significant effects of drug treatment, either on HR prior to occlusion or during the course of 
ischaemia were observed and as such the protective effects of drug treatments are not likely to be due 
to changes in HR. Although, the protective effect of HR on ischaemia-induced arrhythmias is a 
contentious issue in itself high HR determined incidence of VPBs and low HRs being protected (Bolli, 
Fisher and Entman, 1986; Bernier, Curtis and Hearse, 1989). 
 
5.5.3 Effect of co-administration of CBD and AM251 on ischaemia-
induced ventricular arrhythmias 
 
In this study, it was observed that the individual anti-arrhythmic capacity of CBD and AM251, were 
either enhanced or maintained dependent upon the order in which the compounds were administered. 
These data may suggest that a more complex relationship than just that of inverse agonist/antagonist at 
the CB1 receptor may be occurring and encourages consideration of alternative sites of action. 
Moreover, the disparity between the profiles of the anti-arrhythmic effects of these agents, depending 
upon the order of administration, further implies the involvement of other receptors than simply the 
CB1 receptor.  It has previously been recognised that in a co-administration study involving a CB1 
receptor antagonist and a CB2 receptor agonist, that each alone reduced infarct volume and that when 
co-administered this effect was potentiated. These authors hypothesised that there may be a degree of 
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synergism occurring between the two receptors (Zhang et al., 2008). Furthermore, the likelihood of a 
synergist relationship occurring between CBD and AM251 is not limited to ischaemia and reperfusion 
(I/R), as a previous study in our laboratory has identified possible synergism occurring in the setting of 
platelet aggregation (unpublished data). In particular, the modest ex vivo anti-aggregatory capacity of 
CBD was found to be significantly enhanced in the presence of AM251. Since a degree of crosstalk 
between the CB1 receptor and related sites has already been established it could infer the possibility 
that there may be crosstalk with other related sites.  
 
The putative cannabinoid receptor GPR55, a pharmacological target for both CBD and AM251, as an 
antagonist and agonist, respectively (Pacher and Hasko, 2008; Lim et al., 2009), may be one such 
target. GPR55 receptors were positively identified on endothelial cells, cardiomyocytes and 
inflammatory cells in both sham and ischaemic heart tissue. This confirms earlier reports of the 
presence of low level GPR55 receptor expression in the heart expression of this receptor predominates 
on the plasma membrane and membranes endo-lysosomes in ventricular cardiomyocytes and distinct 
signalling pathways are activated dependent upon receptor location (Yu et al., 2013). Our data 
showing GPR55 receptor staining in the heart supports this and may suggest that if AM251 and/or 
CBD are acting at this receptor to modulate arrhythmia occurrence, it seems likely that they are doing 
so directly at the level of the cardiomyocyte. In support of this, both the CB1 receptor and GPR55 are 
found to interact in vitro. The link between CB1 and GPR55 is determined by integrins, as described in 
more detail in Chapter 5. If conditions of clustered integrins persist, administration of the CB1 and 
GPR55 agonist, AEA, induces CB1-dependent activation of Syk which prevents AEA activation of 
GPR55-induced Ca
2+
 mobilisation from the endoplasmic reticulum (ER). If however, activation of the 
CB1 receptor is prevented by the CB1 receptor antagonist, AM251 (10 µM), integrin clustering is 
disengaged and there is a relief of CB1-mediated inhibition of GPR55. This relief can unmask an 
AEA-induced increase in [Ca
2+
]i by mobilisation from the ER subsequent to GPR55 activation. 
(Waldeck-Weiermair et al., 2008). The question is whether the intracellular accumulation of Ca
2+
, 
which occurs during I/R, is sufficient to induce gross changes in the extracellular Ca
2+
 concentration, 
adequate to induce integrin clustering. This is doubtful and prevention of intracellular Ca
2+ 
accumulation via an inhibition of GPR55’s ability to mobilise Ca2+ from the ER, would irrefutably 
worsen the Ca
2+
 overload typical of I/R.  
 
The notion that the cardioprotective effects of CBD and AM251 may be mediated by distinct receptors 
is further substantiated by data in this study which shows that CBD alone appears to suppress phase Ib 
re-entry-induced arrhythmias, while AM251 alone appears to suppress phase Ia catecholamine flux-
induced arrhythmias. In the co-administration studies, AM251 followed by CBD showed an additive 
effect in terms of reducing the arrhythmia incidence during the ischaemic period, however the same 
was not observed in the CBD then AM251 treatment group. The observed reduction in reentry-
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induced arrhythmias with CBD may be in part due to a direct electrophysiological effect, as described 
in detail earlier in this discussion.  With regard to the AM251-mediated reduction in catecholamine-
induced arrhythmias (again covered earlier in this discussion) this may have been induced by changes 
in the availability of NA. Again, the inconsistency in the arrhythmic phases affected by the order of 
administration, indicates that the order of receptor occupancy and the sites of occupancy are critical. 
The anti-arrhythmic effects of each alone are summative when AM251 is given before CBD, but not 
in the reverse order. We postulate that since both compounds act at CB1 and GPR55, is it sensible to 
assume that the observed effects must in some way involve these receptors. The detailed mechanism 
proposed is outlined in Figure 5.21 and Figure 5.22. 
 
Of course, the observed disparity of anti-arrhythmic capacity of co-administration of CBD and AM251 
depending on the order of administration could simply be down to preferential activation of their 
respective pharmacological targets. To summarise their respective pharmacologies; CBD acts as an 
inverse agonist at CB1 and at GPR55 as an antagonist, whereas AM251 acts as an antagonist at CB1 
and at GPR55 as an agonist. CBD is a weak inverse agonist of the CB1 receptor (IC50 3.35µM; 
Thomas et al., 2007) compared with the relatively more potent antagonist AM251 (IC50 8nM), thus 
when AM251 is administered prior to CBD, blockade of the CB1 receptor would likely occur. As 
illustrated in Figure 5.21, CBD would then be left to block GPR55, possibly preventing any significant 
intracellular Ca
2+
 mobilisation, achieved through occupancy by an endogenous ligand at this receptor 
(Lauckner et al., 2008). In addition, blockade of the CB1 receptor by AM251 may facilitate the 
endogenous cardioprotective cannabinoids to mediate protection by preferential activation of the CB2 
receptor (Zhang et al., 2008; Lim et al., 2009). Therefore, the full extent of CB2 receptor involvement 
in the mediation of the cardioprotective effects of CBD and AM251 requires further investigation.   
 
Co-administration in the reverse order (CBD followed by AM251) did not produce the same additive 
effect in terms of the cardioprotection afforded when AM251 was administered before CBD. This may 
in part be due to pre-treatment with CBD interacting with and blocking tonic activity at the CB1 
receptor (and thus preventing AM251 from gaining access to the receptor site). Activation of  CB1 has 
been shown to be proarrhythmic in a model of global ischaemia in the isolated rat heart (Andrag and 
Curtis, 2013).  Figure 5.21 and Figure 5.22 illustrates a proposed hypothesis to explain the current 
findings. We hypothesise that CBD may be acting principally at the CB1 receptor if it is given prior to 
AM251 administration and, although the beneficial or indeed detrimental role of the CB1 receptor in 
I/R remain disputed, the blockade of tonic activity by CBD might be responsible for the conferred 
anti-arrhythmic effect. Consequently, when AM251 is then administered the remaining site of action 
could be GPR55, resulting in the potentiation of ischaemia-induced arrhythmias quantified over the 30 
minute ischaemic period. Indeed GPR55 activation has been identified as a potential mediator of cell 
injury (Kapur et al., 2009; Sharir and Abood, 2010).  
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Alone, CBD and AM251 bolus administration produced a small reduction in VF incidence. The effects 
of CBD on VF were markedly enhanced by AM251 (AM251 then CBD), however co-administration 
in the reverse order (CBD then AM251) completely reversed the small reduction in VF mediated by 
AM251.  These data would suggest the involvement of more than just the CB1 receptor in the 
mediation of reduction in VF incidence.  
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CB1 GPR55 
CBD AM251 
Ischaemia 
2AG/AEA 
Figure 5.21 Proposed pharmacological activation of the CB1 receptor and GPR55 depending on the 
order of administration of CBD and AM251. It is proposed that when AM251 administration 
preceeds that of CBD, there is pharmacological blockade (antagonism – green arrow) of the CB1 
receptor by AM251. This would allow 2AG and AEA (whose production is upregulated as a 
consequence of ischaemia) to activate CB2 receptor exclusively. The second effect may involve CBD 
acting at GPR55 as its site of action at CB1 is no longer available as a result of occupation by 
AM251. CBD would antagonise (green arrow) GPR55 potentially preventing intracellular Ca
2+
 
mobilisation induced by an endogenous ligand such as LPI. Dashed arrows indicate the additional 
pharmacological actions of CBD, AM251 and the endocannabinoids, those actions being prevented 
by the proposed activity indicated by the bold arrows (blue arrow – agonism; red arrow – inverse 
agonism, grey arrow – agonism). 
AM251 then CBD 
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CB1 GPR55 
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Figure 5.22 Proposed pharmacological activation of the CB1 receptor and GPR55 depending on the 
order of administration of CBD and AM251. We propose that when AM251 is given after bolus 
CBD administration, CBD acts principally at CB1 receptors as an inverse agonist (red arrow), thus 
preventing constitutive receptor activity. CB1 receptor activation in MI has been demonstrated to 
be proarrhythmic (Andrag and Curtis, 2013). What is more, AM251 when administered could act 
as an agonist at GPR55 (blue arrow). GPR55 has been implicated in the development of 
arrhythmias in myocardial ischaemia. Dashed arrows indicate the additional pharmacological 
actions of CBD, AM251 and the endocannabinoids, those actions being prevented by the proposed 
activity indicated by the bold arrows (green arrow – antagonism; grey arrow – agonism). 
CBD then AM251 
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5.5.4 Summary and conclusions 
 
This study confirmed previous observations which showed that CBD is anti-arrhythmic and is the first 
to demonstrate that AM251 is cardioprotective in an anaesthetised rat model of MI. Moreover, co-
administration of CBD and AM251, in either order was identified as anti-arrhythmic. Interestingly, the 
order of administration of CBD and AM251 appears to affect the degree of potentiation of anti-
arrhythmicity of either compound alone. None of the drug treatment regimes had any significant effect 
on recovery of MABP following ligation of the coronary artery. However, attempts to identify the 
receptors responsible for mediating the anti-arrhythmic effects of either drug were hampered by the 
complex pharmacology of the two compounds, which in both cases involved CB1 and GPR55 and the 
likelihood of ‘cross-talk’ between the two receptors. As a result the next series of studies sought to 
explore the role of [Ca
2+
]i in the action of both CBD and AM251. 
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6. Development of a 
method to measure 
changes in [Ca2+]i in 
isolated rat ventricular 
myocytes 
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6.1 Introduction 
 
Intracellular Ca
2+ 
([Ca
2+
]i) plays a fundamental role in the propagation of the spontaneously generated 
action potentials of the SA node, while the inward movement of Ca
2+
 in atrial and ventricular 
myocytes creates the prolonged depolarisation typical of these cells, known as the plateau phase 
(Irisaw, Brown and Giles, 1993; Levick, 2003; Pollock and Richards, 2004; Figure 1.2). The electrical 
excitation of cardiac myocytes initiates contraction in a process termed excitation-contraction coupling 
(Bers, 2002). The synchronous contraction of atrial and ventricular syncytiums ensures the efficient 
pumping of the heart and propulsion of blood to the lungs and systemic circulation (Levick, 2003; 
Pollock and Richards, 2004). The reliance of the heart on Ca
2+
 was first identified in 1883 (Ringer), 
and since that discovery it has been shown that without extracellular Ca
2+
, Ca
2+
-induced rises in 
intracellular Ca
2+
 cannot occur, leading to prevention of myocardial contraction (Levick, 2003). 
 
Perturbation of physiological concentrations of Ca
2+
 rapidly results in deterioration of cardiac cell 
physiology. Increased Ca
2+
 in cardiac myocytes predisposes the heart to electrical instability and, 
consequently the likelihood of triggered automaticity, reentry and electrical inhomogeneity leading to 
subsequent ventricular fibrillation and tachycardia (Lubbe, Podzuweit and Opie, 1992; Ugdyzhekova 
et al., 2001). [Ca
2+
]i overload subsequent to a period of ischaemia can also result in reoxygenation-
induced contracture in rat perfused hearts (Steenbergen et al., 1990). Hypercontracture is a perpetual, 
ischaemia-induced, stiffening of the myocardium which, if persistent enough, inhibits the recovery of 
contractile function of the myocardium (Ladilov et al., 2003). Thus, given the fundamental role [Ca
2+
]i 
plays in the electrophysiology and mechanical function of the heart, it is important to consider the role 
it may play in the mediation of the anti-arrhythmic effects of CBD and AM251 that were described in 
Chapter 5. 
 
6.1.1 Myocardial ischaemia and Ca2+ 
 
As detailed in Chapter 1, the electrophysiological changes induced by an episode of acute MI begin 
with the extracellular accumulation of K
+ 
within 10 seconds of cessation of coronary flow (Hill and 
Gettes, 1980; Hirche et al., 1980; Nayler, 1981; Fozzard and Makielski, 1985; Janse, 2000). This 
begins a cascade of ionic disturbances, with the rise in [Ca
2+
]i occurring subsequent to the extracellular 
[K
+
]e rise and intracellular [Na
+
]i accumulation and with comparative delay to K
+
 and Na
+
 (Allen and 
Orchard, 1983). Concomitant to these ionic changes, there is a depolarisation of cells within the 
ischaemic zone, in a process thought consequent to alterations in [K
+
]e (Kleber, 1983; Coronel et al., 
1988; Janse and Wit, 1989). 
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In the early stages of acute MI the perturbation in [Ca
2+
]i is caused initially by displacement of Ca
2+
 
from its intracellular cytoplasmic buffer sites by accumulating H
+
 (Gambassi et al., 1993; Isenberg et 
al., 1993; Carmeliet, 1999). Reversal of the Na
+
-Ca
2+
 exchanger, induced in compensation for the 
concurrent rise in [Na
+
]i, then further increases [Ca
2+
]i, as demonstrated in isolated rat heart and 
isolated ferret papillary muscle (Figure 6.1; Smith and Allen, 1988; Tani and Neely, 1989; Haigney et 
al., 1994; Chen and Li, 2012; Ottolia et al., 2013). Finally, the inadequate SR re-uptake of Ca
2+
, 
following slowing of the ATP dependent Ca
2+
 pump due to reduction of the maximal rate (Vmax) of 
Ca
2+
 movement, increases [Ca
2+
]i further still (Kaplan et al., 1992; Carmeliet, 1999; Ottolia et al., 
2013). 
 
Thandroyen et al. (1992) used an isolated, cultured rat ventricular myocyte model to determine the 
sequence of ionic alterations which transpire as a consequence of hypoxia, and how these relate to the 
initiation and development of cellular injury. In this model, metabolic inhibition by hypoxia resulted in 
a loss of intracellular K
+
 and magnesium ions (Mg
2+
) with a concomitant gain of intracellular Na
+
 and 
Ca
2+
 (Buja et al., 1985; Morris et al., 1989; Jones et al., 1989; Buja et al., 1990; Thandroyen et al., 
1992). The changes in [Ca
2+
]i induced by hypoxia in isolated rat ventricular myocytes are dependent 
on simultaneous extracellular acidosis (Pravdic, Vladic and Bosnjak, 2009). These biochemical 
changes are similar to those observed in both in vitro and in vivo models of hypoxia (Buja et al., 1985; 
Morris et al., 1989; Jones et al., 1989; Buja et al., 1990; Thandroyen et al., 1992). Thus it is clear that 
changes in [Ca
2+
]i, by the induction of MI, can have a significant and profound effect on the 
electrophysiology of the myocardium, which ultimately provides an environment ideal for the 
generation of VPBs. 
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Figure 6.1 Schematic of Ca
2+
 signalling in the cardiac myocyte (blue arrows) and changes in this signalling 
induced by MI (red arrows). Depolarisation of the area around the t-tubule begins the process of 
contraction of the cardiac myocyte through stimulation of Ca
2+
 entry by way of the voltage-dependent 
LTCC. Ca
2+
 entry triggers further rises in cytosolic Ca
2+
 by ryanodine receptor-mediated release from the 
SR. The intracellular Ca
2+
 binds to the myofilaments initiating contraction. In the setting of MI there is a 
reversal of Na
+
-Ca
2+
 exchanger (NCX) and inadequate SR reuptake of Ca
2+
 by the  sarcoplasmic 
reticulum calcium transport ATPase (SERCA), which leads to cytosolic and mitochondrial Ca
2+
 overload. 
These perturbations coupled with the loss of Na
+
-K
+
 ATPase and acidosis, leads to the increased likelihood 
of mPTP opening in the IMM. Adapted from Crompton, 1999; Bers, 2000; Suleiman, Halestrap and 
Griffiths, 2001. 
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6.1.2 Effect of accumulating [Ca2+]i following acute myocardial ischaemia 
 
Changes in ion flux induced by acute ischaemia change the basic electrophysiological properties of the 
cardiac cell (Janse and Wit, 1989). This results in a reduction in conduction velocity, variability in 
refractoriness and provides a suitable milieu for the genesis of arrhythmias (Czarnecka, Lewartowski 
and Prokopczk, 1973; Downer, Janse and Durrer, 1977; Kleber et al., 1978; Janse and Wit, 1989). 
Indeed, accumulation of [Ca
2+
]i in isolated cardiomyocytes (to micromolar concentrations), has been 
found to precede the commencement of spontaneous fibrillation in neonatal rat myocytes. This 
intracellular accumulation of [Ca
2+
]i, as a consequence of the progressive extracellular [Ca
2+
] 
elevation, was used to identify the role [Ca
2+
]i played in the development of premature beats 
(Thandroyen et al., 1991). Increased [Ca
2+
]i is typically found after a period of MI (Steenbergen et al., 
1990; Carmeliet, 1999). In fact, elevated [Ca
2+
]i has been identified as a mediator in the induction of 
triggered automaticity, reentry and electrical inhomogeneity (Clusin, Buchbinder and Harrison, 1983; 
Opie et al., 1988; Thandroyen et al., 1991), which are critical precursors to the occurrence of VF and 
VT (Lubbe, Podzuweit and Opie, 1992).  
 
In addition to the electrophysiological abnormalities that increased [Ca
2+
]i can produce, additional 
pathogenic alterations may occur which can limit the recovery of the post-ischaemic myocardium. The 
prevention of adequate ATP synthesis, coupled with the ionic imbalances that occur during MI, can 
impair the regulatory processes that maintain baseline [Ca
2+
]i within the 10
-7
M range in the cardiac 
myocyte (Steenbergen et al., 1990). As detailed above, MI is associated with increases in [Ca
2+
]i and it 
is this accumulation of [Ca
2+
]i that can induce Ca
2+
 overload-induced contracture upon reperfusion 
(Ladilov et al., 2003; Piper, Meuter and Schafer, 2003). The high [Ca
2+
]i coupled with re-activation of 
ATP synthesis upon reperfusion leads to uncontrolled initiation of contraction in cardiac myofibrils 
ultimately leading to the shortening and stiffening of the myocardium which is termed contracture 
(Steenbergen et al., 1990; Ladilov et al., 2003; Piper, Meuter and Schafer, 2003). The development of 
contracture in the post-ischaemic myocardium, if persistent, can lead to cytoskeletal defects that cause 
structural instability in cardiac myocytes (Piper, Meuter and Schafer, 2003). 
 
High [Ca
2+
]i following MI can induce opening of the mPTP which causes apoptotic and necrotic cell 
death upon reperfusion of the ischaemic myocardium (Hausenloy, Duchen and Yellon, 2003). The 
uptake of Ca
2+
 by mitochondria during a period of ischaemia is the crucial factor that will ultimately 
predict the death or survival of the cardiomyocyte, since this is the driving force in changing the 
probability of the opening of the mPTP (Crompton and Costi, 1988; Hausenloy, Duchen and Yellon, 
2003).  
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6.1.3 Cannabinoids and [Ca2+]i 
 
The determination of survival of cardiac myocytes following an episode of acute MI can thus be, at 
least in part, attributed to the maintenance of homeostasis of [Ca
2+
]i (Janse and Wit, 1989; Carmeliet, 
1999; Hausenloy, Duchen and Yellon, 2003). What is more, calcium-mediated perturbations in normal 
electrophysiology, for example slowing of the action potential, early and delayed after depolarisations 
and reentry, have been implicated in the development of arrhythmias (Thandroyen et al., 1991; 
Kranias and Bers, 2007). Reduction of [Ca
2+
]i through the use of Ca
2+ 
channel blockers have been 
shown to reduce arrhythmia incidence in an isolated multicellular cardiomyocyte model (Thandroyen 
et al., 1991). Cannabinoids (synthetic, endogenous and plant-derived alike) have been shown to act on 
both Ca
2+
-dependent processes and on Ca
2+
 homeostasis on post-synaptic cells of the nervous system, 
at the TRPV1 receptor and in the heart (Brenowitz and Regehr, 2003; van der Stelt et al., 2005; Currie 
et al., 2008; Drysdale et al., 2009). Ca
2+
 signalling implicated in the generation of arrhythmias in rats 
has been linked to IP3 receptor mediated signalling (Mackenzie et al., 2002) and furthermore, 
endothelin-induced arrhythmogenic Ca
2+ 
mobilisation in mice can be ameliorated in IP3 receptor 
knock-out mice (Li et al., 2005). Interestingly, IP3 receptor-mediated Ca
2+
 mobilisation can also be 
modified by AEA and AM251 (Currie et al., 2008), suggesting a role for cannabinoids in the 
modulation of Ca
2+
 signalling. Indeed, CBD has been shown to alter [Ca
2+
]i in numerous cell types 
including, but not limited to, hippocampal neurons, leukocytes and mast cells (Kaplan et al., 2003; 
Drysdale et al., 2006; Giudice et al., 2007), although to date there is no data on its effect on Ca
2+
 in 
cardiomyocytes. CBD is known to effect [Ca
2+
]i changes by modulating NMDA-elicited Ca
2+
 signals 
and through inhibition of voltage-gated calcium channels (Mackie and Hille, 1992; Twitchell, Brown 
and Mackie, 1997; Netzeband et al., 1999; Drysdale et al., 2006). In neurons and glial cells, CBD 
causes an increase in [Ca
2+
]i that is sustained even after washout of CBD, and is independent of an 
action at CB1 receptors (Drysdale et al., 2006) and is believed to be due to release of Ca
2+ 
from 
intracellular stores. In support of the latter, Ryan et al. (2009) demonstrated that application of CBD to 
primary rodent hippocampal cells kept under conditions of high excitability, reduced [Ca
2+
]i and 
prevented [Ca
2+
]i oscillations, leading them to propose that the intracellular site of action of CBD was 
principally the mitochondrial sodium-calcium exchanger.  
 
Additionally, AM251 has been shown to prevent dysfunction of mitochondria in a model of hepatic 
lipogenesis (Chen, Ho and Lee, 2013) and CBD can modulate [Ca
2+
]i depending on the excitability of 
the cell in a manner in part aided by mitochondria (Ryan et al., 2009). 
 
 - 137 - 
 
Thus, in light of the anti-arrhythmic effects observed with CBD and AM251 in this present study, this 
study explored their potential to modulate Ca
2+
 and mitochondrial membrane potential as a possible 
mechanism underlying their anti-arrhythmic effects. 
 
6.1.4 Use of an ex vivo model of simulated ischaemia in freshly isolated rat 
cardiomyocytes 
 
In light of the findings from the in vivo studies (described in Chapter 5) which identified the anti-
arrhythmic capacity of CBD and AM251 it was postulated that a potential mechanism of their action 
was to stabilise [Ca
2+
]i following induction of acute MI. Furthermore, in light of the pharmacological 
targets of both CBD and AM251 being similar, namely CB1 receptors and GPR55, it was pertinent to 
attempt to investigate the involvement of these receptors in any observed changes in [Ca
2+
]i during 
normoxia and simulated ischaemia. Thus the aims of this study were to: 
 To optimise a method for the isolation of ventricular cardiomyocytes from the rat heart, 
 To develop a method to detect changes in cardiomyocyte [Ca2+]i using fluorescent 
microscopy,  
 To establish an ex vivo model of simulated ischaemia (in an effort to mimic the effects of 
oxygen deprivation induced by acute, regional MI in vivo) to determine the effects of this 
pathophysiological state on [Ca
2+
]i in isolated cardiomyocytes,  
 A further aim was to identify whether CBD and/or AM251 affect basal [Ca2+]i or any changes 
in [Ca
2+
]i mediated by simulated ischaemia and whether these changes are mediated by CB1 or 
GPR55 receptors using a similar pharmacological approach to that used for the arrhythmia 
studies.  
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6.2 Methods 
 
6.2.1 Preparation of cell extracts from adult rat ventricles and detection 
of intracellular Ca
2+
 in isolated ventricular myocytes 
 
Male Sprague Dawley rats (n=29; before exclusion criteria were applied; final n numbers can be found 
in the appropriate results section) were euthanised by CO2 asphyxiation as described in section 2.4.1.  
 
6.2.2 Enzyme digestion and isolation of adult rat ventricular 
cardiomyocytes 
 
The method of cell isolation from adult rat ventricles is described in Chapter 2. Isolation of cells was 
achieved by a modification of the original protocol described by Bates and Gurney et al., (1999), 
specifically: 
 
1. To improve cell yield and cell viability during the isolation process, a number of 
modifications were made to the technique; firstly, perfusion times for each of the solutions 
were extended to allow adequate time for perfusate to percolate through the entirety of the 
tissue mass. Perfusion extensions were thus, 6 minutes with Ca
2+
-free solution, 3 minutes with 
Ca
2+
-free solution containing proteinase and 11 minutes with Ca
2+
-free solution containing 
collagenase and hyaluronidase. 
2. Upon conclusion of ventricular mincing, the tissue was transferred to a microcentrifuge tube 
where it was bathed in Krebs-Henseleit solution and gently titurated with a glass-fired pipette 
prior to placing in an incubator at 37°C until required for fluorescence staining. The original 
protocol from which these modifications were made is detailed in appendix II. 
 
Viable cells were those which showed typical morphology of a cardiomyocyte when observed under a 
light microscope, namely an elongated, rod-shaped cell, with a smooth outer edge. Cardiomyocytes 
which have been over digested during enzymatic dispersion will typically be more spherical in shape. 
The identification of striations also helped to confirm the successful isolation of the correct cell type 
(Figure 6.3).  
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6.2.3 Identification of the effect of CBD and AM251 on the mitochondrial 
membrane potential  
 
Having obtained viable cardiomyocytes, a series of experiments was performed that sought to identify 
the effect of CBD and AM251 on mitochondria membrane potential using redox sensor red CC-1 (CC-
1), a redox sensitive fluorescent dye which selectivity accumulates in mitochondria (and lysosomes) 
following oxidisation in the cytosol of the cell (Shukla et al., 2003). The hypothesis for this series of 
experiments was that CBD or AM251 may be preventing or delaying depolarisation of the 
mitochondria due to mPTP opening, which typically occurs following ischaemia (Siddall et al., 2013). 
Thus, CC-1 was used as a detector of mitochondrial membrane potential and FCCP was used to 
uncouple the mitochondria in order to identify if CBD or AM251 could reduce membrane 
depolarisation. The initial experiments aimed to identify the optimal concentrations of CC-1 and the 
mitochondrial uncoupling agent, FCCP, the latter of which was used to indicate the effect of 
mitochondrial uncoupling, on fluorescence intensity. The concentrations of CC-1 used were 1, 3 or 
5µM and the concentration range of FCCP tested was 10 and 1µM and 100nM. Cells were isolated as 
described in section 6.2.2. 300µl of cell suspension was pipetted into each well of the 96 well plate 
(Millipore, Massachusetts, USA), cells were allowed 1, 3 or 5 hours to become adherent in an 
incubator at 37°C. Plates were laminin coated by incubating each well with 50µl with laminin 
overnight. FCCP was incubated (37°C) for 10 minutes prior to CC-1 addition. CC-1 was incubated for 
10 minutes at 37°C. The bath solution was pipetted off from each well before cells were washed once 
in Krebs solution; each well was then refilled with 300µl of Krebs solution. Fluorescence intensity 
was read using a Bio-tek FL600 microplate flourescence reader (MTX Lab Systems Inc, Virginia, 
USA) the data for which was relayed to a desktop computer equipped with CS4 software. Plates were 
read from below and sensitivity was set to 25, excitation wavelength was set to 560/20 and emission 
wavelength to 590/20.  
 
6.2.4 The effect of CBD and AM251 on [Ca2+]i in normoxia and simulated 
ischaemia 
 
The next series of experiments were designed to try and assess cardiomyocyte [Ca
2+
]i using fluorescent 
microscopy in both normoxia and simulated ischaemia. The experimental design was changed from 
that described in section 6.2.3 because of the difficulty in determining significant changes in 
fluorescent intensity between blank and CC-1 loaded cardiomyocytes. While an inital aim during 
design of the CAO experiments, was to investigate both the electrophysiological (anti-arrhythmic) and 
tissue sparing (infarct size) of CBD, in the interest of time, the study only investigated the former and 
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so, study of a tissue sparing end-point (effect on mPTP) in the isolated cardiomyocytes was no longer 
applicable. Therefore the experiments were designed to investigate any effect of CBD and AM251 on 
ischaemia-induced changes in [Ca
2+
]i, that have been identified as a trigger for multiple forms of 
ectopic activity (Clusin, Buchbinder and Harrison, 1983; Opie et al., 1988; Thandroyen et al., 1991; 
Lubbe, Podzuweit and Opie, 1992).  
 
Figure 6.2 illustrates the experimental protocol used in this study. Healthy cells isolated from 
ventricular tissues were subject to investigation of the effect of a single drug treatment on [Ca
2+
]i. 
Experimental drug treatment groups were; (i) vehicle control (0.002% dimethyl sulfoxide and 0.25% 
ethanol (EtOH)), (ii) CBD (3µM), (iii) AM251 (25µM), (iv) CBD in the presence of AM251, (v) 
AM251 in the presence of CBD. [Ca
2+
]i was detected by loading isolated ventricular cardiomyocytes 
with the acetoxymethyl (AM) ester of fluo-4 as described in section 2.4.2. Fluo-4 AM (5µM) was used 
as tool to determine [Ca
2+
]i changes in isolated ventricular cardiomyocytes and thus changes in fluo-4 
AM fluorescence are referred to as changes in [Ca
2+
]i. All drug treatments were added to the cell-fluo-
4 AM suspension after 20 minutes of fluo-4 AM incubation and the remainder of the incubation period 
occurred at room temperature. 100µl of the fluorescence-loaded labelled cells were then pipetted onto 
a perfusion chamber mounted on the stage of a Leica DMI 4000B microscope. These cells were 
brought into focus at x200 magnification using phase light before being illuminated with fluorescent 
light (100w Hg lamp) filtered by the blue-green-red filter cube (excitation band Pass 495/15; 
dichromatic mirror 510 and suppression filter 530/30).  
 
The movie setting of the Leica image capture software was then initiated to capture the pre-wash cell 
fluorescence. Cells were then superfused with Krebs-Henseleit solution at a rate of 1ml min
-1
. Images 
of cells were recorded during this wash period. The bath solution was continually aspirated off by way 
of a Dymax air pump (Charles Austen Pumps Ltd, Surrey, UK). Cells were finally stimulated by 
switching to a Krebs-Henseleit solution (Table 6.1) containing 60mM KCl and image sequences 
recorded. All normoxic solutions were maintained by bubbling solutions with a 95% O2 and 5% CO2 
gas mix. 
 
For simulation of ischaemia, the experimental protocol was comparable to that for normoxic cells with 
the exception that Krebs-Henseleit solution was replaced with an ‘ischaemic’ bath solution at the wash 
stage of the protocol (Table 6.1) in that the solutions in these series of experiments were gassed with 
95% N2/5% CO2. 
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Figure 6.2 Drug treatment and experimental protocol for normoxic isolated cardiomyocytes 
  
Fluo-4 AM 
incubation 
•Fluo-4 AM (5µM) incubated for 
30 minutes at room temperature 
•Drugs/vehicle added after 20 
minutes at room temperature 
Prewash 
•Cells illuminated with  
fluorescent light 
Wash 
•Cells perfused with Krebs 
solution gassed with 95% O2 and 
5% CO2 
•Baseline cells imaged using Leica 
image capture software 
•Subsequent measurements of 
fluoresecent intensity used to 
indicate [Ca2+]i in baseline 
conditions 
Stimulation 
•Cells stimulated  to contract with 
60mM KCl 
Cells perfused 
with Krebs 
solution 
•Bubbled with 95% O2 and 5% CO2 
•Stimulated cells imaged using 
Leica image capture software 
•Subsequent measurements of 
fluoresecent intensity used to 
indicate [Ca2+]i in baseline 
conditions 
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Krebs-Henseleit buffer solution and ischaemic bath solution 
 
Salt Normoxic concentration Ischaemia concentration 
NaCl 120mM 141.5mM 
KCl 2.5mM 8mM 
MgCl2 2.5mM 1mM 
NaH2PO4 0.5mM 1.2mM 
KH2PO4 0.5mM - 
NaHCO3 15mM 8.5mM 
CaCl2 1mM 1.8mM 
Glucose 10mM 5.5mM 
HEPES 5mM - 
Distilled water 1000ml 1000ml 
pH 7.4 6.8 
 
 
Table 6.1 Composition of Krebs-Henseleit solution and the ischaemic bath solution 
 
6.2.5 Exclusion criteria 
 
The exclusion criterion for these data was a lack of change in fluorescence to stimulation with 60mM 
potassium chloride (KCl). 
 
6.2.6 Data analysis and expression 
 
Images were sampled at a frequency of 1Hz. All images were normalised to background fluorescence. 
Fluo-4 AM fluorescence in cardiomyocytes was initially calculated as the grey scale value over the 
length of 17 pixels in each myocyte, and the same measurement was taken from a cell-free area of 
each image to allow for normalisation. Mean changes from baseline in response to both drug additions 
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and subsequent KCl stimulation were then calculated in conditions of normoxia and simulated 
ischaemia. 
 
To determine any changes in baseline [Ca
2+
]i by the drug intervention, results were expressed as fold 
change in florescence compared with baseline value (F/F0), where F is the measured, unstimulated 
fluorescence in drug-treated cells and F0 is the unstimulated fluorescence in separate vehicle-treated 
cells.  
 
                                           
                                          
                                             
 
 
Equation 5.1 Equation for calculation of fold changes in baseline fluorescence in isolated cardiomyocytes. 
For cells stimulated with 60mM KCl, results were expressed as fold changes in peak fluorescence 
compared with baseline value (F/F0), where F is the fluorescence measured after drug addition and F0 
is the corresponding baseline fluorescence for that drug treatment. 
 
                                          
                                       
                                           
 
 
Equation 5.2 Equation for calculation of fold changes in peak fluorescence in isolated cardiomyocytes. 
 
For the fluorescence intensity data from the CC-1 experiments, average well fluorescence intensity 
was measured in triplicate for each treatment and then repeated in cells from at least 3 more rat hearts. 
 
6.2.7 Statistical analyses 
 
Statistical analyses were performed on all data sets with a one-way ANOVA and Dunnett’s post-hoc 
test and significance accepted as P<0.05. The exception to this was the analysis of the effect of 
ischaemia on baseline and peak fluorescence in vehicle control cells, which was analysed using a 
Student’s t test. Group sizes before application of exclusion criteria were as follows; Vehicle (n=6);  
CBD (n=5); AM251 (n=5); CBD then AM251 (n=4) and AM251 then CBD (n=5). Fluorescence for 
each intervention was measured in more than one cell (usually 2-3). These readings were then 
averaged to produce a single n number for each experiment, with the final n numbers stated being 
representative of the total number of hearts per group. 
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6.3 Results 
 
6.3.1 Identification of rat ventricular cardiomyocytes 
 
Figure 6.3 shows an example of a viable cardiomyocytes isolated by enzymatic dispersion described in 
section 6.2.2. This rod-shaped cardiomyocyte has been incubated with fluo-4 AM which is dispersed 
uniformly through the cardiomyocyte. The dark and light striated pattern shows the parallel actin and 
myosin filaments. 
 
6.3.2 Determination of optimum CC-1 and FCCP concentrations for 
quantification of changes in mitochondrial membrane potential  
 
To optimise the concentration of CC-1 isolated cardiomyocytes were loaded with a concentration 
range of 1, 3 and 5 µM were tested. There was no significant difference in fluorescence intensity 
between any of the concentrations tested (35 ± 7, 35 ± 5, 30 ± 9 vs. 41 ± 9; CC-1 1, 3 and 5µM, 
respectively vs. blank; Figure 6.4), thus, the subsequent experiments were completed at the lowest 
concentration of CC-1. Addition of FCCP had no significant effect on fluorescence intensity at any 
concentration, compared with either blank or CC-1 (1µM)-treated cells (Figure 6.5). 
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Figure 6.3 An example adult rat ventricular cardiomyocyte showing striated banding. Ventricular 
cardiomyocytes were isolated by enzymatic dispersion and tituration, incubated with fluo-4 AM and 
viewed at x200 magnification. 
  
Striations 
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Figure 6.4 The effect of increasing concentrations of CC-1 on fluorescence intensity. Isolated ventricular 
cardiomyocytes were incubated with different concentrations of CC-1 to determine the optimal 
concentration for the quantification of fluorescence intensity.  Data are expressed as mean fluorescence 
intensity ± SEM (arbitrary units; A.U). Samples were measured in triplicate, n=5. 
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Figure 6.5 The effect of increasing concentrations of CC-1 fluorescence intensity. Isolated ventricular 
cardiomyocytes were incubated with CC-1 and increasing concentrations of FCCP to determine the 
optimal concentration of FCCP to induce significant changes in CC-1 fluorescence intensity. Data are 
expressed as mean fluorescence intensity ± SEM (arbitrary units; A.U). Samples were measured in 
triplicate, n=4-5. 
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6.3.3 Effect of ischaemia on baseline and peak [Ca2+]i 
 
Induction of simulated ischaemia on isolated cardiomyocytes resulted in a small decrease in baseline 
[Ca
2+
]i compared with the baseline measurements from cells perfused with normoxic solution (0.78 ± 
0.23 vs. 1 F/F0; Figure 6.6), however this was not a statistically significant effect. Upon stimulation 
with KCl, normoxic cardiomyocytes exhibited a 1.39 ± 0.14 fold increase in [Ca
2+
]i from baseline 
(Figure 6.7). Under conditions of simulated ischaemia, KCl induced an enhanced fluorescence signal 
compared to that observed in normoxic cells (2.24 ± 1.46 vs. 1.39 ± 0.14 F/F0; P=0.05; Figure 6.7). 
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Figure 6.6 Effect of simulated ischaemia on baseline fluo-4 AM fluorescence in isolated cardiomyocytes. 
Data are expressed as the mean ± SEM fold change from baseline fluorescence in normoxic cells ± SEM 
(n=3-5).  
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Figure 6.7 Effect of simulated ischaemia on peak fluorescence, elicited by 60mM KCl. Results are 
expressed as a fold change in mean peak fluorescence (n=3-5). 
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6.4 Discussion 
 
The aim of this series of experiments was to develop a model of isolation of rodent ventricular 
cardiomyocytes and to preliminarily determine the effects of CBD and AM251, alone and in 
combination, on baseline and KCl-stimulated [Ca
2+
]i in cardiomyocytes under normoxic and simulated 
ischaemic conditions.  
 
6.4.1 Method development of isolation of ventricular cardiomyocytes 
 
The principal aim of this series of experiments was to attempt to develop a model to successfully 
isolate ventricular cardiomyocytes from adult rat hearts. The initial protocol employed (Bates and 
Gurney, 1999) was modified as described in section 6.2.2 in an effect to improve cell yield and the 
reproducibility of quality isolations from adult rat hearts. In spite of these modifications, the isolation 
process remained only partially successful and thus, the preliminary data presented herein represents 
the effects of simulated ischaemia and drug interventions on [Ca
2+
]i  on cells whose appearance 
typified a cardiomyocyte when viewed on an inverted light microscope and which subsequently 
responded, by a change in fluo 4-AM fluorescence intensity, to application of 60mM KCl (as 
described in the experimental protocol; figure 6.2). 
 
The protocol (Bates and Gurney, 1999; Ma et al., 2006) of enzymatic dispersion of cardiomyocytes 
from ventricular tissue with collagenase, proteinase and hyaluronidase allows cells to be isolated by 
digestion of soluble and insoluble collagen, hydrolysis of protein polypeptide chains and cleavage of 
the glycosaminoglycan, hyaluronan, respectively (Stern and Jedrzejas, 2006). However small changes 
in tissue levels of the respective targets may mean inadequate or over-digested ventricular tissue. In 
either circumstance, there would be minimal, if any, functioning cells yielded by enzymatic 
dispersion.  Age-dependent differences in collagen content of cardiac tissues have been demonstrated 
by Annoni et al. (1998) but not in rats aged less than 12 months. Significant differences in interstitial 
collagen content were only observed in rats aged 19 months (Annoni et al., 1998). As such, it is 
unlikely that over the duration of the period of the present study, during which rats hearts were 
harvested for the enzymatic dispersion of cardiomyocytes, that there would have been a significant 
age-dependent change in cardiac collagen content.  
 
Early isolation of adult rat ventricular cardiomyocytes often produced Ca
2+
-intolerant cardiomyocytes 
which were only viable for a few hours post-isolation. The protocols used to yield such cells involved 
enzymatic dispersion (with collagenase and hyaluronidase or trypsin; Vahouny, 1970; Fabiato and 
 - 152 - 
 
Fabiato, 1972) of tissue chunks or by retrograde perfusion of the intact heart. It was demonstrated that, 
in these isolated cells, during the process of returning cells to a bathing medium containing 
physiological [Ca
2+
], the cardiomyocytes became metabolically deregulated and this led to 
hypercontracture, ischaemia and membrane damage (Brierley et al., 1985; Thum and Borlak, 2000). 
Aggressive digestion of cardiomyocytes can lead to membrane damage and may be the cause of Ca
2+
 
intolerance, and is typified by a change in the morphology from rod-shaped to spherical and high 
levels of lactate dehydrogenase (LDH) and creatine kinase (CK) activity. Moreover, these enzymes are 
good indicators for membrane integrity/damage (Thum and Borlak, 2000).  The quantification of 
viable cells in earlier studies showed a range of viability (55-92%; % of rod-shaped cells) depending 
on the isolation technique employed with the latter and more successful isolation protocol using an 
enzyme solution containing Joklik solution supplemented with butandione monoxime (BDM), 
collagenase type II and bovine serum albumin (Vahouny, 1970; Fabiato and Fabiato, 1972; Grosso et 
al., 1977; Nag and Zak, 1979; Nag et al., 1983; Bkaily et al., 1984; Van der Heide, 1995; Kivisto, 
1995; Weisensee, 1995; Thum and Borlak, 2000). Unfortunately cell viability was not quantified in 
this study, however from my observations I suspect that the protocol used for this study yielded 
viability similar to the early adult cardiomyocyte isolation studies. With this in mind, it may be that 
during isolation in this study, the retrograde perfusion of the heart tissue with the enzyme solutions 
was too long and the cell membranes became damaged. Thum and Borlak (2000) demonstrated that 
addition of the cytoprotective agent BDM significantly reduced LDH and CK activity during isolation 
which may indicate healthier cardiomyocyte cell membranes. As such, it may have been pertinent to 
include BDM into the perfusion solutions for this study. Improved yield and viability has also been 
observed with the addition of EDTA early in the isolation process; these improvements were thought 
to be due to modulation of tight junctions between cardiomyocytes which in turn reduces membrane 
damage (Thum and Borlak, 2000). Inclusion of these two agents thus may have improved the 
reproducibility of cell isolation in this study. 
 
This study used a nominally Ca
2+
-free solution during the enzymatic dispersion of cardiomyocytes by 
retrograde perfusion as described previously (Bates and Gurney, 1999). Following retrograde 
perfusion the bathing solution was switched immediately to a Ca
2+
-containing Krebs solution, which 
helped to prevent further enzymatic digestion of the cardiomyocytes. More recent investigators have 
described a more gradual, step-wise replacement of Ca
2+
 into the bathing solution over the course of 
20 minutes (Lim et al., 2008). This may prevent hypercontracture, ischaemia and membrane damage 
in cells which may otherwise be lost upon rapid Ca
2+
 replacement (Brierley et al., 1985; Thum and 
Borlak, 2000). 
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6.4.2 Development of a method to quantify changes in mitochondrial 
membrane potential 
 
This study initially sought to gain preliminary data of the effect of CBD and AM251 on mitochondrial 
membrane potential, which was to be determined by a change in fluorescence intensity of the redox 
sensor red CC-1-loaded cardiomyocytes read on a plate reader and compared with the mitochondrial 
protonophore FCCP. This was on the premise that CBD and/or AM251 may be conferring 
cardioprotection (chapter 5) by acting to stabilise mitochondrial membrane potential since AM251 has 
been shown to attenuate dysfunction of mitochondria in a model of hepatic lipogenesis (Chen, Ho and 
Lee, 2013) and CBD can modulate [Ca
2+
]i depending on the excitability of the cell in a manner in part 
aided by mitochondria (Ryan et al., 2009). Blank and CC-1 loaded cells showed similar fluorescence 
intensity and moreover, there was no change in fluorescence intensity when mitochondria were 
uncoupled by any of the concentrations of FCCP tested. It was suspected that a significant number of 
the isolated cardiomyocytes were being lost during the washing process and so plates were 
subsequently laminin coated and cells were allowed to adhere for 1, 3 or 5 hours to determine if there 
was an improvement in fluorescent intensity (appendix 3). This however failed to improve quantifiable 
fluorescence. Although it was surmised that cardiomyocytes were free-floating and therefore, 
unaffected by laminin coating of plates, colleagues at Astra Zeneca are currently investigating the 
physiology of adherent cardiomyocytes using a bind scanner. The difficulty in determining 
fluorescence intensity using this protocol could therefore be due to low cell yield and as such it was 
thought pertinent to instead quantify fluorescence using the technique detailed in section 6.2.3, as this 
protocol is less reliant on high cell yield as the plate reader protocol. In addition, more recently it was 
shown that AM251 could have a negative impact on mitochondrial membrane potential by modulation 
of oestrogen-related receptor α (ERRα; Krzysik-Walker et al., 2013). With these findings in mind, it 
was thought that investigation of the effect of CBD and AM251 on [Ca
2+
]i may give a better insight 
into the mechanism by which these agents are anti-arrhythmic, since it is well recognised that 
modification of [Ca
2+
]i reduces arrhythmia. This is in fact thought to be due to reduction in overall 
cellular Ca
2+
 rather than an effect directly on the mitochondria (Brown and O’Rourke, 2010). Thus, for 
subsequent experiments the new protocol was employed. 
 
6.4.3 Effect of simulated ischaemia on baseline and KCl-stimulated [Ca2+]i 
 
Fluo-4 AM is a cell permeant fluorescent Ca
2+
 indicator which is excited upon Ca
2+
 binding; as such, 
an increase in fluo-4 AM fluorescence is indicative of increased intracellular [Ca
2+
]i.  
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In conditions of simulated ischaemia there was a slight decrease in baseline fluo-4 AM fluorescence, 
indicative of a reduction in [Ca
2+
]i. This is in contrast to findings by Li et al. (2013), who found that 
simulated ischaemia in cardiomyocytes progressively increased baseline [Ca
2+
]i. This may be due to 
the duration of simulated ischaemia in the present study (20 minutes) which was significantly shorter 
than the 60 minutes used in the Li et al. (2013) study. Similarly, in the in vivo setting, induction of 
ischaemia results in a comparatively slow rise in Ca
2+ 
(Levick, 2003). 
 
In control (non drug-treated) cells, upon stimulation with KCl, cardiomyocyte [Ca
2+
]i was increased by 
approximately 1.5-fold under normoxic conditions.  When challenged with KCl under simulated 
ischaemia an approximate 2.5-fold increase in [Ca
2+
]i was observed, although this did not achieve 
statistical significance when compared with normoxic conditions. The increase in [Ca
2+
]i observed 
under conditions of simulated ischaemia were also observed in a more long-term investigation of 
[Ca
2+
]i in a mouse model of chronic heart failure (CHF) after in vivo myocardial infarction. Isolated 
cardiomyocytes from this mouse model of CHF, showed that both 1 week and 10 weeks post-MI, Ca
2+
 
transients were higher than in sham animals due to increased Ca
2+
 influx and higher SR Ca
2+
 
concentrations, that being Ca
2+
 mobilisation was mediated by electrical field stimulation which was 
used in the present study as opposed to KCl (Mork et al., 2009). 
 
6.4.4 Effects of CBD in normoxic cells on baseline and simulated [Ca2+]i 
 
This study demonstrated that under normoxic conditions, CBD had no effect on baseline [Ca
2+
]i in 
single ventricular cardiomyocytes which is in contrast with findings observed previously in a study of 
hippocampal cells. Drysdale et al. (2006) showed that CBD (1µM) was a potent mobiliser of [Ca
2+
], 
from both intracellular stores and entry via LTCCs, in neurones and glial cells from the hippocampus. 
However, they did note a degree of variability in the responses to CBD depending on cell type; while 
77% of glia responded to CBD, only 55% of neurones did. On the basis of the present findings, it may 
be that cardiomyocytes are unresponsive to CBD. Furthermore, the study by Drysdale et al. suggests 
that [Ca
2+
]i mobilisation in response to CBD may be CB1 receptor independent on the basis that the 
glia responded most frequently but do not express this receptor. As discussed in the introduction, CBD 
has been proposed to mediate reductions in [Ca
2+
]i in conditions of high excitability in hippocampal 
cells by inhibition of the mitochondrial sodium-calcium exchanger (Ryan et al., 2009) and as such, it 
is unlikely this lack of responsiveness to CBD in our cardiomyocytes is as a result of lack of receptors 
through which CBD may mediate this reduction in [Ca
2+
]i.  
 
In contrast to the effect of CBD alone, AM251 pre-treatment unmasked an increase in [Ca
2+
]i in 
response to CBD. This is consistent with the findings of Drysdale et al. (2006), who observed that the 
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response of hippocampal cells to CBD was markedly increased in the presence of a CB1 receptor 
antagonist. They proposed that this CB1 receptor antagonist-mediated facilitation of the effect of CBD 
on [Ca
2+
]i was due to prevention of voltage-gated Ca
2+
 channel blockade by the tonically active CB1 
receptor. Furthermore, they proposed that CBD’s effects were due to release of Ca2+ from intracellular 
stores, rather than Ca
2+
 entry itself, on the basis that the [Ca
2+
]i response was blocked by thapsigargin 
and facilitated by a CB1 receptor antagonist. Thus, it could be that in the presence of CB1 receptor 
blockade CBD is better able to facilitate Ca
2+
 release from intracellular stores, through a possible 
action at GPR55.  However, activation of GPR55 results in Ca
2+
 mobilisation via Gq-facilitated LTCC 
activation and release of Ca
2+
 from intracellular stores via inositol 1,4,5-triphosphate (IP3R) and 
ryanodine (RyR) receptors (Figure 6.13; Lauckner et al., 2008; Waldeck-Weiermair et al., 2008, Yu et 
al., 2013). Therefore it is more likely that, when free to act as a GPR55 antagonist, CBD inhibits, 
rather than facilitate, any increase in [Ca
2+
]i.  
 
6.4.5 Effects of CBD on [Ca2+]i in simulated ischaemia 
 
Similar to its effects under normoxic conditions, CBD had no effect on [Ca
2+
]i under either baseline 
conditions or in KCl-stimulated cells subjected to simulated ischaemia. Thus it is unlikely that that the 
anti-arrhythmic effects of CBD described in the previous chapter are through an effect on [Ca
2+
]i at the 
level of the cardiomyocyte. 
 
In contrast to the effect of pre-treatment with AM251 prior to CBD application on KCl-induced 
increases in [Ca
2+
] under normoxic conditions, under conditions of simulated ischaemia, co-application 
of AM251 suppressed the rise in [Ca
2+
]i suggesting that ischaemia per se induces changes that leads to 
a reduction in the [Ca
2+
]i response. Levels of circulating endocannabinoids have been shown to 
increase after induction of acute ischaemia and AEA has been shown to be released directly from 
cardiomyocytes (Mukhopadhyay et al., 2007) and to inhibit the function of LTCCs.  Thus, under 
conditions of ischaemia AEA released from the cardiomyocytes may inhibit the KCl-stimulated rise in 
[Ca
2+
]i through blockade of LTCCs, thus negating the effect of any CBD-mediated rise in [Ca
2+
]i.  
 
6.4.6 Effects of AM251 on baseline and stimulated [Ca2+]i in normoxic and 
hypoxic cardiomyocytes 
 
AM251 alone induced a significant increase in both baseline and KCl-induced increases in [Ca
2+
]i in 
normoxic, isolated cardiomyocytes, which is consistent with a previous study demonstrating that 
AM251 increases Ca
2+
 currents in HEK 293 cells (Vasquez et al., 2003). If the effects of AM251 are 
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through its action as a CB1 antagonist, then this increase in [Ca
2+
]i may be due to lifting the CB1-
mediated inhibition of GPR55 signalling as described above. However, CB1 receptors are expressed 
only sparsely on normal, healthy cardiomyocytes, which suggests that in normoxic cells the actions of 
AM251 are likely to be independent of CB1 receptors, and thus more likely involve the activation of 
GPR55 which, would increase internal Ca
2+ 
(Lepicier et al., 2007). As mentioned above, GPR55 
activation in cardiomyocytes has been shown to regulate [Ca
2+
]i in a L-type Ca
2+
 channel, IP3R and 
RyR-dependent manner (Henstridge et al., 2009; Yu et al., 2013). In addition, GPR55 receptor 
activation can induce depolarisation of the cardiomyocyte (Bondarenko et al., 2010; Yu et al., 2013). 
Importantly, GPR55 receptor activation can induce different electrophysiological responses depending 
on whether activation is sarcolemmal or intracellular, with the former depolarising and the latter 
hyperpolarising the cardiomyocyte (Error! Reference source not found.6.16; Yu et al., 2013). The 
finding that the increases in baseline and peak [Ca
2+
]i elicited by AM251 were attenuated when cells 
were pre-treated with CBD  prior to AM251 supports the notion of an action of AM251 at GPR55. 
 
In contrast to the effects on normoxic cardiomyocytes, AM251 decreased the KCl-induced increase in 
[Ca
2+
]i and had no effect on baseline [Ca
2+
]i. Moreover, the effect on KCl-induced changes in [Ca
2+
]i 
was not modulated by CBD pre-treatment. This suggests once again that ischaemia can alter the 
response of cardiomyocyte [Ca
2+
]i to AM251.  As discussed in section 6.4.3, the most likely mediator 
of reduced [Ca
2+
]i in conditions of ischaemia would be increased circulating endocannabinoids that 
inhibit Ca
2+
 influx through the LTCCs (Mukhopadhyay et al., 2007). Alternatively, hypoxia/ischaemia 
may influence the expression of the receptors within the myocardium, since the expression of both 
CB1 (Lepicier et al., 2007) and GPR55 (chapter 5) have both been shown to be augmented in 
ischaemia/infarcted myocardium; this would inevitably result in alterations in the pharmacological 
response to agents acting at these receptors. More specifically, data from our lab has shown that LPI, 
the endogenous ligand for GPR55, can only increase infarct size when given prior to ischaemia and 
not post-MI (Robertson-Gray, unpublished). This may suggest that ischaemia is associated with a 
reduction in GPR55 expression and this may explain the opposing effects of AM251 in the isolated 
cardiomyocytes.  
 
6.4.7  Study limitations 
 
The model of simulated ischaemia in isolated ventricular cardiomyocytes used in the present study is 
similar to that implemented by O’Brien and Howlett (2008). While is does not mimic precisely the 
effects of in vivo MI, the purpose of this study was to further elucidate the anti-arrhythmic effects of 
CBD and AM251 and more specifically, whether they might be acting to alter [Ca
2+
]i. As such 
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investigation of the isolated cardiomyocyte under conditions of hypoxia, substrate deprivation, and 
ionic imbalance was a fair representation of in vivo conditions (Guo et al., 2013). 
 
Acute in vivo ischaemia induced by ligation of a coronary artery causes cessation of local circulation, 
thus inducing oxygen deprivation and metabolite accumulation. In the in vitro model of simulated 
ischaemia used in this study, an ischaemic bath solution was superfused to the cardiomyocyte 
perfusion chamber. Therefore, in this model, there was no cessation of circulation as would be 
observed in vivo. Critically, purine precursors, amphiphiles and protons would be washed out, thereby 
preventing replication of the deleterious effects of metabolite accumulation (Carmeliet, 1999). 
 
In conditions of acute hypoxia, there are changes in ion channel function which consequently induce 
ion concentration perturbations, including but not limited to; the late Na
+ 
which is amplified, the fast 
Na
+
 which is reduced, the L-type Ca
2+
 current through which basal current is diminished, and finally, 
the delayed rectifier K
+
 current, through which the slow component is decreased. The perturbations in 
ion homeostasis change action potential morphology duration little unless coupled with β-
adrenoceptor stimulation (Guar, Rudy and Hool, 2009). The changes in ion channel function following 
acute hypoxia are similar to those induced by ischaemia, although since action potential morphology is 
altered less, the ion perturbations are less extreme. In hypoxia, the action potential is shortened as in 
conditions of coronary artery occlusion but the fall in resting membrane potential is not as great, 
furthermore, the maximum upstroke velocity decreases are not as significant (McDonald and 
MacLeod, 1973; Carmeliet, 1978; Janse and Wit, 1989; Pacini and Kane, 1991; Carmeliet, 1999).  It 
has been identified that a combination of lactate (10mM), acidosis (pH 6.8) and the bioactive lipid, α-
lysophosphatidylcholine (LPC; 5µM), most closely reflected the changes in action potential observed 
in vivo, however, these in vitro changes were best observed in what would be the late phase of 
arrhythmia occurrence in vivo (>6 hours post-occlusion). The changes in AP characteristics induced by 
combined acidosis, hypoxia and elevated extracellular K
+
, conditions we employed, produced reliable 
reductions in resting membrane potential, action potential amplitude and action potential duration at 
50 and 90% repolarisation levels (Pacini and Kane, 1991) thus supporting the use of these conditions 
in our model.  
 
The model described herein cannot therefore completely represent the plethora of deleterious changes 
induced by acute MI in vivo. However the hypoxic conditions, combined with an ischaemia-like 
superfusate, are a viable representation in the isolated, ex vivo setting.  
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6.4.8 Summary and conclusions 
 
The key findings are that, CBD has no significant effect on [Ca
2+
]i in normoxia or simulated 
ischaemia, however, AM251 pre-treatment unmasked an increase in [Ca
2+
]i, possibly induced by 
activation of SR release or by GPR55-mediated activation by AM251. AM251 however, increased 
baseline [Ca
2+
]i, likely due to GPR55 activation as this response could be muted by CBD pre-
treatment, implying a simple, agonist-antagonist effect of the two compounds at GPR55. AM251 
either alone or in combination with CBD reduced [Ca
2+
]i in hypoxic cardiomyocytes and this may 
explain the anti-arrhythmic effects of this drug we described in chapter 5. 
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7. General Discussion 
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7.1 Main findings 
 
7.1.1 CBD and AM251 mediate hypotension in the anaesthetised rat 
 
The role that CB1 receptors play in mediating changes in haemodynamic variables has been reasonably 
well characterised, having been identified as the principal mediators of the prolonged hypotension 
which typifies phase III of the haemodynamic response to bolus I.V. cannabinoid administration (Jarai 
et al., 1999; Ledent et al., 1999). As detailed in sections 4.4.1 and 4.4.2, this study further supports 
these data by demonstrating that the selective CB1 receptor agonist, ACEA, produces a significant fall 
in MABP following bolus I.V. administration. Furthermore, the CB1 receptor antagonist AM251 had 
the capacity to abrogate the depressor response induced by ACEA, thus strongly suggesting that the 
effects of ACEA were mediated by the CB1 receptors. 
 
Unlike the role of CB1 receptors in blood pressure regulation, the role of GPR55 has received much 
less attention, yet increasing evidence suggests that this recently deorphanised GPCR may play an 
important physiological role. In particular it has been identified to play a role in bone metabolism 
(Whyte et al., 2009; Sharir et al., 2012), skin tumour development (Perez-Gomez et al., 2013), and the 
prevention of oxidative damage and neutrophil migration (McHugh and Ross, 2009; Balenga et al., 
2011; Henstridge et al., 2011). Alone it was observed that AM251 induced a transient depressor 
response which could not be explained as a CB1 receptor mediated effect given that antagonism at CB1 
would be expected to increase, rather than decrease, blood pressure (Montecucco and Di Marzo, 
2012). As well as being a CB1 antagonist however, AM251 is a potent GPR55 receptor agonist 
(Ryberg et al., 2007), and as such, it is possible that the transient fall in MABP induced by AM251 is a 
GPR55-dependent effect. 
 
In addition to the haemodynamic changes mediated by each of these agents alone, pre-treatment with 
CBD abrogated the AM251 mediated antagonism of ACEA’s depressor effects. CBD (Ryberg et al., 
2007) and AM251 (Fischbach et al., 2007; Johns et al., 2007; Waldeck-Weiermair et al., 2007) have 
opposing pharmacological activity at GPR55, as antagonist and agonist, respectively, and as such it 
would be unlikely that this abrogation is solely through a GPR55-mediated effect. Rather, literature 
exists which suggests that there is a degree of crosstalk between the CB1 and GPR55 receptors with 
GPR55 signalling being inhibited by CB1 receptor activation in a process dependent on the activation 
status of integrins (Waldeck-Weiermair et al., 2008). Therefore if this cross-talk is relevant to 
modulation of haemodynamic variables then it is possible that CBD is not acting as an antagonist at 
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GPR55 but rather as a weak antagonist or inverse agonist at CB1, thus uplifting CB1-mediated 
suppression of GPR55 signalling thus allowing AM251 to induce a more profound hypotension.  
 
7.1.2 The selective GPR55 agonist, O-1602, does not mediate hypotension 
in the anaesthetised rat 
 
To confirm that the transient hypotension mediated by AM251 was a GPR55-medited effect the 
selective GPR55 agonist, O-1602 was employed; however, this failed to induce any change in MABP 
or HR, even at the highest dose (100ng kg
-1
) as described in sections 4.4.5. Recent data has however, 
cast doubt over the legitimacy of O-1602 as a GPR55 ligand and suggestion was made that rather that 
GPR55, GPR18 is its principal pharmacological target (Johns et al., 2009; Kapur et al., 2009; McHugh 
and Ross, 2009). Thus the lack of O-1602 induced hypotension in the anaesthetised rat does not rule 
out a role for GPR55 in BP regulation. 
 
7.1.3 Pre-ischaemia bolus AM251 administration confers protection 
against ischaemia-induced ventricular arrhythmias in vivo 
 
Numerous studies exist which investigate the effects of cannabinoids in the cardiovascular system 
including examination of the negative ionotropy induced by CB1 receptor activation (Ford et al., 2002; 
Bonz et al., 2003) and vasodilator effects of the endocannabinoid AEA (O’Sullivan et al., 2004; 
Mukhopadhyay et al., 2002). More recently our lab identified the cardioprotective effects of the 
phytocannabinoid, CBD (Walsh et al., 2010). Thus the aim of the present study was to elucidate the 
targets which may confer this cardioprotection. 
 
This study has, for the first time, demonstrated the anti-arrhythmic effect of the CB1 receptor 
antagonist and GPR55 receptor agonist, AM251 in a rat model of acute MI. Although this contrasts 
with existing literature (Hajrasouliha et al., 2008), this may be explained by the fact that the VT 
incidence in their control animals was comparable in magnitude to that observed for our AM251-
treated animals and therefore, much lower than our control incidences. As detailed in section 5.5.2, it 
was initially postulated that the anti-arrhythmic effects of AM251 may be conferred by way of 
compensatory activation of CB2 receptors owing to the inhibition of CB1 receptors coupled with the 
possibility that CB1 receptor expression is reduced during periods of increased endocannabinoid tone, 
which in the setting of ischaemia, would persist (Mukhopadhyay et al., 2007; Nucci et al., 2007). The 
role of CB2 receptor activation in cardioprotection has been more thoroughly investigated than that of 
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CB1, and it is acknowledged to provide protection (Krylatov et al., 2001; Lucsokova et al., 2008; Lim 
et al., 2009). Interestingly however, the present study demonstrated that AM251 had a marked 
suppressant effect on arrhythmias during acute MI which were likely to be induced by excess 
catecholamine release (i.e. phase Ib). One possibility is that AM251 achieves this through inhibition of 
tyrosine hydroxylase expression, which it has already been demonstrated to reduce in fawn-hooded 
rats (Femenia et al., 2010). Tyrosine hydroxylase is a critical catalyst of the rate limiting step in the 
production of adrenaline and noradrenaline (Femenia et al., 2010). 
 
7.1.4 Co-administration of CBD and AM251 can potentiate the reduction 
in arrhythmia incidence of either alone 
 
In order to identify potential targets which may mediate the anti-arrhythmic effects of CBD (Walsh et 
al., 2010), the effect of CBD in the presence of AM251, which was initially used as a CB1 antagonist, 
was investigated. During these investigations it became clear than AM251 alone was also able to 
reduce the incidence of VT and total VPBs and furthermore, depending on the order of administration, 
co-administration of CBD and AM251 could potentiate the observed reductions in VT incidence and 
total VPBs compared when either agent is administered alone. The disparity in the degree of 
protection afforded by CBD and AM251 depending on the order of administration, points to the 
involvement of other receptors, than just the CB1 receptor. Therefore it is possible that there is a 
degree of synergism between CBD and AM251 at common receptor targets, and this is supported by 
unpublished observations from our laboratory that have demonstrated that the modest ex vivo anti-
aggregatory capacity of CBD is enhanced in the presence of AM251. The common receptor targets 
may include the putative cannabinoid receptor GPR55. CBD and AM251 both act at GPR55, as an 
antagonist and agonist, respectively, moreover, CB1 receptors and GPR55 receptors have been shown 
to interact in vitro (Lauckner et al., 2008; Pacher and Hasko, 2008; Waldeck-Weiermair et al., 2008; 
Lim et al., 2009). However, while it seems unlikely that this synergism is the means via which AM251 
and CBD confer an anti-arrhythmic effect, considering the individual actions of these compounds at 
these receptors the difference in their anti-arrhythmic capacity based on order of administration may 
simply be due to a preferential activation of these targets based on their pharmacologies as detailed in 
figures 5.21 and 5.22. 
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7.1.5 AM251 can regulate [Ca2+]i in cardiomyocytes 
 
As detailed in section 6.3.4 and 6.3.5, AM251 can increase [Ca
2+
]i in baseline and stimulated 
normoxic cardiomyocytes. Although AM251 was initially employed as a CB1 receptor antagonist in 
the haemodynamic study (Chapter 3) it is now evident that AM251 is not a selective antagonist for 
CB1 but can in addition, act as an agonist at GPR55 (Ryberg et al., 2007). The present data supported 
observations made by Li et al. (2013) and since GPR55 receptor activation can increase [Ca
2+
]i by 
mechanisms including LTCC activation and IP3R and RyR mediated release from intracellular stores 
(Yu et al., 2013), it seems possible that the increase in [Ca
2+
]i mediated by AM251 is due to activation 
of GPR55.  
 
Conversely, AM251 appeared to induce a decrease in [Ca
2+
]i in stimulated, cardiomyocytes under 
ischaemic conditions. This effect was unaltered when CBD was co-administered. The data therefore 
suggested that ischaemia itself was altering the response of AM251 on [Ca
2+
]i in cardiomyocytes. 
Furthermore, our immunohistochemical identification of GPR55 in heart tissue (described in chapter 
5) shows that GPR55 receptor expression may be changed following ischaemia and thus, AM251 may 
no longer be acting predominantly at GPR55 but rather as an antagonist at CB1 receptors which are 
tonically active (Romano et al., 2013). 
 
7.1.6 CBD does not mediate changes in [Ca2+]i in cardiomyocytes 
 
CBD had no effect on [Ca
2+
]i in baseline or stimulated cardiomyocytes, under either normoxic or 
hypoxic conditions. This contrasted with data from Drysdale et al. (2006), who found CBD to be a 
potent mobiliser of Ca
2+
 in neurones and glia. However, these authors noted that there was a degree of 
variability in responses to CBD depending on the cell type and thus, it may be that myocytes are 
relatively unresponsive to CBD. On the basis that CBD does not affect a change in [Ca
2+
]i in myocytes 
under hypoxic conditions, it seems unlikely that the current findings and the previously reported anti-
arrhythmic effects of CBD are mediated by a change in [Ca
2+
]i at the level of the cardiomyocyte 
(Walsh et al., 2010). 
 
Pre-treatment with AM251 unmasked an ability of CBD to increase baseline and stimulated [Ca
2+
]i in 
normoxic cells. This data supports previous observations which noted that the response of 
hippocampal cells to CBD was increased in the presence of a CB1 receptor antagonist (Drysdale et al., 
2006). These authors proposed that the facilitation of [Ca
2+
]i mobilisation was due to relief of voltage-
gated Ca
2+
 channel blockade by the tonically active CB1 receptor. I also considered the potential 
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involvement of GPR55 given the pharmacological profiles of CBD and AM251 at this receptor. 
GPR55 activation is acknowledged to mediate an increase in [Ca
2+
]i and thus, the increase in [Ca
2+
]i 
conferred by CBD and AM251 and not CBD alone may be due to activation of GPR55 by AM251. 
However, CBD and AM251 did not increase [Ca
2+
]i in conditions of hypoxia, in fact there was a trend 
toward a reduction in [Ca
2+
]i in conditions of hypoxia. This may suggest that hypoxia itself could be 
inducing a change which may affect [Ca
2+
]i at the level of the cardiomyocyte. Recently, our group has 
shown that LPI can increase infarct size when given pre- but not post-ischaemia which would support 
the hypothesis that GPR55 activity is modulated by ischaemia (Robertson-Gray, unpublished). 
 
7.1.7 Clinical relevance 
 
This study has demonstrated the beneficial role of cannabinoid and GPR55 receptor ligands in 
reducing ischaemia-induced ventricular arrhythmias and furthermore, regulating [Ca
2+
]i in conditions 
associated with hypoxia. In the clinical setting MI is the cause of angina and cardiac arrhythmias 
(Crossman, 2004). Prolonged periods of ischaemia can cause cardiomyocyte death by myocardial 
infarction which is defined by ST, T and QRS complex changes on an ECG and an increase in blood 
concentrations of specific biomarkers like cardiac troponin. Acute coronary events like myocardial 
infarction continue to have a high mortality rate due to life-threatening in the first couple of hours and 
furthermore, fatalities in the first month can range from 30-50 % (Armstrong et al., 1972; Tunstall-
Pedoe et al., 1999; Van de Werf et al., 2003). Although these studies focussed on the pre-ischaemic 
administration of CBD and AM251 and thus this treatment would not be clinically practical for 
myocardial infarction or other acute coronary events, it may be practical for use on occasions which 
necessitate cessation of normal circulatory function, for example, coronary artery bypass grafts during 
which ischaemia-reperfusion injury routinely occurs (Sabbagh et al., 2013). 
 
7.2 Future work 
 
7.2.1 The role of GPR55 in regulating [Ca2+]i 
 
The current literature and this data suggest a role for the GPR55 receptor in regulating [Ca
2+
]i at the 
level of the cardiomyocyte in conditions of normoxia, and perhaps also in hypoxic conditions, as such 
and due to the preliminary nature of the isolated cardiomyocyte data presented in this thesis it would 
be interesting to repeat the investigations of the effects of AM251 in GPR55
-/-
 cardiomyocytes to 
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precisely determine the role this receptor may be playing. Furthermore, it would be interesting to 
determine if the effects of AM251 are due to selective GPR55 activation or whether its ability to act at 
CB1 receptors also plays a role. Recently, some groups have identified novel GPR55 ligands which 
lack activity at CB1 and CB2 and so use of these could possibly indicate if CB1 has any involvement or 
not (Brown et al., 2011; Kotsikorou et al., 2011; Kargl et al., 2012). 
 
7.2.2 Cross-talk between CB1 and GPR55 
 
It has been recognised that the activation and consequent signalling cascades of CB1 and GPR55 
receptors are linked (Waldeck-Weiermair et al., 2008; Kargl et al., 2012). Kargl et al. (2012) showed 
that GPR55 and CB1 receptors can form heteromers and that this process can modulate the signalling 
properties of each receptor. Therefore, it would be interesting to investigate whether the responses to 
CBD and AM251 are similar in cells expressing each receptor alone and those expressing the 
heteromeric receptors to determine if a difference exists between the responses. Moreover, if these 
responses were compared in isolated cardiomyocytes in particular they would give an indication as the 
whether ‘cross-talk’ is involved in the changes previously observed in [Ca2+]i.  
 
7.2.3 Examination of the effect of GPR55 on ischaemia-induced 
ventricular arrhythmias 
 
Our lab has previously sought to investigate the role of GPR55 receptors in a mouse model of acute 
MI; however the effect of AM251 on ischaemia-induced arrhythmias was not quantified. To better 
understand the involvement of GPR55 and CB1 receptors in mediating the cardioprotective effects of 
AM251 and CBD, it would be interesting to repeat this study in the GPR55
-/-
 model  
 
7.2.4 Determination of the effect of AM251 and CBD on infarct size 
 
It would be interesting to identify whether the effects of CBD on ventricular arrhythmias extend to 
myocardial necrosis. As such it would be beneficial to investigate the effect of AM251 and CBD on 
infarct size.  
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7.3 Conclusions 
 
This study has shown that both the CB1 receptor and GPR55 have the potential to induce 
haemodynamic changes despite the complex nature of ligand specificity encountered. Moreover, it has 
been demonstrated that, while both CBD and AM251 compounds have the capacity to reduce 
ischaemia-induced ventricular arrhythmias, they probably mediate these changes at distinct sites. In 
particular, the cardioprotective effects of CBD do not appear to be mediated by a change in [Ca
2+
]i at 
the level of the cardiomyocyte. In contrast, the anti-arrhythmic effects of AM251 are unlikely due to 
an effect on [Ca
2+
]i. This data suggests a role for the GPR55 receptor in mediating changes in Ca
2+
 and 
also in reducing ischaemia-induced ventricular arrhythmias and thus, it may represent a promising new 
target for ameliorating the pathological effects of cardiovascular disease.  
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Materials list 
 
ACEA: purchased pre-dissolved in ethanol (EtOH), this was evaporated off in a steady stream of 
nitrogen, before being re-solubilised in tween 80, DMSO and NaCl (to the ratio 1:2:8, respectively) to 
a concentration of 3mg ml
-1
. Tocris Bioscience, Bristol, UK, 
ADP: Diluted in saline to a concentration to 5µM. Chrono-log, Havertown, USA, 
AKT1 primary antibody (rabbit polyclonal; phospho S473): Was diluted in TBS. Abcam, Cambridge, 
UK, 
AM251: solubilised in tween 80, DMSO and NaCl (to the ratio 1:2:8, respectively. Tocris Bioscience, 
Bristol, UK, 
Anandamide (AEA): pre-dissolved in EtOH to a concentration 5mg ml
-1
. Diluted for experimental 
purposes, as required. Tocris Bioscience, Bristol, UK, 
Background Sniper: ready-to-use blocking reagent. Biocare Medical, Concord, USA, 
Betazoid DAB chromogen kit: prepared as per instructions with the DAB chromogen kit. Biocare 
Medical, Concord, USA, 
CBD: solubilised in EtOH. Tocris Bioscience, Bristol, UK, 
CB1 receptor primary antibody (rabbit polyclonal): Was diluted in TBS. Abcam, Cambridge, UK, 
Collagenase (Worthington class; Type II from Clostridium histolyticum): solubilised in nominally-free 
Ca
2+
 buffer solution. Sigma-Aldrich. Gillingham, UK, 
DaVinci Green Dilutent: universal dilutent for GPR55 dissolution. Biocare Medical, Concord, USA, 
DIVA decloaker (10x): ready-to-use buffer for antigen unmasking. HistoLab Products AB, 
Gothenburg, Sweden, 
Evans Blue dye: solubilised in distilled water. Sigma-Aldrich, Gillingham, UK, 
Fluo-4AM: re-constituted in 100% DMSO to a concentration of 5mM. Diluted in to the appropriate 
working concentration in micro-centrifuge tubes containing 1ml cell suspension. Molecular Probes 
Invitrogen, Paisley, UK, 
Formal fixx: A ready-to-use 10% neutral buffered formalin solution. Thermo Fisher Scientific, 
Leicestershire, UK, 
GPR55 primary antibody (rabbit polyclonal; LS-A6817 and LS-A162): Diluted in DaVinci Green 
Dilutent. MBL International Corporation, Massachusetts, USA,  
Haematoxylin Harris’: Ready-to-use solution. Sigma-Aldrich, Gillingham, UK, 
Heparinised saline: Diluted in 0.9% NaCl. Leo Laboratories Buckinghamshire, UK, 
Hyaluronidase (Type I-S; from bovine testes): Solubilised in nominally-free Ca
2+
 buffer solution. 
Sigma-Aldrich, Gillingham, UK, 
Hydrogen peroxide (H2O2): Diluted with distilled water as appropriate. Sigma-Aldrich, Gillingham, 
UK, 
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ImmPRESS reagent: ready-to-use solution provided with the ImmPRESS universal antibody (anti-
mouse Ig/anti-rabbit Ig, peroxidase) polymer detection kit. Vector Labs, Burlingame, USA, 
Immu-mount: An aqueous, non-fluorescing mounting media. Anatomical Pathology International, 
Cheshire, UK, 
KCl: solubilised in distilled water to a stock concentration of 2M, 
MACH 3 rabbit HRP detection kit: pre-prepared two-step polymer detection kit. Biocare Medical, 
Concord, USA, 
Mountex Mounting Medium: Histoab, Sweden, 
Noradrenaline: re-constituted in 0.5M HCl to a concentration of 50mg ml
-1
, with working stocks of 
0.1µM, 
Normal horse blocking serum (2.5%): ready-to-use solution provided with the ImmPRESS universal 
antibody (anti-mouse Ig/anti-rabbit Ig, peroxidase) polymer detection kit. Vector Labs, Burlingame, 
USA, 
O-1602: solubilised in 100% methyl acetate to a working concentration of 10mg ml
-1
. Working stock 
concentration of 30ng ml
-1
 prepared from serial dilutions in saline of 100µg ml
-1
 to 1000ng ml
-1
. 
Tocris Bioscience, Bristol, UK, 
Pentobarbital sodium salt: solubilised in NaCl to a concentration of 60mg ml
-1
 on a daily basis. Sigma-
Aldrich, Gillingham, UK, 
Periodic acid: ready-to-use 1% solution provided with the periodic acid-Schiff (PAS) kit. Sigma-
Aldrich, Gillingham, UK, 
Peroxidazed 1: ready-to-use blocking reagent. Biocare Medical, Concord, USA, 
Phosphate-buffered saline (PBS): 1 PBS tablet dissolved in 100 ml of distilled water. Final solution 
composition; 137mM NaCl, 10mM phosphate, 2.7mM KCl: pH 7.4. Sigma-Aldrich, Gillingham, UK, 
Proteinase (Type XXIV; bacterial): dissoluted in nominally-free Ca
2+
 buffer solution. Sigma-Aldrich, 
Gillingham, UK, 
Rabbit IgG: reconstituted in 1ml of distilled water. Diluted in TBS as to be Eqimolar with the primary 
antibody. Vector Laboratories, Burlingame, USA, 
Saline: 0.9% NaCl in distilled water, 
Schiff’s reagent: ready-to-use solution provided with the periodic acid-schiff (PAS) kit. Sigma-
Aldrich, Gillingham, UK, 
Tachas Haematoxylin: Biocare Medical, Concord, USA, 
Taurine: dissoluted in nominally-free Ca
2+
 buffer solution. Sigma-Aldrich, Gillingham, UK, 
TBS automation wash buffer (20X): diluted as per manufacturer’s instructions. Biocare Medical, 
Concord, USA, 
TBS plus 0.025% triton X-100: triton x-100 dissoluted in TBS, 
Toluidine blue (0.1% w/v): 1% toluidine blue top stock prepared in 70% ethanol. Working stock of 
0.1% prepared in saline. Thermo Fisher Scientific, Leicestershire, UK, 
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Triphenyltetrazonium chloride (TTC): solubilised in distilled water. Sigma-Aldrich, Gillingham, UK, 
URB 597: solubilised in EtOH and diluted as appropriate. Enzo Life Sciences, Exeter, UK, 
VectaMount: Vector Labs, Burlingame, USA, 
Vector VIP: prepared as per protocol provided with the VIP substrate kit for peroxidase. Vector Labs, 
Burlingame, USA, 
Verapamil: re-constituted in distilled water. Sigma-Aldrich, Gillingham, UK, 
2-arachidonylglycerol: solubilised in EtOH. Tocris Bioscience, Bristol, UK. 
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Cardiomyocyte isolation 
 
Original protocol for the preparation of cell extracts from adult rat 
ventricular myocytes 
 
After terminal anaesthesia with 2ml sodium pentobarbital sodium salt (Sigma-Aldrich), hearts were 
excised and the aorta cannulated before being mounted on the Langendorff apparatus (as described by 
Bates and Gurney, 1999). The hearts were then subjected to retrograde perfusion, maintained at 12ml 
ml
-1
 and 37°C, with a nominally Ca
2+
-free buffer solution (Solution A). This ensured that blood was 
washed from the coronary vasculature. Solution A contained (in mM): 120 NaCl, 5.4 KCl, 5 MgSO4, 5 
C3H3NaO3, 20 glucose, 20 taurine and 10 HEPES (pH 6.96). After 5 minutes of perfusion with 
solution A, perfusion was continued with solution A containing 4U ml
-1
 proteinase (sigma type XXIV) 
for 2 minutes. The final perfusate was solution A, containing 0.3mg ml
-1
 collagenase (Worthington 
class 2) and 0.6 mg ml
-1
 hyaluronidase for 5-10 minutes. Following completion of perfusion, hearts 
were dismounted from the Langendorff apparatus, atria cut from the ventricles and discarded. The 
ventricular tissue was then  finely minced in warm KB solution, which contained (in mM): 30 KCl, 3 
MgSO4, 30 KH2PO4, 10 glucose, 20 taurine, 10 HEPES, 85 KOH, 50 glutamic acid and 0.5 EGTA 
(pH 7.4). The minced tissue was then centrifuged briefly, re-suspended in solution A, if being used 
immediately, or KB solution, if being stored in the fridge overnight. 
  
 - 211 - 
 
APPENDIX III 
  
 - 212 - 
 
Optimisation of cell adherence of isolated ventricular cardiomyocytes 
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Figure III.I The effect of extended adherence of ventricular cardiomyocytes on fluorescence intensity. 
Samples were measured in triplicate (n=1). 
 
A range of adherence times were investigated in order to determine if fluorescence intensity in isolated 
cardiomyocytes could be improved by cardiomyocytes being adhered to laminin-coated plates prior to 
incubation with CC-1. Although this experiment was only performed on an n of 1, there appeared to 
be no benefit to allowing cells longer to adhere before commencing the experimental protocol. 
 
 
